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Abstract 
Parkinson’s disease (PD) motor and non-motor symptoms progress relentlessly leading to 
frequent hospitalisations and an increase in the economic and societal burden of the disease. 
A major challenge in assessing treatments which can potentially reduce neurodegeneration, 
is the lack of tools that can be used to identify individuals with early PD with high 
sensitivity and specificity. 
There were several facets to this thesis, which were aimed at addressing these issues. Firstly 
a retrospective analysis of PD hospital admissions was conducted to provide background 
data on hospitalisation and clinical coding accuracy. A systematic review of literature for 
interventions to reduce hospital admissions was performed. Effect of treatments for PD 
motor symptoms on hospitalisation was also evaluated. Lastly, screening of potential 
lanthanide and 19 Fluorine based MRI probes for future use as diagnostic tools in PD was 
conducted. 
Results of these studies highlight significant underreporting of PD hospitalisation which has 
a negative effect on PD resource allocation. A lack of robust evidence for measures which 
reduce PD admissions was demonstrated. Although the initial attempts to develop a novel 
MRI sensitive tool for use in PD were negative, the study refined a protocol that has potential 
for use in screening future probes.  
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CHAPTER 1: INTRODUCTION 
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1.1. Epidemiology 
Parkinson’s disease (PD) is the second commonest progressive neurodegenerative disease, 
which predominantly affects individuals above the age of 60 years (Nussbaum and Ellis, 
2003). In 2005, disease prevalence in Europe was estimated to range from 108 to 257 per 100 
000 and an incidence rate of 11 to 19 per 10 000 was reported (Von Campenhausen et al., 
2005). The wide variation in prevalence is probably due to different methodologies, age 
groups, and diagnostic criteria used in different studies (de Rijk et al., 1997). 
Age is the most important risk factor for the disease. The effect of age on disease prevalence 
was demonstrated in a recent systematic review, which assessed the worldwide prevalence of 
PD (Pringsheim et al., 2014). Meta-analysis of data from included studies showed an increase 
in disease prevalence with age: from 41 per 100 000 in the 40-49 years age group, rising to 
173 per 100 000 between 50-59 years, and 1087 per 100 000 in the 70-79 years group 
(Pringsheim et al., 2014).Therefore, the number of individuals affected by the disease is 
predicted to increase with improving quality of life and increasing life expectancy of 
populations in developed countries (de Lau and Breteler, 2006, Driver et al., 2009). An 
association between risk of the disease and gender has also been reported, with males having 
a 1.5-2 times higher incidence of the disease than females (Twelves et al., 2003).  
The exact cause of PD is unknown but it is thought to involve an interaction between genetic 
and environmental factors (de Lau and Breteler, 2006). Mendelian genetic cases only 
contribute to a small proportion (10%) (de Lau and Breteler, 2006), suggesting that 
environmental factors play a larger part in disease causation. Controversy surrounds which 
environmental factors are relevant in PD. Some epidemiological studies reported an increased 
risk of the disease with exposure to pesticides, heavy metals such as manganese and iron, 
rural, and farm living, but others have produced conflicting results (de Lau and Breteler, 2006, 
3 
 
Wirdefeldt et al., 2011). Additional evidence for environmental factors playing a part in 
disease causation comes from animal studies which demonstrated nigrostriatal degeneration 
and increased alpha-synuclein expression following exposure to pesticides such as rotenone, 
paraquat, and organochlorines (Wirdefeldt et al., 2011). 
A number of lifestyle habits maybe protective against the disease. For example, cigarette 
smoking is reported to halve the risk of PD, possibly via the stimulatory and potential neuro-
protective effects of nicotine on dopaminergic neurons (Wirdefeldt et al., 2011). Vitamin E 
and caffeine consumption may also reduce the risk of the disease (Wirdefeldt et al., 2011, de 
Lau and Breteler, 2006). Lastly, an inverse, but weak association between exercise and risk 
of PD has also been reported (Wirdefeldt et al., 2011). 
1.2 Pathophysiology  
The pathological signature of the disease includes depletion of dopaminergic cells in the 
substantia nigra pars compacta and Lewy bodies in the cytoplasm of the remaining neurons 
(Greenfield and Bosanquet, 1953). The Lewy bodies are predominantly composed of alpha-
synuclein (Spillantini et al., 1997). Underlying molecular mechanisms in the pathogenesis of 
both idiopathic and familial PD are complex. Mitochondrial dysfunction, abnormal protein 
accumulation, and oxidative stress are thought to be involved in processes leading to neuronal 
degeneration (Wood-Kaczmar et al., 2006, Lim and Zhang, 2013). Evidence for this comes 
from studies involving genes implicated in familial PD (Wood-Kaczmar et al., 2006). Both 
familial PD due to alpha-synuclein gene (SNCA) mutation and idiopathic PD are characterised 
by alpha-synuclein aggregation in the intra-cytoplasmic inclusions (Wood-Kaczmar et al., 
2006, Devine et al., 2011), suggesting a role for alpha-synuclein accumulation in the 
pathogenesis of the condition. However, it remains unclear whether Lewy bodies are toxic to 
4 
 
cells or their deposition signifies a cellular response to another pathologic substrate or process 
(Devine et al., 2011, Wood-Kaczmar et al., 2006).  
The ubiquitin-protease system and autophagy are the principle systems involved in the 
processes leading to degradation of misfolded proteins and damaged organelles (De Rosa et 
al., 2015). Target proteins bind to ubiquitin and are presented to proteasomes where 
degradation occurs (De Rosa et al., 2015). Dysfunction of these protein clearance systems 
may also play a role in PD pathogenesis. Inhibition of ubiquitin-protease system and 
proteasome function in rat ventral mesencephalon culture led to accumulation of alpha-
synuclein and ubiquitin positive inclusions, and degeneration of dopaminergic neurons in a 
study by McNaught et al. (2002) (McNaught et al., 2002). Further evidence for the 
involvement of abnormal protein clearance in PD pathogenesis comes from the observation 
that mutation of genes involved in the ubiquitin-protease system also lead to familial PD (De 
Rosa et al., 2015). For example, parkin mutations lead to loss of activity of E3 ubiquitin ligase 
which is important in the ubiquitin proteasome system (Shimura et al., 2001), and the 
ubiquitin C-terminal hydrolase L1 (UCH-L1) mutation, has been described in familial 
PD(McNaught et al., 2002). Damaged organelles and aggregated proteins are also degraded 
by lysosomes via a process called autophagy (Hara et al., 2006) and mutation of the genes 
which encode for some lysosome proteins [e.g. glucocerebrosidase (GBA) and ATP132A2] 
are also associated with an increased risk of PD (De Rosa et al., 2015). 
The role of mitochondrial dysfunction in PD was demonstrated in pathological studies 
showing reduced mitochondrial complex 1 levels in PD brains (Keeney et al., 2006). 
Additional support comes from the observation that exposure to the toxin 1-methy-4-phenyl-
1, 2, 3, 6-tetrapyridine (MPTP), a mitochondria complex 1 inhibitor results in a phenotype 
similar to that seen in sporadic PD (Keeney et al., 2006). In addition, rotenone, another 
5 
 
mitochondrial complex 1 inhibitor, induced dopaminergic neuron degeneration in animal 
studies (Sherer TB, 2003). Furthermore, mitochondrial abnormalities have been demonstrated 
in cells derived from individuals with Leucine-rich Repeat Kinase 2 (LRRK2) G2019S 
mutation, an autosomal dominantly inherited mutation (Wang et al., 2012a, Cooper et al., 
2012).  Mitochondrial dysfunction is a common pathway that potentially leads to neuronal 
death in early onset autosomal recessive PD secondary to Parkin, PTEN- induced putative 
kinase (PINK1) and DJ-1 mutations (Thomas et al., 2011). How this results in 
neurodegeneration remains uncertain, but is thought to interfere with mitochondrial function 
either by accumulation of an unknown pathogenic substrate or ubiquitin dependent signalling 
(Dawson et al., 2010). PINK1, a mitochondrial protein kinase plays an important part in 
mitochondrial homeostasis (Trempe and Fon, 2013). DJ-1 protein acts as molecular 
chaperone in mitochondrial oxidative pathways (Dawson et al., 2010). Thomas et al 2011 
showed that DJ-1 loss of function led to mitochondrial fragmentation suggesting a possible 
role of oxidative stress in dopaminergic degeneration (Thomas et al., 2011). These studies 
demonstrate the complexity of PD pathogenesis. Several mechanisms are implicated but the 
exact pathophysiology for the disease remains unknown.  
 
1.3. Clinical features of PD 
Motor features 
It is now well recognised that PD has a prodromal phase, and that motor symptoms only 
appear when there is at least 80% reduction in striatal dopamine levels (Bernheimer et al., 
1973). The cardinal motor symptoms of the disease are: tremor, rigidity, bradykinesia, and 
postural instability. The first three are often present when a clinical diagnosis is made but 
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postural instability is frequently seen in more advanced stages of the disease. Motor symptoms 
in PD typically have a unilateral onset. With time, symptoms progress to involve the 
contralateral side. A 4-7 Hz rest tremor is characteristic of the condition, (Pfeiffer, 2015) but 
a postural re-emergent tremor may also be present (Pfeiffer, 2015). The tremor often starts in 
one upper limb but other parts including the lower limbs, lips or chin tremor can be involved. 
Pathophysiology of rest tremor in PD is uncertain. The observation that the rest tremor does 
not always respond to dopaminergic treatments, suggests that pathways other than the 
nigrostriatal dopaminergic neurons may be involved (Pfeiffer, 2015). Some authors postulate 
that basal ganglia dysfunction acts as a trigger and cerebellar networks drive the rest tremor, 
but it remains uncertain if these pathways interact at the level of the thalamus or the cortex 
(Hallett, 2012). 
 Bradykinesia is defined as slowness of movements and is secondary to dopaminergic cell 
loss and in the nigrostriatal pathway (Pfeiffer, 2015). In addition to abnormal speed of 
movement, the definition of bradykinesia also encompasses hesitation, loss of rhythm of 
movements, absence and reduction in amplitude of movements: akinesia and hypokinesia 
respectively (Heldman et al., 2011, Pfeiffer, 2015). When using clinical diagnostic criteria, 
bradykinesia has to be present before a parkinsonian syndrome can be considered (Gibb and 
Lees, 1988). Patients often complain of generalised slowness of movement, difficulty with 
movement initiation, and problems with performing fine motor tasks. On clinical 
examination, affected individuals may exhibit the following features: freezing, reduced arm 
swing, expressionless faces, and difficulty in initiating movements (Berardelli et al., 2001). 
Other signs include micrographia, reduced blinking rate, hypophonic speech, hesitation and 
arrests on foot or finger tapping.  
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Rigidity in PD, is characterised by uniform resistance to passive movement also termed ‘lead-
pipe rigidity’, but cogwheel rigidity may also be detected when tremor is superimposed on 
rigidity (Broussolle et al., 2007). In the early stages of the disease, rigidity may be difficult to 
detect (Pfeiffer, 2015). In such cases, the Froment’s manoeuvre can be used to augment the 
clinical finding: facilitation manoeuvres such as repetitive movements of the contralateral 
limb or arithmetic tests are used to reinforce the rigidity (Broussolle et al., 2007). The 
pathophysiology of rigidity in PD is uncertain but may involve reticulospinal tracts. Changes 
in the activity of spinal inhibitory neurons lead to tonic facilitation of the alpha motor neurons, 
hence the rigidity in PD (Santens et al., 2003). 
Postural instability is more common in the later stages of the disease and is a major contributor 
to the risk of falls in PD (Kim et al., 2013). Basal ganglia dysfunction is thought to play a role 
in the development of postural instability in PD (Kim et al., 2013). Other motor features, such 
as dyskinesias and ‘on off’ fluctuations, are a consequence of long-term dopaminergic 
treatment.  
Non-motor features  
The neurodegenerative process is not limited to the dopaminergic system, but involves other 
neuronal networks which results in the non-motor symptom complex (table 1) (Chaudhuri et 
al., 2006). For example, cholinergic denervation has been linked to Rapid eye movement 
(REM) behaviour sleep disorder (RBD): a sleep disorder marked by loss of muscle atonia 
during REM sleep (Kotagal et al., 2012). Cholinergic dysfunction has also been demonstrated 
in PD dementia (Bohnen et al., 2003). Anxiety and mood disorders in PD were shown to 
correlate with a reduction in dopamine and noradrenaline innervation in the locus coeruleus 
and limbic regions in PD (Remy et al., 2005). 
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Table 1: Spectrum of Non-motor symptoms in Parkinson’s’ disease 
 
Neuropsychiatric symptoms 
Depression, apathy, anxiety 
Anhedonia 
Attention deficit 
Hallucinations, illusion, delusions 
Dementia 
Obsessional behaviour (usually drug induced), 
repetitive behaviour 
Confusion 
Delirium (could be drug induced) 
Panic attacks 
 
Sleep disorders 
Restless legs and periodic limb movements 
Rapid eye movement (REM) sleep behaviour 
disorder and REM loss of atonia 
Non-REM-sleep related movement disorders 
Excessive daytime somnolence 
Vivid dreaming 
Insomnia 
Sleep disordered breathing 
 
Autonomic symptoms 
Bladder disturbances 
Urgency 
Nocturia 
Frequency 
Sweating 
Orthostatic hypotension 
Falls related to orthostatic hypotension 
Coat-hanger pain 
Sexual dysfunction 
Hypersexuality (likely to be drug induced) 
Erectile impotence 
Dry eyes (xerostomia) 
 
Gastrointestinal symptoms (overlaps with 
autonomic symptoms) 
Dribbling of saliva 
Ageusia 
Dysphagia and choking 
Reflux, vomiting 
Nausea 
Constipation 
Unsatisfactory voiding of bowel 
Faecal incontinence 
 
Sensory symptoms 
Pain 
Paraesthesia 
Olfactory disturbance 
Other symptoms 
Fatigue 
Diplopia 
Blurred vision 
Seborrhoea 
Weight loss 
Weight gain (possibly drug induced) 
 
"Reprinted from The Lancet, Vol. 5, Chaudhuri, KR., Healy, DG & Schapira, AHV. Non-motor 
symptoms of Parkinson's disease: diagnosis and management 235-245, Copyright (2006), with 
permission from Elsevier." 
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Other PD non-motor symptoms include: olfactory dysfunction, sleep disturbances, 
gastrointestinal disturbances, autonomic dysfunction, fatigue, pain, and hallucinations 
(Chaudhuri et al., 2006).  
Clinical phenotypes 
The clinical phenotype in PD is heterogeneous. This may be due to multiple underlying 
pathophysiological mechanisms as well as a result of influence from various genetic factors 
(Lewis et al., 2005). Grouping patients into different subtypes may have prognostic 
implications and also influence treatment choices (van Rooden et al., 2010). Two main disease 
subtypes have been described and these are based on predominant motor phenotype. Firstly, 
tremor dominant PD is characterised by slow disease progression (Thenganatt and Jankovic, 
2014). The second subtype is the akinetic rigid syndrome or postural instability and gait 
disorder (PIGD) which is associated with a poor prognosis, more rapid disease course, and 
higher non-motor symptom burden including depression, apathy, cognitive decline, 
hyposmia, and RBD (Thenganatt and Jankovic, 2014, Wu et al., 2016). Finally, a mixed or 
indeterminate group which overlaps between the two main subtypes has also been described 
(Marras, 2015). Other authors have used statistical methods such as cluster analysis to classify 
patients into different subgroups. Lewis et al. (2005) described four disease subtypes using 
cluster analysis of clinical data derived from 120 PD patients with early disease (Lewis et al., 
2005). A ‘young onset’ subgroup was identified and this was characterised by a benign disease 
course with slow progression, mild motor symptoms, no cognitive impairment, but more 
treatment related motor complications when compared to other clusters (Lewis et al., 2005). 
The ‘tremor dominant’ subgroup showed a slow disease progression, and no cognitive 
impairment or depression (Lewis et al., 2005). A ‘non-tremor dominant’ cluster was also 
described. This group had a more rapid disease course, higher depression scores and poor 
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cognition (Lewis et al., 2005). Lastly, ‘rapid disease progression’ subgroup with minimal 
cognitive impairment and less levodopa response when compared to other subgroups (Lewis 
et al., 2005). This group may represent patients with atypical PD, although study authors 
thought this was unlikely since standard clinical criteria were used to make a diagnosis. 
Similar clusters were also identified in recent studies (Liu et al., 2011, Ma et al., 2015). A 
systematic review of data driven methods to identify PD subtypes showed inconsistencies in 
the clusters described across the included studies (van Rooden et al., 2010). The differences 
may be a result of variability in the parameters included in the cluster analysis and also 
inclusion of patients with different disease duration (van Rooden et al., 2010). 
Braak hypothesis and evolution of symptoms 
Some non-motor symptoms have been shown to predate the onset of the motor syndrome by 
many years (premotor phase), but others including dementia tend to occur in the later stages 
of the disease (Chaudhuri et al., 2006). The evolution of both motor and non-motor symptoms 
from the premotor phase to advanced stages of the disease was delineated in the Braak 
hypothesis discussed below (figure 1). Braak et al. (2002), used a six stage system to describe 
the progression of Lewy body pathology. This hypothesis provides an explanation why some 
symptoms occur  before the onset of motor symptoms, and others in more advanced stages of 
the disease (Braak et al., 2002). In Stage 1, Lewy body pathology is seen in the olfactory bulb, 
the myenteric plexus of the gut, and the dorsal motor nucleus of the vagus nerve (Braak et al., 
2002). This may explain the occurrence of olfactory dysfunction (Stiasny-Kolster et al., 2005) 
and gastrointestinal symptoms in the premotor phase of the disease. From the vagus nerve, 
the pathology ascends into the brain stem to involve various nuclei including the locus 
coeruleus, caudal raphe nuclei, and the reticular formation in Braak stage 2 (Braak et al., 
2002). RBD is thought to occur during this stage (Stiasny-Kolster et al., 2005). The classical 
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motor symptoms of the disease appear in Stage 3 when there is involvement of the substantia 
nigra (Braak et al., 2002). As the disease continues to progress, the neuropathological changes 
worsen in previously affected regions and the pathology also ascends to involve the forebrain 
and cerebral cortex in Stages 5 and 6 (Braak et al., 2002), leading to cognitive impairment 
Figure 1: Braak hypothesis, spread of Lewy body pathology in Parkinson’s disease 
 
            Braak et al 2002, upward spread of Lewy body pathology in PD (b) Stage 1 and 2: Lewy body 
deposition in olfactory bulb and involvement of brainstem nuclei. (c) Stage 3: substantia nigra, basal 
forebrain (d) stage 5 and 6 
Figure obtained from Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rub 
U (2002) Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's 
disease (preclinical and clinical stages). Journal of Neurology 249, 1-1, with permission from 
Springer. 
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            And dementia. Although this staging system is widely accepted, it has a number of 
limitations. Post-mortem studies have shown that the disease pathology does not strictly 
follow the caudo-rostral ascension described by Braak and colleagues. For example, Dickson 
et al.(2008) showed that asymptomatic individuals who were found to have incidental Lewy 
body deposition at post-mortem, had a similar pattern of alpha-synuclein deposition in 
multiple brain regions to that found in the group with clinical PD, but the alpha-synuclein 
body load was lower in the earlier group (Dickson et al., 2008). Furthermore, tyrosine 
hydroxylase immunostaining was reduced in cardiac sympathetic terminals of both 
individuals with PD and those with incidental Lewy bodies (Dickson et al., 2008). Since 
individuals with incidental Lewy body deposition are thought to have preclinical PD 
(DelleDonne et al., 2008), Dickson et al. (2008) findings suggest widespread Lewy body 
deposition in the preclinical stage of the disease with the load increasing as the disease 
progresses (Dickson et al., 2008). This is in contrast to Braak et al. (2002) who proposed that 
the pathology spreads upwards from the lower brainstem nuclei (Braak et al., 2002). Another 
post-mortem study showed that 55% of patients with extensive alpha-synuclein pathology 
corresponding to stage 5-6 of Braak staging, did not have extrapyramidal signs or dementia 
(Parkkinen et al., 2008). In addition a subgroup had pathology in the substantia nigra, basal 
forebrain, and cortex, but brain stem nuclei including locus ceoruleus and the dorsal motor 
nuclei of the vagus were spared (Parkkinen et al., 2008). These findings suggest that the 
Braak staging system may not be useful in predicting progression of neurodegeneration in 
PD or Lewy body dementia (Parkkinen et al., 2008).  It is also important to highlight that 
neurodegeneration and Lewy body deposition in PD is not only localised to the central 
nervous system. For example, Lewy body deposition has been demonstrated in the enteric 
(Hilton et al., 2014, Beach et al., 2010) and sympathetic nervous system (Beach et al., 2010), 
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which suggest that both peripheral and central nervous system neurodegeneration occurs in 
PD. Lewy body deposition in the peripheral nervous system may explain the occurrence of 
non-motor symptoms such as postural hypotension and gastrointestinal symptoms.  
 
1.4. Differential diagnosis 
In clinical practice, a diagnosis of PD is made when motor symptoms emerge and is based on 
the United Kingdom (UK) Queens Square Brain Bank Criteria: table 2 (Gibb and Lees, 1988). 
The presence of bradykinesia is an essential requirement. Either rest tremor, rigidity and or 
postural instability have to be present in a parkinsonian syndrome (Gibb and Lees, 1988). The 
following atypical features must be excluded during patient assessment: previous history of 
head trauma, stroke, encephalitis, neuroleptic exposure, absence of levodopa response, 
supranuclear gaze palsy, and early autonomic involvement (Gibb and Lees, 1988). Unilateral 
onset of symptoms, progressive rest tremor, levodopa responsiveness, dyskinesias, and 
hyposmia are all supportive of a diagnosis of idiopathic PD (Gibb and Lees, 1988). More 
recently, the Movement Disorders Society (MDS) task force, published the MDS-Clinical 
Diagnostic Criteria for PD: MDS-PD criteria (Postuma et al., 2015). These new criteria 
include some of the core features of the UK PD Brain Bank Criteria but also incorporated 
non-motor symptoms, since these are a vital component of the disease. Both clinical criteria 
use a staged approach in making a PD diagnosis, and require the presence of bradykinesia and 
either rest tremor or rigidity for Parkinsonism to be considered (Postuma et al., 2015, Gibb 
and Lees, 1988). But, there are a number of differences between the two criteria. Firstly, the 
MDS-PD Criteria do not include postural instability in defining Parkinsonism, since the 
presence of postural  
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Table 2: The UK Parkinson’s Disease Society Brain Bank criteria 
 
 
 
Step 1 Diagnosis of Parkinsonian syndrome 
* Bradykinesia (slowness of initiation of voluntary movement with progressive reduction 
* in speed and amplitude of repetitive actions) 
And at least one of the following: 
muscular rigidity 
4-6 Hz rest tremor 
postural instability not caused by primary visual, vestibular, cerebellar, or 
proprioceptive dysfunction. 
 
Step 2 Exclusion criteria for Parkinson's disease 
* History of repeated strokes with stepwise progression of parkinsonian features 
* History of repeated head injury 
* History of definite encephalitis 
* Oculogyric crises 
* Neuroleptic treatment at onset of symptoms 
* More than one affected relative 
* Sustained remission 
* Strictly unilateral features after 3 years 
* Supranuclear gaze palsy 
* Cerebellar signs 
* Early severe autonomic involvement 
* Early severe dementia with disturbances of memory, language, and praxis 
* Babinski sign 
* Presence of cerebral tumour or communicating hydrocephalus on CT scan 
* Negative response to large doses of levodopa (if malabsorption excluded) 
* MPTP exposure 
 
Step 3 Supportive prospective positive criteria for Parkinson's disease 
(Three or more required for diagnosis of definite Parkinson's disease) 
* Unilateral onset 
* Rest tremor present 
* Progressive disorder 
* Persistent asymmetry affecting side of onset most 
* Excellent response (70-100%) to levodopa 
* Severe levodopa-induced chorea 
* Levodopa response for 5 years or more 
* Clinical course of 10 years or more 
Table 2 obtained from Gibb W, Lees A (1988) The relevance of the Lewy body to the 
pathogenesis of idiopathic Parkinson's disease. Journal of Neurology, Neurosurgery, and 
Psychiatry 51, 745-752, with permission from BMJ publishing group. 
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instability in the early stages of the disease indicates an alternative parkinsonian syndrome  
(Postuma et al., 2015). Because of the problems with sensitivity and specificity of available 
diagnostic criteria, the MDS Criteria divided the diagnosis into clinically established PD and 
clinically probable PD which allows use of this criteria for research purposes and also in 
making a diagnosis of PD in routine clinical practice (Postuma et al., 2015). 
Another important distinction is that the occurrence of dementia in the early stages of the 
disease is not considered as an exclusion criteria, therefore the MDS-PD Criteria allows 
dementia with Lewy bodies to be classified as a subtype of PD (Postuma et al., 2015). The 
MDS-PD Criteria also include investigations such as cardiac metaiodobenzylguanidine 
(MIBG) scintigraphy and olfactory tests in its supportive criteria (Postuma et al., 2015). 
Although the UK Brain Bank Criteria have been widely adopted, it is associated with a high 
misdiagnosis rate. Conditions such as essential tremor, Alzheimer’s disease, along with other 
parkinsonian syndromes including Multiple System Atrophy (MSA), vascular Parkinsonism, 
and Progressive Supranuclear Palsy (PSP) are often misdiagnosed as idiopathic PD and vice 
versa  (Hughes et al., 1992, Meara J, 1999). An early clinico-pathological study of 100 cases 
with a clinical diagnosis of PD made by neurologists and geriatricians reported a diagnostic 
error rate of 24%: 76 cases had pathological findings characteristic of PD and the 24% cases 
misdiagnosed as PD during life had MSA, PSP, and Alzheimer type pathology (Hughes et al., 
1992)). In another study from North Wales, only 53% of patients treated with PD medications 
in the community fulfilled the UK PD Brain Bank Criteria for PD (Meara J, 1999). In a more 
recent clinico-pathological study, only 10% of cases diagnosed as PD using the clinical 
diagnostic criteria were redefined to other diagnoses at post-mortem, showing an improved 
diagnostic accuracy compared to previous studies (Hughes et al., 2001). In its early stages, 
PD is often difficult to diagnose. A study by Adler et al. (2014) used neuropathological 
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confirmation as the gold standard for PD diagnosis and showed low diagnostic accuracy of a 
clinical diagnosis of probable or possible PD especially in early disease: 26% and 88% 
respectively (Adler et al., 2014). In this study responsiveness to dopaminergic medication, 
longer disease duration and hyposmia increased the positive predictive value for probable PD 
(Adler et al., 2014).  
The gold standard or definitive diagnosis of idiopathic PD can only be confirmed at post-
mortem when characteristic features of nigrostriatal dopaminergic cell loss and 
intracytoplasmic inclusions or Lewy bodies are detected (Greenfield and Bosanquet, 1953). 
At present, there is no validated tool that can accurately diagnose PD and differentiate it from 
atypical Parkinsonism pre-mortem. Implications of incorrectly labelling patients with PD as 
atypical Parkinsonism or vice versa are multiple. Firstly, atypical parkinsonian syndromes 
such as MSA and PSP have a worse prognosis when compared to PD and response to the 
available dopaminergic treatments is often poor (Christine and Aminoff, 2004). Patients with 
non-degenerative Parkinsonism may be exposed to PD medications and their associated side 
effects, which may impair quality of life. Further, when assessing the effect of potential 
neuroprotective treatments, it is essential that the correct diagnosis is assigned since including 
patients with other diagnoses who might not respond to the treatment as well, might interfere 
with interpretation of results from such trials (Chahine and Stern, 2011). 
1.5 Investigations 
PD diagnosis is clinical and investigations are useful in excluding conditions that may mimic 
PD. In the UK, two imaging modalities are used in clinical practice: Magnetic Resonance 
Imaging (MRI) is used to exclude structural abnormalities; and functional imaging which aids 
in visualising dopaminergic cell loss in the nigrostriatal pathway using radionuclide imaging 
17 
 
techniques [Positron emission Tomography ( PET) and Single Photon Emission Computed 
Tomography (SPECT)] (Brooks, 2010).  
Magnetic resonance imaging  
MRI has the advantage of being widely available, non-invasive and does not use radioisotopes 
(Peran et al., 2010). The utility of MRI in PD in clinical practice is limited to exclusion of 
secondary causes of Parkinsonism such as strokes, hydrocephalus and other structural 
abnormalities (Brooks, 2010, Brooks and Pavese, 2011). In the majority of patients with 
idiopathic PD, MRI brain is normal (Brooks, 2010). There may be a potential for use in 
distinguishing PD from MSA and PSP (Bhattacharya et al., 2002), but studies have shown 
conflicting results. Specific MRI features such as putaminal atrophy, middle cerebellar 
peduncle (MCP)  signal abnormality and atrophy of the brainstem were found in patients with 
MSA-P (MSA- Parkinsonism) and not in any of the PD patients, so the authors proposed a 
potential role of MRI brain in aiding the diagnosis of MSA (Bhattacharya et al., 2002). 
Significantly more patients with MSA-P had putaminal hypodensity when compared to PD 
patients (Bhattacharya et al., 2002). In contrast, another study reported that putaminal 
hypodensity was not specific for either PD or MSA (Lee et al., 2004). Hyperintensity of MCP 
has also been shown to have high sensitivity and specificity: 85.2% and 100% respectively, 
in differentiating patients with MSA-C from PD, PSP, and controls.  The ‘hot cross bun’ sign 
is another characteristic radiological feature which supports a clinical diagnosis of MSA 
(Shrivastava, 2007), and can be used to differentiate MSA cases from PD, but the sign has 
low specificity, as it also been demonstrated in patients with spinocerebellar ataxias   (Lee et 
al., 2009). Measuring MCP width has also been proposed as a way of differentiating PD from 
MSA, with MSA patients showing significantly smaller MCP width compared to idiopathic 
PD patients (Nicoletti G, 2006). Longoni et al. (2011), used MRI as a diagnostic tool and 
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authors were able to separate PSP patients form PD and healthy controls. The authors 
measured the ratio of the pons to midbrain area (pons/midbrain: P/M), the MCP to superior 
cerebellar peduncle (SCP) width ratio (MCP/SCP) and calculated the [P/M * MCP/SCP], a 
parameter called MR Parkinsonism index (Longoni et al., 2011). When compared to PD 
patients and controls, individuals with PSP had higher  P/M ratios and MR Parkinsonism 
index, suggesting that midbrain atrophy can be used to separate these groups of patients 
(Longoni et al., 2011). The MR Parkinsonism index was shown to have high sensitivity and 
specificity in differentiating PD from PSP-Richardson syndrome patients: 100% and 92% 
respectively (Longoni et al., 2011). Similarly the P/M ratio also had high sensitivity (90%) 
and specificity (96%) in differentiating the two groups, but the same parameters did not 
achieve similar sensitivity in separating PSP-Parkinsonism from PD patients (Longoni et al., 
2011). Other studies have also reported low sensitivity when MRI is used to differentiate 
between PD from atypical Parkinsonism (Lee et al., 2004, Meijer et al., 2012).  
Radionuclide imaging  
PET and SPECT imaging provide a direct way of estimating dopaminergic cell loss, a key 
pathological process in PD (figure 2). This is done by using radiotracers which bind to targets 
on the presynaptic or post synaptic dopaminergic terminals (Cummings et al., 2011). 
Examples of these radiotracers are shown in figure 2. SPECT imaging is more widely 
available, but PET provides better sensitivity and image resolution (Zhu et al., 2014). A 
significant drawback of using PET is radiotracers have shorter half-lives compared to SPECT 
ligands and therefore require onsite production of ligands which makes PET more expensive 
(Thobois et al., 2001). 
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Figure 2: PET and SPECT radio ligands and binding sites on the dopaminergic terminal 
 
 
Figure obtained from Cummings JL, Henchcliffe C, Schaier S, Simuni T, Waxman A, Kemp P 
(2011). The role of dopaminergic imaging in patients with symptoms of dopaminergic system 
neurodegeneration. Brain 134, 3146-3166, with permission from Oxford University press. 
Schematic diagram showing location of the dopamine transporter (DAT), vesicular 
monoamine transporter (VMAT), amino acid transporter, and D2 receptors on the 
dopaminergic terminal and examples of SPECT and PET radioligands which bind to each of 
these receptors. DAT (green) in present on the presynaptic membrane. Dopamine (orange), 
a DAT substrate and is transported into the presynaptic terminal via DAT, and is 
subsequently pumped into intracellular vesicles via VMAT (pink). D2 receptors (purple) are 
present on the postsynaptic membrane.  
 
Targets for radioligands in PD 
Aromatic Acid Decarboxylase (AADC) activity 
 [18F]-DOPA, is a fluorinated levodopa analogue used in PET imaging for measuring 
dopamine synthesis, uptake into storage vesicles, and metabolism (Forsback et al., 2004). The 
probe is actively taken up by striatal dopaminergic neurons and decarboxylated to fluoro-
dopamine by aromatic acid decarboxylase (AADC). Fluoro-dopamine is then transported into 
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storage vesicles (Ravina et al., 2005). [18F]-DOPA uptake has been shown to correlate with 
nigral cell counts (Snow et al., 1993).  However, cell loss results in a compensatory AADC 
up regulation, therefore [18F]-DOPA uptake tends to overestimate dopaminergic innervation 
in the striatum (Bruck et al., 2009, Lee et al., 2000). In Parkinson’s disease, conversion of 
DOPA to dopamine by AADC is thought to be the rate limiting step, therefore [18F]-DOPA 
is likely to reflect AADC activity (Ravina et al., 2005, Lee et al., 2000). 
 [18F]-DOPA PET shows reduced striatal uptake in PD patients compared to controls: figure 
3 (Rinne et al., 2001). The reduced striatal uptake in PD is not homogeneous, with marked 
reduction in uptake in the putamen compared to the caudate: figure 3 (Bruck et al., 2009, 
Rinne et al., 2001, Lee et al., 2000). Tracer uptake in the putamen and caudate was shown to 
correlate with disease stage and severity of rigidity and bradykinesia but not tremor (Otsuka, 
1996).  In some studies, putamen uptake only correlated with motor and total Unified 
Parkinson’s Disease Rating Scale (UPDRS) scores (Morrish, 1996).  
Vesicular monoamine transporter (VMAT) ligands 
[11C] dihydrotetrabenazine (DTBZ) and (18F)-9-flouropropyl- +-dihydrotetrabenazine PET 
ligands bind to VMAT2, which actively pumps dopamine into storage vesicles (Lin et al., 
2014, Wilson and Kish, 1996). Up to 95% of VMAT binding in the striatum is associated 
with dopaminergic terminals (Frey et al., 1996)(Frey et al., 1996). (11C) DTBZ is therefore 
considered to be a sensitive marker of presynaptic dopaminergic terminals with studies 
demonstrating reduced contralateral striatal binding in PD patients compared to controls: 
figure 3 (Frey et al., 1996, Bohnen et al., 2006, Martin et al., 2008). The pattern of uptake is 
similar to that reported with the dopamine transporter (DAT) showing more marked reduction 
in putaminal than caudate uptake in PD compared to control (Bohnen et al., 2006, Frey et al., 
1996). Reduction in (11C) DTBZ striatal binding correlates with bradykinesia and disease 
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duration (Martin et al., 2008, Bohnen et al., 2006). A recent study used PET ligand (18F)-9-
flouropropyl- +-dihydrotetrabenazine to differentiate PD patients from healthy control 
showed sensitivity and specificity of 100% in differentiating PD patients from healthy 
controls (Lin et al., 2014). In another study 18F-9-flouropropyl- +-dihydrotetrabenazine 
binding correlated with disease duration and UPDRS scores (Hsiao et al., 2014). 
VMAT ligands are less likely to be influenced by compensatory mechanisms that occur 
secondary to dopaminergic terminal loss such as the up-regulation of AADC activity and 
reduced DAT expression (Vander Borght et al., 1995). In addition, VMAT binding is thought 
to be less susceptible to regulation by treatments that interfere with synaptic dopaminergic 
levels and post synaptic receptor function (Vander Borght et al., 1995, Wilson and Kish, 
1996). This suggests that VMAT binding can be used as an accurate marker of dopaminergic 
neuronal integrity and also as potential tool for assessing response to treatment (Vander 
Borght et al., 1995). However, VMAT tracer binding in the brain is not specific to 
dopaminergic neurons and has been demonstrated in other regions rich in serotonergic and 
noradrenergic neurons such as locus coeruleus, raphe nucleus, and the hypothalamus (Wilson 
and Kish, 1996). 
 
Post synaptic receptor ligands  
PET ligand (11C) raclopride and SPECT [123I] iodobenzamine (1BZM) have been used to label 
post synaptic dopamine receptors (Brooks and Pavese, 2011). Striatal 11C raclopride uptake 
is increased in PD compared to control, reflecting an up-regulation of dopamine D2 post 
synaptic receptors which occurs with dopaminergic neuronal loss (Rinne, 1995). 
Dopamine transporter ligands 
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Most of the ligands used in PET and SPECT imaging are cocaine analogues with high affinity 
for DAT (Thobois et al., 2001). Examples of ligands used for SPECT imaging include Iodine 
-1233-carbomethoxy-3-(-4-iodophenyltropane) ([123I] B- CIT), [123I] FP-CIT, and [99mTc] 
TRODAT-1 (Cummings et al., 2011). PET DAT ligands include, [11C] Cocaine, [3H] WIN, 
[11C] altropane, [11C]/ [18F] B-CFT and [11C] FE-CIT (Cummings et al., 2011).  
Nigrostriatal neuronal degeneration has been shown to be paralleled with a reduction in 
dopamine transporter density (Fischman, 1998). SPECT [123I] B-CIT binding is reduced in 
both the PD striatum contralateral and ipsilateral to the affected side compared to controls 
(Vermeulen et al., 1995). [123I] FP-CIT striatal uptake has also been assessed in early PD, late 
PD, and healthy controls. Results were in concordance with [123I] B- CIT findings showing 
reduced tracer uptake in ipsilateral and contralateral caudate and putamen of PD patients 
compared to controls (Vermeulen et al., 1995). A more marked reduction in uptake in the 
contralateral striatum particularly the posterior putamen, was seen in PD patients than controls 
(Vermeulen et al., 1995, Booij et al., 1997). Similarly, striatal hypofunction has been 
demonstrated in PD using other DAT ligands: [123I]PE21 (Prunier et al., 2003)  [123I]altropane 
(Fischman, 1998)), [99mTc]TRODAT-1 (Huang et al., 2001), [11C]B-CFT (Laihinen et al., 
1995), and [18F]CFT (Rinne et al., 2001). The SPECT ligands [123I] B- CIT and [123I] altropane 
showed comparable sensitivity to [18F]-DOPA PET in distinguishing early PD from healthy 
controls (Ishikawa et al., 1996, Fischman, 1998). DAT radiotracer uptake has also been shown 
to correlate with disease stage (Booij et al., 1997, Laihinen et al., 1995, Prunier et al., 2003), 
bradykinesia, and rigidity scores (Benamer et al., 2003).  
The ability of SPECT and PET tracers to discriminate early PD from healthy controls supports 
its use as a diagnostic tool in early PD. [123I] FP-CIT (DaTSCAN) is now widely available for 
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use in clinical practice and is recommended for use in cases of diagnostic uncertainty 
(Berardelli et al., 2013).  
 
Figure 3: Images of healthy control and PD striatum using SPECT (DAT and VMAT) and [18F]-
DOPA PET ligands. 
 
 
Images above show the reduction in ligand uptake in the posterior putamen in PD  
Figure obtained from Brooks DJ, Pavese N (2011) Imaging biomarkers in Parkinson's  
Disease. Progress in Neurobiology 95, 614-628, with permission from Elsevier 
 
Transcranial sonography (TCS) 
In some countries, transcranial ultrasonography (TCS) is used in clinical practice to provide 
supportive information for PD diagnosis. TCS typically shows substantia nigra 
hyperechogenicity in PD subjects which is not found in healthy individuals (Li et al., 2016). 
Iron accumulation is thought to contribute to substantia nigra hyperechogenicity in PD (Berg 
et al., 2002). A systematic review and meta-analysis which included 31 studies from 13 
different countries assessed the diagnostic accuracy of TCS in PD (Li et al., 2016). Data for 
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1 926 individuals with PD and 2 460 controls was included. Pooled data showed that TCS 
had a high sensitivity and specificity of 83% and 87% respectively when used in making a 
PD diagnosis (Li et al., 2016). 
In addition to its role in discriminating PD from healthy controls, TCS has also been shown 
to be useful in differentiating PD from atypical Parkinsonism. Normal substantia nigra 
echogenicity is suggestive of MSA-P and hyperechogenicity of the lentiform nucleus 
combined with dilatation of the third ventricle is indicative of PSP (Walter et al., 2007). 
However, TCS has its limitations. Up to 60% of individuals in the Asian population may have 
an insufficient temporal window and it is not always possible to perform TCS in these 
individuals (Li et al., 2016). Sensitivity and specificity figures reported across different 
studies have not been consistent (Li et al., 2016). Lastly substantia nigra hyperechogenicity 
may not be specific to PD as it was also reported in 70% of patients with amyotrophic lateral 
sclerosis (Fathinia et al., 2013) and 9% of healthy controls (Berg et al., 2002). 
1.6. Biomarkers 
           According to the Biomarkers Definitions Working Group, a biomarker is a ‘characteristic that 
is objectively measured and evaluated as an indicator of normal biologic processes, 
pathogenic processes or pharmacological response to a therapeutic intervention’(Biomarkers 
Definitions Working Group, 2001). Several clinical, biological and imaging tools have been 
studied in PD and some of the imaging tools are now in use in clinical practice. These tools 
have shown promising results as potential biomarkers, but most are associated with major 
drawbacks. Figure 4 summaries the role of biomarkers in PD. In PD biomarkers maybe used 
in pre-symptomatic diagnosis, which provides a window for use of neuroprotective 
treatments. A tool which provides high diagnostic sensitivity and specificity is required. This 
will aid in identifying patients with early stage disease before significant neurodegeneration 
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occurs, and such patients may benefit from disease modifying treatments or cure when these 
treatments become available. Tools for assessing disease severity and progression are also 
required in PD. At present, the UPDRS is the standard tool for assessing disease severity, 
progression, and response to treatment in clinical practice and trials (Movement Disorder 
Society Task Force on Rating Scales for Parkinson’s Disease, 2003). Its use has been limited 
by poor inter-rater reliability as reported in some studies (Movement Disorder Society Task 
Force on Rating Scales for Parkinson’s Disease, 2003). UPDRS scores also improve with 
symptomatic treatment for PD making it less ideal to assess disease progression in clinical 
trials of disease modifying treatments (Morgan et al., 2010). More recently, the Movement 
Disorders Society has modified the UPDRS to deal with these shortcomings and to include 
non-motor symptoms assessment (Goetz et al., 2008). A  recent sytematic review showed the 
lack of evidence for a robust biomarker for assessing disease progression in PD and also 
highlighted the significant methodological flaws in  the 183 included studies.(McGhee et al., 
2013) Major limitations were the small sample sizes, insufficent data reporting, limited 
statistical analyses, and the crossectional nature of a large proportion (85%) of the studies 
.(McGhee et al., 2013)  In view of these shortcomings, the review authors made several 
recommendations for future studies. Careful selection of a specific pathophysiological aspect 
of the disease which can be measured reliably across studies is pivotal in biomarker 
development. (McGhee et al., 2013)  In addition, further progress can be made improving the 
quality of the studies. Ideally biomarker studies should include of large sample sizes  and be 
conducted in a longitudinal, and prospective fashion with sufficient follow up periods to allow 
measurement of  clinical and biomarker outcomes at several time points. (McGhee et al., 
2013)  
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Figure 4: The role of biomarkers in premotor and symptomatic phases of Parkinson's disease 
 
Figure 4 obtained from Lebouvier T, Tasselli M, Paillusson S, Pouclet H, Neunlist M, Derkinderen P 
(2010) Biopsable neural tissues: toward new biomarkers for Parkinson’s disease? Frontiers in 
Psychiatry 1. Open access article 
 
1.6.1. Clinical markers 
 
As alluded to in the previous section, the presence of motor features is critical in making a 
clinical diagnosis of PD but these symptoms occur when a significant proportion of 
dopaminergic neurons have been lost (Bernheimer et al., 1973). Olfactory dysfunction, RBD, 
constipation, and depression occur in the premotor phase and therefore have a potential role 
in premotor diagnosis: figure 4 (Morgan et al., 2010, Lebouvier et al., 2010). Olfactory 
deficits are prevalent in people with PD and a recent meta-analysis showed that this non-
motor symptom occurs in approximately 76% of PD patients, (Chen et al., 2015) and predates 
the motor syndrome by at least 4 years (Ross et al., 2008). Thus, screening for hyposmia may 
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be useful for premotor diagnosis of PD. Further, other Parkinsonian syndromes MSA, PSP, 
and CBD) are often associated with little or no olfactory deficit, allowing this clinical marker 
to be used to differentiate PD from other parkinsonian syndromes (Hawkes, 2003), although 
this may be limited by low specificity and sensitivity (Hawkes, 2003). In addition, hyposmia 
cannot be used to reliably distinguish PD from other neurodegenerative conditions such as 
Alzheimer’s disease and DLB which may also be associated with marked olfactory deficits 
(Hawkes, 2003, Chahine and Stern, 2011).  Another limitation is that olfactory dysfunction 
does not correlate with disease activity, hence is not a useful marker for disease progression 
(Chahine and Stern, 2011). The short latency period between hyposmia detection and PD 
diagnosis, (Ross et al., 2008) may also limit the window for potential use of neuroprotective 
treatments. 
RBD also predates the development of motor features in the synucleopathies by over 10 years 
(Iranzo et al., 2006). The long latency before onset of motor symptoms makes it ideal in the 
preclinical diagnosis of PD. The 10 year risk of developing a neurodegenerative disorder in 
individuals with RBD was reported to be approximately 41%, in a study by Postuma and 
colleagues (Postuma et al., 2009a). A more recent study showed that an even higher 
proportion of patients (82%) with RBD developed a synucleopathy (Iranzo et al., 2013).  
Constipation also predates the motor syndrome in PD (Abbott et al., 2003). A major 
disadvantage of employing this as a clinical marker is that, the prevalence of constipation is 
much higher than that of PD in the general population, which reduces its specificity as a 
preclinical marker (Postuma et al., 2010).  
Other non-motor symptoms such as depression and anxiety are also potential preclinical 
markers, but utility as preclinical markers is limited by low specificity (Postuma et al., 2010). 
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Another study showed that other preclinical markers of PD such as olfactory dysfunction, 
abnormal colour vision, and autonomic dysfunction were more common in patients with RBD 
compared to controls (Postuma et al., 2009b). Therefore, a combination of these clinical 
markers may increase the utility of RBD in preclinical diagnosis. 
 
1.6.2. Biochemical markers 
 
Biological markers in both saliva, blood and CSF have shown potential utility in diagnosis 
and disease progression (Chahine and Stern, 2011, Morgan et al., 2010). Use of these markers 
is advantageous because samples are easy to obtain and costs are low. CSF markers including 
alpha-synuclein, and beta amyloid 1-42 (Aβ1-42), neurofilament light chain protein (NFL), 
DJ-1, and tau protein have been evaluated, but results have not been consistent across studies 
(Bäckström et al., 2015, Herbert et al., 2015, Waragai et al., 2006). A recent prospective study 
including 128 patients with Parkinsonism and 30 healthy controls evaluated the utility of 
several CSF markers including NFL, alpha-synuclein, Aβ1-42, and heart fatty acid binding 
protein as diagnostic markers in PD (Bäckström et al., 2015). Alpha-synuclein levels were 
similar in both PD and healthy controls, (Bäckström et al., 2015) which contrasts with 
findings from previous studies which demonstrated lower alpha-synuclein levels in PD 
patients compared to controls (van Dijk et al., 2014, Mollenhauer et al., 2011). Bäckström 
and colleagues also reported lower Aβ1-42 levels and elevated NFL levels in the PD group 
compared to controls, (Bäckström et al., 2015) suggesting a role of NFL and Aβ1-42 in PD 
diagnosis. In the same study, the authors were able to separate PD patients from those with 
PSP using CSF NFL and Aβ1-42 levels: PSP patients had higher CSF NFL levels and low 
CSF Aβ41 protein compared to PD and at 1 year follow up (Bäckström et al., 2015). The 
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NFL/Aβ41 ratio had high specificity (93%) and sensitivity (89%) for differentiating PSP from 
PD (Bäckström et al., 2015). However, MSA patients could not be separated from PD based 
on these markers, (Bäckström et al., 2015) which conflicts with the findings of a previous 
report: Hebert et al. (2015) reported higher CSF NFL levels in MSA than PD and suggested 
that this marker could be used with a high degree of accuracy to discriminate PD from MSA 
(Herbert et al., 2015). In terms of predicting patients who may develop PD dementia, high 
CSF NFL, low Aβ1-42, and high heart fatty binding protein may be useful (Bäckström et al., 
2015). Similarly, Terrelonge and colleagues reported an association between low baseline 
CSF Aβ1-42 levels and development of cognitive impairment at 2 years in patients with early 
drug naïve PD (Terrelonge et al., 2015). The role of plasma and CSF DJ-I levels in PD 
diagnosis has also been assessed and was shown to be significantly higher in PD patients 
compared to non-PD controls (Waragai et al., 2006, Waragai et al., 2007). Conversely, 
another study found no difference in DJ-1levels in the serum of PD patients and age-matched 
healthy controls (Maita et al., 2008). It has also been shown that CSF DJ-1 has no correlation 
with disease stage (Waragai et al., 2006).  
Correlation between CSF markers and dopaminergic deficit on Positron Emission 
Tomography (PET) imaging was evaluated in a small study which included eight patients 
with PD secondary to LRRK2 mutation and 18 symptomatic carriers (Shi et al., 2012). They 
found no association between CSF DJ-1 or alpha-synuclein with imaging findings and no 
correlation between the CSF marker levels and disease progression in asymptomatic LRRK2 
carriers (Shi et al., 2012). Others studies have compared salivary DJ-1 levels in PD patients 
and healthy controls and found no significant difference between the two groups (Kang et al., 
2014). Salivary DJ-1 levels were significantly higher in patients with advanced disease (H&Y 
stage 4) compared to earlier stages of the disease and healthy controls (Kang et al., 2014). 
30 
 
The same study also demonstrated a weak correlation between DJ-1 levels and putamen 
(99m)Tc-TRODAT-1 uptake suggesting a potential role of this marker in assessing disease 
progression (Kang et al., 2014). Others authors have shown an increased risk of cognitive 
decline with low plasma epidermal growth factor levels (Chen-Plotkin et al., 2011) suggesting 
a role predicting cognitive decline in PD.  
So far, studies which assessed utility of biological fluids as diagnostic or prognostic markers 
have produced conflicting results. This may be to do with the use of different assays or 
methods for assessing the markers. Standardisation of these assays may provide more reliable 
or uniform results. Another limitation is the small sample sizes used in the studies. Larger 
studies employing standardised techniques are required to confirm or refute usefulness of 
these markers in PD.   
1.6.3. Imaging markers 
 
There has been major progress in imaging biomarker research in PD in the last 20 years. MRI, 
PET, and SPECT imaging techniques have shown promising results as potential biomarkers 
in PD but these tools also have their disadvantages.  
1.6.3.1. Magnetic resonance Imaging in Parkinson’s disease 
 
 Although the role of MRI as a clinical diagnostic tool at present is only limited to excluding 
structural abnormalities, various MRI techniques have been developed, and shown to have 
potential use as biomarkers in PD.  
MRI and iron imaging 
Iron accumulation in the substantial nigra is one mechanism thought to underlie the 
pathological process in PD, by facilitating free radical formation and lipid peroxidation 
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(Griffiths et al., 1999, Dexter et al., 1987). Pathological studies have shown increased iron 
content in the substantia nigra of PD brains compared to non-PD controls (Dexter et al., 1987, 
Griffiths et al., 1999). MRI relaxometry including T2 and T2* weighted images have been 
used to measure iron content in the brain, and on these sequences iron containing structures 
appear hypointense (Lehericy et al., 2012). An increase in T2 relaxation rate (R2) and 
shortening of T2 relation time correspond with increased iron concentration (Wallis et al., 
2008). Studies have shown significantly higher R2 in the substantia nigra of PD patients 
compared to healthy volunteers, which correlated with increased iron content in PD (Graham 
et al., 2000, Ulla et al., 2013). Iron accumulation measured by these MRI techniques also 
correlated with disease severity, suggesting a potential role of MRI as a prognostic marker for 
motor progression (Wallis et al., 2008, Ulla et al., 2013). Nevertheless, other studies did not 
find a similar correlation between disease severity and iron accumulation (Graham et al., 
2000). Susceptibility weighted imaging (SWI) is another technique for estimating iron 
deposition using phase imaging and is dependent on the magnetic susceptibility of tissues 
relative to their surroundings  (Haacke et al., 2004, Zhang et al., 2010). SWI has been used to 
discriminate PD from controls and SWI parameter showed correlation with UPDRS scores 
(Zhang et al., 2010). Another small study used SWI to differentiate PD from MSA patients 
on the basis of higher iron deposition in the putamina of MSA-P patients (Wang et al., 2012b). 
Magnetisation Transfer 
Magnetisation Transfer (MT) improves the differentiation between grey and white matter by 
measuring energy transfer between protons in dense tissues such as myelin and free water 
after MT pulse (Lehericy et al., 2012).  MT ratio (MTR) corresponds to the degree of axonal 
and myelin loss which gives a reflection of the underlying pathology (Lehericy et al., 2012). 
MTR can be abnormal when there are no detectable changes on conventional MRI sequences 
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(Tambasco et al., 2011). MTR has been used in differentiating parkinsonian syndromes but 
other studies showed inconsistent results (Eckert et al., 2004, Tambasco et al., 2003, Hanyu 
et al., 2001). When used to assess brain regions that are affected by the disease in patients 
with different disease severity, Tambasco et al. (2011) reported reduced MTR in the following 
brain regions of all PD patients compared controls: substantia nigra, putamen, parietal and 
periventricular white matter (Tambasco et al., 2011). When PD patients with more advanced 
disease were compared to those with mild disease and controls other brain regions including 
the frontal white matter, lateral thalamus, caudate, and pons were also affected (Tambasco et 
al., 2011). These findings suggest that this technique may be used to track progression of 
neurodegeneration, but this requires further verification in larger studies. 
  
Magnetic Resonance Diffusion Tensor Imaging (DTI) 
Magnetic Resonance DTI is an MRI technique which measures two parameters: mean 
diffusivity (MD), which increases with alterations of microstructures and increase in fluid 
accumulation in the extracellular space, and anisotropy which, measures the ease of diffusion 
of water molecules along white matter tracts (Lehericy et al., 2012). Disruption of neural 
tracts due to any pathology, restricts moment of water molecules, which is reflected by a 
reduction in fractional anisotropy: FA (Brooks, 2010). In MPTP animal model of PD, DTI 
showed increased mean diffusivity (MD) and reduced fractional anisotropy (FA) in the 
substantia nigra compared to control (Boska et al., 2007). A significant correlation between 
dopaminergic cell loss in the substantia nigra and transverse diffusivity was also found (Boska 
et al., 2007). DTI has also been used in human studies to differentiate patients with PD from 
healthy controls and demonstrated significant reduction in substantia nigral FA of PD patients 
(Vaillancourt et al., 2009, Chan et al., 2007, Peran et al., 2010). Vaillancourt et al. (2009) 
reported sensitivity and specificity of 100% in differentiating PD from healthy controls when 
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using 3.0T MRI DTI sequences (Vaillancourt et al., 2009). The study demonstrated reduced 
FA in the middle and caudal part of the substantia nigra with the greatest significance in FA 
of caudal of the substantia nigra (Vaillancourt et al., 2009). This finding corresponds to the 
pattern of regional neurodegeneration in the substantia nigra which has been demonstrated in 
pathological studies (Fearnley and Lees, 1991). In contrast to this, Acquino et al. (2013) 
reported no difference in substantia nigra FA and MD between controls and PD patients 
(Aquino et al., 2013). Also, a recent systematic review and meta-analysis of studies on FA 
and MD in PD showed an increase in MD in substantia nigra and no significant reduction in 
FA  (Schwarz et al., 2013). 
DTI has been used to differentiate PD from atypical Parkinsonism (MSA and PSA) with 90% 
sensitivity and 100% specificity when combining different measures of the technique 
(Prodoehl et al., 2013).  
DTI is a promising diagnostic technique but it has produced inconsistent results across 
different studies. This may be a result of different image analysis techniques and MRI field 
strength used in these studies (Chan et al., 2007, Vaillancourt et al., 2009, Schwarz et al., 
2013).  
The role of MR DTI in preclinical diagnosis has also been explored. Schefler et al. (2011) 
showed reduced FA in the midbrain and rostral pons and increased MD in pontine reticular 
formation of patients with idiopathic RBD compared to control (Scherfler et al., 2011). These 
findings are consistent with the location of brainstem nuclei that may be involved in RBD 
pathogenesis (Scherfler et al., 2011) and RBD is known to precede neurodegenerative 
disorders including PD. Longitudinal studies are now required to provide information on 
whether MRI techniques such as DTI are useful tools in the preclinical diagnosis of PD. 
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Magnetic resonance spectroscopy  
Magnetic resonance spectroscopy (MRS) provides spectral information on different 
metabolites including creatine, N-acetyl aspartate (NAA), choline (Cho), myoinositol, and 
lactate (Lehericy et al., 2012). Levels of metabolites in tissues give an indication of the 
ongoing molecular or metabolic processes in the particular brain region where they are 
measured (Lehericy et al., 2012). The disadvantage of using such a technique in PD is that 
the substantia nigra is small, which causes difficulties in detecting metabolic changes, and 
iron accumulation in the structure interferes with the quality of the data produced on MRS 
(Groger et al., 2011). Use of high field strength is likely to resolve this problem (Zhou et al., 
2014). 
Groger et al. (2011) used 3T MRS to compare substantia nigra metabolic changes between 
PD patients and controls (Groger et al., 2011). The authors reported decreased NAA/Cr ratio 
in the rostral and increased NAA/Cr ratio in caudal substania nigra in PD patients when 
compared to healthy subjects (Groger et al., 2011). Similarly, a recent study which used 3T 
MRS measured the ratio of sum of the NAA and n-acetyl aspartate glutamate concentration 
and Cr (tNAA/Cr) in the substantia nigra of PD patients and compared it to age-matched 
controls and reported lower tNAA/Cr in PD patients at baseline (Seraji-Bozorgzad et al., 
2015). There was a 4.4% decline in the ratio at three months follow up in the PD group but 
this was not seen in the control group, implying a potential role of MRS in assessing 
progression (Seraji-Bozorgzad et al., 2015). Study authors also reported an asymmetry in the 
tNAA/Cr in the substantia nigra of PD patients when the symptomatic and asymptomatic sides 
were compared (Seraji-Bozorgzad et al., 2015). Several other studies have also measured 
NAA/Cr ratios in other brain regions including the motor cortex, (Lucetti et al., 2001), 
temporo-parietal cortex, (Hu et al., 1999) and posterior cingulate cortex (Camicioli et al., 
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2004) and reported lower values in PD patients compared to control groups. The low NAA 
levels suggest neuronal loss and also mitochondrial dysfunction, a potential 
pathophysiological mechanism in PD (Ciurleo et al., 2014). In contrast, Federico et al. (1997) 
did not find any difference in metabolite ratios between PD patients and controls when MRS 
of the lentiform nucleus was performed (Federico et al., 1997). However, they did report 
significant differences between PSP and MSA patients compared to control, (Federico et al., 
1997) implying a potential use of MRS in differentiating between PD and atypical 
Parkinsonism (Federico et al., 1997).  
MRS has also been used to assess the effect of dopaminergic treatments on different 
metabolites and reported conflicting results.  For example, Chaudhuri et al. (1996) reported 
reduced NAA/Cr and NAA/Cho ratio in the putamen of dyskinetic and levodopa treated PD 
patients compared to controls (Chaudhuri et al., 1996). In contrast Ellis et al. (1997) showed 
reduced NAA/Cho in the putamen of untreated PD patients compared to controls but no 
difference in the ratio when levodopa treated PD patients were compared with controls.(Ellis 
et al., 1997) There was no significant difference in NAA/(Cr+ProCr) when PD and control 
groups were compared (Ellis et al., 1997). Ciurleo et al. (2015) measured NAA/Cr and 
NAA/cho and Cho/Cr ratio in the motor cortex of PD patients and controls and reported lower 
NAA/Cr and NAA/Cho ratios in PD patients at baseline. After 10 months of ropinirole 
treatment, PD patients showed a significant increase in NAA/Cr and NAA/Cho ratio which 
correlated with UPDRS motors scores (Ciurleo et al., 2015).  
These findings suggest that MRS may have a potential role in diagnosis, differentiating PD 
from its atypical forms, and in assessing effects of treatment (Ciurleo et al., 2014).   
High field strength MRI 
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Dopaminergic neuron degeneration is difficult to image using MRI techniques currently 
available in routine clinical practice using field strengths up to 3T. Recent small studies have 
shown that MRI sensitivity as a diagnostic tool in PD can be increased if ultra-high field 
strengths are used. Using 7T MRI, Blazejewska and colleagues were able to delineate 
nigrosome 1, a substructure of the substantia nigra pars compacta containing the highest 
density of dopaminergic neurons (Blazejewska et al., 2013). Five nigrosomes make up the 
pars compacta which stain poorly for the protein calbindin D28k,  and Nigrosome 1, which is 
lens shaped, is the largest of these sub-regions (Damier et al., 1999). Blazejewska et al. (2013) 
compared midbrains of 10 PD patients and eight healthy controls using 7T MRI (T2*, and 
MT-T weighted images). They were able to differentiate the two groups based on the presence 
of T2* weighted and MT-T1 hyperintense structure (nigrosome 1) in the dorsal part of the 
substantia nigra pars compacta in healthy controls (figure 5). This area of hyperintensity was 
not seen in PD brains because of increased iron accumulation and loss of dopaminergic 
neurons in the nigrosome 1 (Blazejewska et al., 2013). This was consistent with MRI and 
histology finding which confirmed low neuromelanin and tyrosine hydroxylase levels in the 
nigrosome 1 of the PD brain (Blazejewska et al., 2013). 
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Figure 5: 7T MRI (T2* weighted images) of Parkinson's disease patients versus controls. 
 
 
PD: Parkinson’s disease, HC: healthy control. 
Figure 5 obtained from Blazejewska AI, Schwarz ST, Pitiot A, Stephenson MC, Lowe J, Bajaj N, 
Bowtell RW, Auer DP, Gowland PA (2013) Visualization of nigrosome 1 and its loss in PD: Patho-
anatomical correlation and in vivo 7 T MRI. Neurology 81, 534-540. With permission from Wolters 
Kluwer Health. 
 
Similarly, an area of hyperintensity in the dorsomedial substantia nigra pars compacta was 
seen in controls subjects but not in PD patients in another study, which used 7T MRI brain 
(Kwon et al., 2012). The authors performed a retrospective analysis of MRI data and showed 
that nigrosome 1 could be clearly visualised using 3T MRI and they were able to separate PD 
patients from non-PD controls with high sensitivity and specificity (100% and 90% 
respectively) (Schwarz et al., 2014). A group in Korea performed 7T MRI T2* weighted 
sequences on eight PD patients and eight controls and were able to show morphological 
differences in the lateral border of the substantia nigra between the two groups (Cho et al., 
2011). The authors also measured the distance between the midline (measured from anterior-
posterior line) to the lateral border of the substantia nigra and calculated the ‘sum of absolute 
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differences’ (Cho et al., 2011). A significant difference in this parameter was found when PD 
patients and controls were compared (Cho et al., 2011). One limitation of this study was that 
data analysis was not uniform: the mean sum of absolute difference for the affected side was 
calculated for PD patients, whereas for controls the mean for the right and left size was 
determined (Cho et al., 2011).  
These studies show that ultra-high field MRI has potential for use as a diagnostic tool, but 
studies have been limited by small numbers. In addition, these techniques have been used in 
individuals with well-established disease, therefore utility of these tests in very early disease 
is uncertain. Further work in larger cohorts with early disease is required to confirm these 
findings. 
Using Multiple MRI techniques 
Combining various MRI techniques described above may increase the reliability and utility 
of MRI as a potential biomarker in PD (Peran et al., 2010). In a study which used 3T MR 
imaging including fractional anisotropy and mean diffusivity and R2* sequences, Peran et al 
(2010) reported a high discriminating power exceeding 95% between PD patients and controls 
(Peran et al., 2010). When used in isolation each of the parameters had much lower 
discriminating power (Peran et al., 2010). Similarly, Menke et al. (2009) used driven 
equilibrium single pulse observation of T1 (DESPOT1) which accurately and quickly 
determines relaxation time and DTI on a 3T MR scanner to obtain data for 10 PD patients and 
an equal number of controls (Menke et al., 2009). Combining the two parameters increased 
the sensitivity and specificity of distinguishing PD patients and controls to 100% and 80% 
respectively (Menke et al., 2009).  
In conclusion, MRI in PD is a promising biomarker but the field is still developing. Studies 
using different MRI techniques have shown changes which correspond to pathological 
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processes and structural changes associated with neurodegeneration in PD. Each technique 
has been used to measure different aspects of PD (e.g. iron accumulation, microstructural 
alterations and atrophy), but these techniques remain suboptimal when used in isolation. 
There is a suggestion of increased sensitivity with using multimodal MRI including ultra-high 
field strength. More work is required to validate these techniques before they can be applied 
into routine clinical practice. 
1.6.3.2. Radionuclide imaging in Parkinson’s disease 
 
Role of PET and SPECT as diagnostic biomarker 
As discussed in the section above, PET and SPECT imaging demonstrates striatal 
hypofunction in PD patients but not in healthy controls (Lin et al., 2014, Bruck et al., 2009, 
Rinne et al., 2001, Vermeulen et al., 1995, Booij et al., 1997). But controversy surrounds 
sensitivity of these imaging tools as diagnostic markers in early PD. For example, SPECT 
123I-F-CIT showed dopaminergic deficit in only 87% (n=33) of 38 patients who fulfilled the 
UKPD diagnostic criteria for PD at base line (Benamer et al., 2003). Similarly, in a 
multicentre prospective study (REAL PET study) to compare the progression in dopaminergic 
deficit progression in patients on levodopa and ropinirole using [18F]-DOPA PET, 11.3% of 
the 186 patients had normal [18F]-DOPA striatal uptake and this remained normal in 19 of 
these patients after a 2 year follow up period (Whone et al., 2003). In another large treatment 
trial, 14.7% of patients with a clinical diagnosis of PD had normal B-CIT SPECT and this 
remained unchanged at 4 years (The Parkinson Study Group, 2004). This group of patients 
with an apparent parkinsonian syndrome but no evidence of nigrostriatal deficit are now 
referred to as ‘Scans Without Evidence of Dopaminergic Deficit’ or SWEDDS (The 
Parkinson Study Group, 2004). 150 of the patients who had a clinical diagnosis of PD based 
on the current clinical criteria and normal scans were followed up for 3 years and only 3% 
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retained the initial PD diagnosis and their scans remained normal (Marshall et al., 2006). 
There are two possible explanations for the discrepancy between the clinical and radiological 
diagnosis. It is possible that the SWEDDS were incorrectly labelled as having PD (Marshall 
et al., 2006). Support for this notion comes from results of the PRECEPT study, a RCT trial 
to assess the safety and effect of CEP-1347 as a disease modifying treatment for PD. The trial 
enrolled 806 early PD patients of which 799 had 123β-CIT SPECT performed at baseline 
(Marek et al., 2014). 11% (n=91) of the latter group were SWEDDS (Marek et al., 2014). 72 
of the SWEDDS had follow up scans at 22 months and of these 92% (n=66) remained in the 
SWEDDS category (Marek et al., 2014). In terms of clinical progression, those who had 
abnormal scans at baseline had a greater change in both the total and motor UPDRS scores 
compared to the SWEDDS (Marek et al., 2014). 
A recent systematic review of SWEDDS follow up studies showed that a large proportion 
have diagnoses other than PD, including adult onset dystonia (Erro et al., 2016). This was 
supported by the findings that they had no bradykinesia, similar electrophysiological findings 
to those with other dystonias, no non-motor symptoms, and a lack of progression 
characteristic of PD (Erro et al., 2016). Other conditions such as normal pressure 
hydrocephalus, age-related subtle extrapyramidal signs, essential tremor, fragile X syndrome, 
and depression may also mimic PD (Erro et al., 2016). Alternatively, it is possible that PET 
and SPECT imaging have limited sensitivity in early PD (The Parkinson Study Group, 2004).  
A small proportion (3-6%) of SWEDDs showed clinical progression and have abnormal scans 
on follow up (Marek et al., 2014, Marshall et al., 2006). In addition another study which 
assessed MIBG cardiac uptake in PD patients, SWEDDS and controls identified two 
SWEDDS who showed clinical progression, levodopa responsiveness, had olfactory 
dysfunction, and reduced MIBG uptake (Jang et al., 2013). This finding suggests that this 
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subgroup of SWEDDS patients probably had false negative DAT SPECT imaging, which 
calls into question the sensitivity of dopamine transporter scan in early PD. De La Fuente-
Fenandez (2012) used a mathematical formula to calculate the diagnostic accuracy of DAT 
SPECT imaging in PD and reported similar diagnostic accuracy to that of a clinical diagnosis 
in early and later disease: 84% and 98% respectively (de la Fuente-Fernández, 2012). The 
accuracy of DAT SPECT imaging in detecting degenerative Parkinsonism was assessed using 
post-mortem data and sensitivity and specificity of 85% and 86% was reported (US FDA 
PCNS Advisory Committee Briefing document, 2009). Since the diagnostic accuracy of both 
DAT SPECT and clinical diagnosis in early disease is not 100%, neuropathological 
confirmation is still required to provide a definitive diagnosis.  A more reliable diagnostic 
biomarker for early disease is therefore needed. 
 
Role of PET and SPECT in pre-motor diagnosis 
Radionuclide imaging has also been used to detect premotor PD. Adam et al. (2005) used 
PET tracer [18F]-DOPA and SPECT tracers: 11C- DTBZ and 11C-MP and compared imaging 
findings of 15 family members of a LRRK2 mutation (four symptomatic and 12 
asymptomatic) versus 33 healthy controls and 67 patients with sporadic PD (Adams et al., 
2005). The pattern of SPECT and PET tracer reduction in the sporadic PD group were similar 
to those with symptomatic LRRK2 mutation (Adams et al., 2005). The study also showed 
reduced DBTZ and MP binding in four asymptomatic LRRK2 mutation carriers (Adams et 
al., 2005). Similarly, PET and SPECT abnormalities were reported in asymptomatic LRRK2 
carriers, in another study (Nandhagopal et al., 2008). When compared to healthy controls, two 
of the asymptomatic LRRK2 carriers showed progression in PET findings on follow up 
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assessment, and one of these subjects developed clinical PD (Nandhagopal et al., 2008). These 
findings suggest a potential role of radionuclide imaging in prodromal disease. 
Role of PET and SPECT in the differential diagnosis of PD. 
[123I] FP-CIT has been employed to differentiate PD from essential tremor with sensitivity of 
96.5% and 100% specificity for essential tremor (Benamer et al., 2000). Similarly, Asenbaum 
et al. (1998) reported normal striatal uptake in essential tremor patients and was able to 
separate PD from essential tremor patients with 93% specificity and 100% sensitivity using 
[1231] B-CIT (Asenbaum et al., 1998). Dystonic tremor may be mistaken for the resting tremor 
of early PD, and [123I] FP-CIT has also been used in differentiating the two, by showing 
normal striatal uptake in the earlier group (Schneider et al., 2007). 
In differentiating idiopathic PD from atypical Parkinsonism, SPECT imaging has poor 
sensitivity (Burn et al., 1994, Pirker et al., 2000). The characteristic feature of all these 
parkinsonian syndromes is neuronal degeneration in the substantia nigra. [18F]DOPA and 
[123I]B-CIT imaging reliably discriminates these syndromes from healthy controls by 
demonstrating reduced striatal uptake (Pirker et al., 2000, Burn et al., 1994). However, there 
is no difference in [123I]B-CIT binding between PD and other parkinsonian syndromes (Pirker 
et al., 2000). Although Burn et al. (1994) showed that by using  discriminant function analysis, 
PD patients could be separated from PSP patients 90% of the time using18F-DOPA imaging, 
the study showed that the test was less reliable in differentiating PD from MSA (Burn et al., 
1994). Others have shown that quantification of midbrain [123I]B-CIT uptake improved 
accuracy in discriminating PD from atypical PD (PSP and MSA-P) (Seppi, 2006). In 
conclusion, PET and SPECT have a limited role in differentiating PD from other degenerative 
forms of Parkinsonism. 
Role of PET and SPECT in monitoring disease progression 
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Radionuclide imaging has been used to assess disease progression in several clinical trials 
with conflicting results. As mentioned above, the REAL-PET study used [18F]-DOPAPET to 
assess the rate of disease progression in PD patients treated with ropinirole versus levodopa 
treatment (Whone et al., 2003). Disease progression was measured as the rate of reduction in 
[18F]-DOPA uptake. Results showed that the rate of reduction in tracer uptake was more 
marked in the levodopa treated group compared to ropinirole group implying that levodopa 
treatment increased disease progression (Whone et al., 2003). However, clinical severity 
measures did not correlate with this finding: clinical outcome was better in the levodopa than 
ropinirole treated group (Whone et al., 2003). The Parkinson’s Disease Study Group also 
compared the disease progression measured by rate of reduction in SPECT [123I] B-CIT 
uptake between a subset of PD patients who had levodopa as initial therapy versus 
pramipexole (Parkinson Study Group Datatop Investigators, 2000). Results from the study 
implied a slower disease progression with pramipexole, but again clinical and imaging 
findings were discordant (Parkinson Study Group Datatop Investigators, 2000).  Another 
large multicentre trial, the Earlier versus Late Levodopa therapy in Parkinson’s disease 
(ELLDOPA) assessed the effect of three different doses of levodopa (150 mg, 300 mg and 
600 mg) on UPDRS scores compared with placebo and evaluated the effect of levodopa on 
disease progression using SPECT [123I]B-CIT (The Parkinson Study Group, 2004). Levodopa 
significantly reduced worsening of motor symptoms in a dose dependent manner whereas the 
placebo arm showed progressive deterioration in clinical symptoms during the study period. 
There was a significant reduction in [123I]B-CIT uptake in the levodopa arm compared to 
placebo group (The Parkinson Study Group, 2004). 
Two possible explanations have been put forward to explain the accelerated decline in 
radiotracer uptake with levodopa. Firstly, levodopa accelerates dopaminergic neuron 
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degeneration (Parkinson Study Group Datatop Investigators, 2000, Whone et al., 2003).   
Against this notion, was the finding that levodopa treated patients had better clinical outcomes 
when compared to patients on dopamine agonists and placebo (Whone et al., 2003, Parkinson 
Study Group Datatop Investigators, 2000, The Parkinson Study Group, 2004). In addition 
after drug washout, patients on placebo had a greater clinical deterioration than the levodopa 
group (The Parkinson Study Group, 2004). If levodopa caused neurotoxicity a deterioration 
in symptoms would have been observed after the drug was stopped (The Parkinson Study 
Group, 2004). Secondly levodopa induces DAT down regulation and hence the apparent 
reduction in tracer uptake (The Parkinson Study Group, 2004, Pavese and Brooks, 2009). 
Against this was the observation that the SWEDDS subgroup in the study who were treated 
with levodopa did not show a similar reduction B-CIT uptake (The Parkinson Study Group, 
2004). Nevertheless, there remains controversy as to whether SWEDDS actually have PD. 
[18F]-DOPA PET has also been used to assess survival of embryonic dopaminergic cell 
transplant and its effect on PD symptoms (Freed et al., 2001). [18F]-DOPA studies in these 
patients showed increased tracer uptake confirming graft survival and function, but there was 
no corresponding clinical improvement (Freed et al., 2001). 
 
Limitations of PET and SPECT as biomarker in PD 
PET and SPECT remain valuable diagnostic tools but sensitivity in early disease is not 
optimal. There is also a possibility that symptomatic treatments for PD can regulate DAT 
expression and AADC activity, (Cummings et al., 2011) which potentially interferes with 
radiotracer uptake and therefore the imaging results (Ravina et al., 2005). The utility of PET 
and SPECT in monitoring disease progression and evaluating the effects of treatment remains 
uncertain as the results from clinical trials so far have been inconclusive. These techniques 
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use radioactive ligands and are also more expensive compared to MRI. In conclusion, there 
remains a need for a sensitive and affordable imaging biomarker that can be used for 
diagnosis, following disease progression, and assessing the effects of treatments. 
 
1.7. Treatment 
Although there is no cure for the disease, available symptomatic treatments effectively control 
motor symptoms and improve quality of life (Miyasaki et al., 2002, Ferreira et al., 2013). 
Levodopa is the main precursor in dopamine synthesis and has been the mainstay of treatment 
for 50 years (Lees et al., 2014). Several other drug classes are licenced for use as monotherapy 
in early Parkinson’s disease and/or adjuvant therapy in later disease.  
Levodopa 
Levodopa provides superior benefits in motor function, activities of daily living, and quality 
of life compared with other drug classes (Miyasaki et al., 2002, Stowe et al., 2009, Ferreira et 
al., 2013). Its effectiveness was confirmed in a randomised controlled trial of 361 untreated 
patients given levodopa 150 mg, 300 mg, 600 mg daily, or placebo. The Unified Parkinson’s 
Disease Rating Scale (UPDRS) is the standard investigator-completed outcome measure used 
in Parkinson’s disease trials. After 40 weeks of treatment, total UPDRS scores in the 
levodopa-treated groups remained significantly better than those of the placebo group 
(1.9±6.0, 1.9±6.9, and 1.4±6.9 for levodopa groups respectively and placebo 7.8±9; P<0.001) 
(The Parkinson Study Group, 2004). A more recent large open-label randomised trial (PD 
MED) in early Parkinson’s disease demonstrated a small benefit of levodopa in patient-rated 
quality of life over dopamine agonists and monoamine oxidase-B inhibitors (PDQ-39 
mobility score mean difference 1.8, 95% CI 0.5-3.0, p=0.005; EuroQol EQ-5D mean 
difference 0.03, 95% CI 0.01-0.05, p=0.002)(PD MED Collaborative Group, 2014). Although 
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the predefined minimum clinically important difference (6 points in the PDQ-39 mobility 
section) was not reached, the small benefits from levodopa were still observed at 7 years 
follow up (PD MED Collaborative Group, 2014). Furthermore, study participants on either 
dopamine agonists or monoamine oxidase B inhibitor therapy had a higher probability of 
requiring add-on treatment than those on levodopa only at 2 years (40% , 64%  and 20% 
respectively; P<0.0001) (PD MED Collaborative Group, 2014). Levodopa is the preferred 
drug for patients with significant motor impairment as it provides superior motor benefits 
compared to other treatments (Miyasaki et al., 2002, Ferreira et al., 2013). Levodopa is also 
the first-line treatment in older patients (above 60 years), particularly when there is cognitive 
impairment, as other dopaminergic treatments increase the risk of neuropsychiatric 
complications (Olanow et al., 2009). 
Levodopa is often well tolerated but chronic use is associated with dyskinesias and motor 
fluctuations which include wearing-off phenomenon and unpredictable on/off fluctuations. 
(Stowe et al., 2009, Ahlskog and Muenter, 2001). These occur in up to 40% of patients after 
5 years of treatment (Ahlskog and Muenter, 2001). 
Dopamine agonists 
Dopamine agonists simulate dopamine by binding directly to post-synaptic dopamine 
receptors in the striatum (Olanow et al., 2009). Non-ergot dopamine agonists include orally 
administered pramipexole and ropinirole, along with transdermal rotigotine. Ergot-derived 
dopamine agonists (cabergoline, bromocriptine and pergolide) are associated with heart-valve 
and retroperitoneal fibrosis (NICE guidelines [CG35], 2006). Their use requires frequent 
monitoring for fibrotic complications, so the National Institute for Health and Care Excellence 
guidelines recommend non-ergot dopamine agonists (NICE guidelines [CG35], 2006). 
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Dopamine agonists are used as initial therapy in young patients and those with mild symptoms 
to delay levodopa use and hence the onset of motor complications (Ferreira et al., 2013, 
Olanow et al., 2009). 
The effectiveness of dopamine agonists in ameliorating motor symptoms has been reported 
in several randomised controlled trials and systematic reviews (Ferreira et al., 2013, Stowe et 
al., 2009, NICE guidelines [CG35], 2006, Poewe et al., 2011, Sethi et al., 1998, Watts et al., 
2007). A systematic review which sought to assess the effectiveness and tolerability of 
dopamine agonists in the treatment early PD, included randomised controlled trials (RCTs), 
comparing dopamine agonist to placebo, levodopa or both (Stowe et al., 2009). Results 
showed that dopamine agonists had superior symptomatic effects when compared to the 
placebo (Stowe et al., 2009). Fewer motor complications were reported in the dopamine 
agonist treated groups compared to levodopa: motor fluctuation [Odds ratio (OR) 0.75, 95% 
CI 0.63-0.90; p=0.02] and dyskinesias [OR 0.15, 95% CI 0.43 -0.59; p< 0.00001], but 
levodopa showed greater improvements in symptoms control (Stowe et al., 2009).  
In addition to their use in early disease, dopamine agonists have also been shown to be 
effective adjuncts to levodopa in advanced disease (LeWitt et al., 2007, Pahwa et al., 2007, 
Schapira et al., 2011). Dopamine agonists also provide greater motor control when compared 
to other adjuvant therapies in advanced PD (Stowe et al., 2011). For example UPDRS scores 
improved by 4.8, 2.9, and 2.0 points in patients treated with dopamine agonists, MAOBI and 
COMTI respectively, p<0.001 (Stowe et al., 2011). 
A major issue facing clinicians, is the management of impulse control disorders which occur 
in approximately 14% of dopamine agonist-treated people (Weintraub et al., 2010). These 
include hyper-sexuality, pathological gambling, excessive shopping, and excessive eating 
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(Weintraub et al., 2010, Weintraub et al., 2015). In a cross sectional study of 3090 idiopathic 
Parkinson’s disease patients, these disorders were more common in dopamine agonists-
treated than patients not on dopamine agonists (17% versus 6.9% P<0.001), (NNH -10) 
(Weintraub et al., 2010). Other impulse control behaviours which occur with levodopa and 
apomorphine include punding (frequency: 1.4-14%), where patients perform repeated, 
pointless actions such as sorting or disassembling objects, and the dopamine dysregulation 
syndrome, which is characterised by a compulsion to overuse dopaminergic medication 
(Weintraub et al., 2015).  
 
Monoamine oxidase B inhibitors (MAOBI) 
 MAOBI are recommended first line treatment in those with mild symptoms, and are also 
used as adjuncts to levodopa in advanced disease (NICE guidelines [CG35], 2006). MAOBI 
(rasagiline and selegiline) selectively inhibit monoamine oxidase type B enzyme which 
metabolises dopamine and thus increase dopamine availability (Olanow et al., 2009).  
A systematic review of the efficacy of MAOBI in early Parkinson’s disease demonstrated a 
small but significant improvement in UPDRS motor scores with MAOBI compared to placebo 
(mean weighted decrease in UPDRS motor scores 3.79 points in favour of MAOBI; 95% CI 
-5.30, -2.27; P<0.00001) (Macleod et al., 2005).  
In a systematic review, more participants in the MAOBI group required add-on therapy 
compared to levodopa and dopamine agonist-treated groups (OR 12.02, 95% CI 6.78-21.31; 
P< 0.00001 and OR2, 95% CI 1.05-3.81; p=0.04, respectively) (Caslake et al., 2009 ). When 
compared to placebo, MAOBI adjunctive therapy in advanced PD led to a significant 
reduction in off time compared to placebo: -0.93 hours/ day, 95% CI -1.25, -0.62; p<0.00001) 
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(Stowe et al., 2010). MAOBI use, also resulted in greater mean daily levodopa dose reduction: 
29.11mg/day (95% CI -43.18, -15.04; p<0.00001) (Stowe et al., 2010). 
Catechol-o-methyl transferase inhibitors (COMTI) 
COMTI such as tolcapone and entacapone inhibit the enzyme COMT which metabolises 
dopamine and thus increase the plasma levels of levodopa (Mizuno et al., 2007). Entacapone 
is a peripheral inhibitor of COMT, whereas tolcapone is thought to have central effects 
(Olanow et al., 2009). COMTI are used as adjunctive treatment to levodopa in advanced 
disease (Olanow et al., 2009) when motor fluctuations have developed. A Cochrane review 
compared COMTI and placebo and showed significant improvements in UPDRS motor 
scores, reduction in off- time and daily levodopa requirements when COMTI were used as an 
adjunct to levodopa:-2.02 points, 95% CI -2.68, -1.37; p<0.00001,  -0.83hours/day, 95% CI -
1.04, -0.62; p<0.00001), and 52.07mg/day, 95% CI -61.09, -43.05; p<0.00001) respectively 
(Stowe et al., 2010). Side effects which are common to all dopaminergic drugs, such as 
nausea, vomiting, somnolence, hallucinations, and hypotension, can occur with COMTI 
treatment. In addition urine discoloration has only been reported with COMTI treated patients 
(Stowe et al., 2010). 
Recently, a new COMTI, opicapone, has been licenced for use as adjuvant therapy in 
advanced PD. Opicapone increases levodopa bioavailability and its efficacy and safety was 
shown in an RCT (Ferreira et al., 2015). Another study to assess the safety and efficacy of 
opicapone demonstrated tolerability, reduction in off-time, and increase in on-time without 
troublesome dyskinesias, in patients treated with opicapone 50 mg when compared to placebo 
(Ferreira et al., 2016). In the same study, opicapone 50 mg was non-inferior to entacapone 
but had superior effects when compared to placebo (Ferreira et al., 2016). In addition to 
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dopaminergic side effects, entacapone can cause diarrhoea and tolcapone can potentially 
cause liver toxicity and therefore requires regular monitoring of liver function when the 
treatment is initiated (Ferreira et al., 2013). Opicapone has the advantage of a once daily 
dosing, so far has not shown any effects on liver function, and does not cause urine 
discoloration (Ferreira et al., 2016). 
Advanced disease treatments 
Pulsatile stimulation of striatal dopaminergic receptors by the short acting levodopa, is 
thought to be the mechanism by which motor complications occur (Olanow et al., 2009).   
When motor fluctuations become refractory to oral therapies, in advanced PD, treatments such 
as apomorphine, levodopa intestinal gel, and subthalamic nucleus (STN) deep brain 
stimulation (DBS) are considered. These treatments provide continuous dopaminergic 
stimulation, (Olanow et al., 2006) and allow a reduction in oral medications which may reduce 
dyskinesias. Factors such as patient’s age, disease duration, the presence of cognitive 
impairment, speech difficulties, and patient preference need to be taken into consideration 
before choosing any of these three treatments (Volkmann et al., 2013). Younger patients 
probably attain greater benefits from STN- DBS compared to older patients above the age 70 
years, but levodopa infusion is effective in both groups, and is also is tolerated well by older 
patients, even those with mild cognitive impairment (Volkmann et al., 2013). Tolerability of 
apomorphine in the latter group is uncertain (Volkmann et al., 2013). DBS is contraindicated 
in individuals with cognitive impairment and depression (NICE guidelines [CG35], 2006). 
Apomorphine is a short acting dopamine agonist which is commonly given subcutaneously, 
either as intermittent injections (rescue therapy for off-episodes), or as continuous infusion 
though a syringe driver during the waking day (Clarke et al., 2009, Volkmann et al., 2013). 
Subcutaneous apomorphine has a rapid onset of action, and is also advantageous in that it 
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bypasses first pass metabolism, and when given as an infusion allows steady plasma and 
central nervous system levels to be reached (LeWitt, 2004). A recent phase two double blind 
RCT which compared subcutaneous apomorphine to placebo in advanced PD, included 16 
patients from four Japanese institutions (Nomoto et al., 2015). When baseline and 20-minute 
post-treatment UPDRS scores where compared, patients treated with apomorphine had a 
significantly greater change in UPDRS motor scores compared to the placebo group: -24 vs -
4.1; p<0.002 (Nomoto et al., 2015). Further evidence for use of apomorphine is from small 
non-controlled studies. From these, a 44% median reduction in off time, and 40% increase in 
on-time without dyskinesias (Volkmann et al., 2013), and improvement in UPDRS motor 
scores was also reported (Clarke et al., 2009). Side effects include sedation, nausea, injection 
site reactions and neuropsychiatric symptoms e.g. confusional states, psychosis, 
hallucinations, and impulse control disorders (Volkmann et al., 2013, Clarke et al., 2009). 
Levodopa gel is administered as a continuous infusion into the jejunum or duodenum, via a 
gastrostomy tube connected to a portable infusion pump (Clarke et al., 2009). This reduces 
erratic absorption which can occur when levodopa is given orally. Levodopa infusion was 
shown to be superior to oral therapies and improved both UPDRS scores and patient quality 
of life in a randomised controlled study (Nyholm et al., 2005). A more recent multicentre 
randomised placebo controlled trial also showed similar improvements in patients with 
advanced PD (Olanow et al., 2014).The study randomised 71 patients to either levodopa-
carbidopa 25/100mg capsules and placebo levodopa-carbidopa infusion gel or placebo 
levodopa capsules and levodopa-carbidopa infusion gel, and followed up the patients for 12 
weeks (Olanow et al., 2014). Study results showed a significant reduction in off-time (-
1.91±0.57 hours; p=0.0015) in the active levodopa infusion gel arm compared to active oral 
levodopa-carbidopa arm. ‘On’ time without dyskinesias was also significantly better with 
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active levodopa infusion compared to oral levodopa-carbidopa treatment: 2.2±0.90hours; 
p=0.0142 (Olanow et al., 2014).  A review of levodopa infusion studies also demonstrated a 
reduction in off-periods by 40-80%, dyskinesias by 60-90%, and also beneficial effect on non-
motor symptoms (Volkmann et al., 2013). Dopaminergic side effects including confusion, 
somnolence, dyskinesias, agitation, were reported, but these were more frequent in the oral 
therapy group (Nyholm et al., 2005). Continuous levodopa infusion strategy provides steady 
plasma levodopa levels, hence constant striatal dopamine levels, which prevents pulsatile 
dopaminergic stimulation, a potential mechanism by which motor complication develop 
(Olanow et al., 2006). 
Bilateral STN DBS involves electrical stimulation of the subthalamic nuclei via electrodes 
inserted stereo-tactically and connected to a neurostimulator implanted in a subclavicular 
pocket (Clarke et al., 2009). There is good quality evidence to support use of DBS in the 
management of advanced PD. RCTs have demonstrated DBS superiority over medical 
therapies in terms of motor scores and quality of life in patients with advanced PD (Williams 
et al., 2010, Deuschl  et al., 2006, Weaver et al., 2009). In a literature review including class 
one (RCT of good quality, providing the highest level of evidence) to class three (case-
control) studies, Volkmann et al. (2013) reported 30-60% improvement in UPDRS motor 
scores, reduction in off time (median 68%), and increase in on time (median 71%), in patients 
treated with STN DBS (Volkmann et al., 2013). There was also a reduction in dyskinesias in 
those treated with STN DBS (Volkmann et al., 2013).  
There have been no direct head-to-head RCTs of advanced disease therapies. An un-
randomised observational study of the three treatments suggested that STN DBS provided 
better motor control and no dyskinesias, whereas patients on levodopa gel had good motor 
control but with mild to moderate dyskinesias (Elia et al., 2012). The apomorphine group had 
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the worst motor scores when compared to STN DBS and levodopa gel groups (Elia et al., 
2012). STN DBS may also improve non-motor symptoms as shown in a recent study which 
demonstrated significant reduction in both clinician and patient rated non-motor symptoms 
scores (Dafsari et al., 2016). Side effects reported in the RCTs included depression, gait 
disturbances, procedure related adverse effects including infection, intracranial bleed, and 
lead migration (Deuschl  et al., 2006, Weaver et al., 2009). 
Rehabilitation  
In the UK, NICE guidance recommends that all patients with PD should have access to 
occupational therapy, physiotherapy and speech and language therapy (NICE guidelines 
[CG35], 2006). These therapies are aimed at helping patients maintain their independence, 
support them to adapt to changes and disability that occur as the disease progresses, (Dixon 
et al., 2007), and also improve quality of life. Available evidence suggests that effectiveness 
of these therapies may be limited. For example a review which assessed effectiveness of 
occupational therapy in PD reported small benefits (Dixon et al., 2007). Results were 
inconclusive since the included studies were limited by small sample sizes and 
methodological flaws (Dixon et al., 2007).  
A systematic review included 39 RCTs which compared physiotherapy to no intervention 
reported a significant improvement in walking speed, freezing of gait, timed up and go test, 
functional reach test, balance, and UPDRS motor and ADL scores, in the physiotherapy group 
(Tomlinson et al., 2013). Physiotherapy had no effect on falls rate, quality of life, and mobility 
as measured by the PDQ-39 (Tomlinson et al., 2013). Another systematic review and meta-
analysis which included only eight RCTs, assessed the effect of physiotherapy techniques 
such as aerobics, stretching, treadmill walking, and stretching exercises on balance and 
postural instability (Yitayeh and Teshome, 2016). When using the falls efficacy scale, a 6.7, 
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95% CI, -14, 0.54; p=0.07 reduction in the incidence of falls with physiotherapy, was 
demonstrated but this did not reach statistical significance (Yitayeh and Teshome, 2016). 
Combining balance training and other physiotherapy techniques improved balance and 
postural instability (Yitayeh and Teshome, 2016).  Further, a recently published RCT which 
included 762 patients with mild to moderate PD compared the effectiveness of individualised 
physiotherapy and occupational therapists versus no therapy on quality of life (QOL) and 
activities of daily living (ADL).(Clarke et al., 2016). The primary outcome was the change in 
NEADL score at three months and secondary outcomes included QOL measured by the 
PDQ39. This study showed no significant benefit of these therapies in patients with mild to 
moderate PD (Clarke et al., 2016). 
A Cochrane review included six RCTs, which assessed two different types of speech and 
language therapy interventions (Herd et al., 2012). Interventions compared in these studies 
included the standard Lee Silverman Voice therapy (LSVT-LOUD), its modified version 
LSVT-ARTIC, and respiration therapy (Herd et al., 2012). Methods of delivering LSVT were 
also compared: face to version versus online delivery. Results of these studies showed greater 
improvements in loudness: 5dB, 95% CI -8.3,-1.7; p=0.003, 5.5dB, 95% CI 3.4, 7.7; 
p<0.00001, and voice monotonicity (0.45 semitones, 95% CI 0.01, 0.93; p=0.04), in patients 
treated with LSVT-LOUD compared to respiration therapy (Herd et al., 2012).  When LSVT-
LOUD and LSVT-ARTIC were compared, the earlier group demonstrated greater 
improvements in speech intelligibility (Herd et al., 2012). The review also showed non-
inferiority of online LSVT delivery compared to face-face intervention. Definitive 
conclusions on the effectiveness of a speech and language therapy techniques over another 
could not be drawn from this review due to the limited number of studies with large sample 
sizes (Herd et al., 2012). 
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There is evidence to suggest that multidisciplinary care results in better patient outcomes. A 
randomised controlled trial included 122 PD patients, and randomly assigned them to either 
multidisciplinary team care or general neurologist care (Van der Marck et al., 2013). The 
primary outcome was a change in quality of life at 8 months follow up, measured by the PDQ 
39. The change in UPDRS motor subscale was also measured as a secondary outcome. Study 
authors reported an improvement in quality of life from baseline in the intervention group 
(Van der Marck et al., 2013). There was a significant difference in the change in PDQ-39 
summary index scores between intervention and control group 3.4, 95% CI 0.5-6.2; P= 0.02) 
(Van der Marck et al., 2013). The study also showed an improvement in UPDRS motor scores 
in the intervention group, which was significantly different from the control group: 4.1points 
95% CI 0.8-7.3; p=0.01) (Van der Marck et al., 2013). Multidisciplinary teams should include 
specialists who can deal with the various motor and non-motor aspects of the disease, which 
may not respond to dopaminergic therapies. Team members may include a PD specialist 
(neurologist or geriatrician), PD nurse specialist, psychiatrist, speech and language therapist, 
physiotherapist, occupational therapist, dietician, social worker, and a urologist (van der 
Marck et al., 2009). In advanced stages of the disease a palliative care consultant may be 
required to manage the terminal aspects of the disease. In the UK the PD nurse specialists 
have a crucial coordinating role among the team members and also act as the first point of 
contact for the patient in both the community and secondary care. The effectiveness of PD 
nurse specialist nurses in PD management was assessed in an RCT which demonstrated better 
patient well-being, with no added costs, when PD nurses were involved in PD care (Jarman 
et al., 2002). The study compared costs, patient well-being (measured by PDQ39, Euro-QOL, 
global subjective wellbeing questionnaire), and health outcomes (mortality, fracture rates, 
stand up test, dot in square test) in patients receiving care from a general practitioner versus 
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PD nurse specialist care (Jarman et al., 2002). After a two year follow up period, there were 
no differences in the measured health outcomes, costs, and patient well-being between the 
two groups. But, when global subjective well-being scores were compared between the two 
groups, patients receiving care from the PD nurse specialist had better scores: mean difference 
-0.23, 95% CI -0.4,-0.06; p=0.008 (Jarman et al., 2002). 
 
 
1.8. Hospitalisation in Parkinson’s disease 
1.8.1. Background 
 
Since there is no cure or disease modifying treatment for PD at present, progressive 
neurodegeneration occurs resulting in worsening of motor and non-motor symptoms 
overtime. Disability due to worsening symptoms ensues with advancing disease (Gershanik, 
2010). When gait and postural instability develops complications such as fall as fractures 
become more frequent (Gershanik, 2010). Although symptomatic treatments for the disease 
have been shown to improve functional independence and quality of life of patients, (Olanow, 
2008) side effects may become problematic especially when treatment regimens become 
complicated in advanced disease. Long-term levodopa use causes motor complication such 
as dyskinesias and on and off fluctuations in up to 80% of patients after 5-10 years 
(Bhidayasiri and Truong, 2008). Such complications add to the disability which occurs with 
advancing disease and also impair quality of life (Gershanik, 2010). Other side effects of 
dopaminergic medications include drowsiness, dizziness, postural hypotension, and 
hallucinations (Stowe et al., 2011). In addition to these problems, non-motor symptoms of the 
disease such as depression and dementia, dysautonomia, dysphagia and speech difficulties 
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progress with time and increase the patient’s reliance on others for assistance with activities 
of daily living (Gershanik, 2010) and may result in institutionalisation. 
It is therefore not surprising that the use of healthcare resources and hospitalisations increase 
with advancing disease. The resulting economic burden is substantial (Low et al., 2015). In 
the UK, the annual cost of the disease was estimated to be approximately £49 million per 
annum (Findley, 2007). A cross sectional survey demonstrated that the highest proportion of 
direct costs for the disease were from NHS cost (38%) followed by social services 35% 
(Findley et al., 2003). Increasing disease severity and patient age were associated with higher 
disease costs (Findley et al., 2003). PD drug costs, rehabilitation (Dodel et al., 1998, Von 
Campenhausen et al., 2011), loss of employment, and early retirement due to the disease also 
contributes to indirect disease costs (Von Campenhausen et al., 2011, Dodel et al., 1998, 
Guttman et al., 2003). In other studies, inpatient care and institutionalisation were shown to 
be the main drivers for direct health care costs (Huse et al., 2005, Findley, 2007, Dodel et al., 
1998).  
When compared to age matched counterparts with other diseases, PD patients have higher 
hospitalisation rates (Guttman et al., 2003, Hobson et al., 2012). In one study, PD patients 
were 1.45 times more likely to be hospitalised than age matched controls without PD 
(Guttman et al., 2003). Similarly, another study showed that patients with PD utilised 
healthcare resources more than their counterparts without the disease: median utilisation of 
controls versus PD patients for emergency room visits (0.6 versus 0.4 p=0.05) and physician’s 
visits (5.9 versus 7.9, p=0.001), respectively (Parashos and O'Brien, 2002, Huse et al., 2005). 
Further, a retrospective study which included 1 469 PD cases and 2 439 controls reported 
higher healthcare resource utilisation including hospitalisation and physician visits among PD 
patients compared to the reference group (Hobson et al., 2012). 
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Once admitted to hospital, PD patients are 2.05 times more likely to have a repeat 
hospitalisation (Hassan et al., 2013). Disease duration, cognitive impairment, drug induced 
psychosis, and co morbidities were shown to increase the risk of readmission to hospital 
(Hassan et al., 2013, Klein et al., 2009).  
1.8.2. What are the reasons for PD patient hospitalisation? 
 
Several factors account for increased hospitalisation in PD. In as many as 50% of cases, the 
reason for emergency hospital admissions can be linked to the disease (Martignoni et al., 
2004).    
Falls 
Falls and fractures account for 13-17% of PD hospital admissions (Temlett and Thompson, 
2006, Woodford and Walker, 2005, Tan et al., 1998). A strong association between falls and 
the rate of hospital encounters has been reported (Hassan et al., 2013, Klein et al., 2009). Falls 
tend to occur more frequently in PD patients compared to the general population (Wood et 
al., 2002). A falls incidence as high as 68% was reported in one prospective study among 109 
PD patients (Wood et al., 2002).  
Several factors explain the increased risk of falls seen in patients with PD. These include old 
age, cognitive impairment, and disease severity (Wood et al., 2002, Contreras and Grandas, 
2012, Wielinski et al., 2005, Kerr, 2010, Allcock et al., 2009). Tan et al showed that 49% of 
PD patients who fell had Hoehn and Yahr (H&Y) stage 4 disease (Tan et al., 1998).  When 
PD patients progress to H&Y 3 postural instability and balance impairment emerges which 
often results in the increased risk of falls (Contreras and Grandas, 2012, Tan et al., 1998). 
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Cholinergic degeneration may also play a part in the causation of falls in PD as demonstrated 
by PET studies (Bohnen et al., 2009).  PD patients with falls had reduced cortical and thalamic 
cholinergic activity compared to controls and PD non-fallers (Bohnen et al., 2009). In 
addition, another study reported a significant correlation between balance and gait instability 
with a reduction in acetylcholinesterase activity (Gilman et al., 2010).  PD fallers were found 
to have worse cognitive scores which suggests that cognitive impairment may contribute to 
the risk of falling (Wielinski et al., 2005, Wood et al., 2002). A small study including 22 PD 
patients demonstrated a correlation between greater postural instability and cognitive 
performance (Nocera et al., 2010). Allcock et al. (2009) also showed an association between 
attention scores and increased frequency of falling (Allcock et al., 2009).  
 In advanced PD, treatment related motor fluctuations and freezing episodes may also increase 
the risk of falls (Wood et al., 2002). An association between use of high doses of levodopa, 
COMTI, cholinesterase inhibitors and neuroleptics with falls, was reported in a retrospective 
study (Contreras and Grandas, 2012). This finding may be attributed to treatment 
complications such as dyskinesias or on and off fluctuations. These treatments are used in 
advanced disease and the apparent association may reflect a group of patients who are at a 
higher predisposition to falls due to other disease related factors such as postural instability 
and cognitive impairment. Dopamine agonists have also been implicated in the causation of 
falls, and postulated mechanisms include sudden onset of sleep and freezing episodes 
(Allcock et al., 2009), and postural hypotension.  
Consequences of falls in patients with PD can be significant. Injuries including lacerations 
and fractures occur and these often result in hospitalisation (Contreras and Grandas, 2012, 
Tan et al., 1998). In one retrospective study examining falls risk factors, frequency, and 
injuries in 1092 PD patients, 54.6% (n=597) of the patients reported a fall. 65% of these 
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sustained an injury of which 33% were fractures and 75.5% required health care resource use 
as a result of the fall (Wielinski et al., 2005).  
Fractures 
Fractures are common in patients with PD compared to age-matched controls (Genever et al., 
2005, Walker et al., 2013, Di Monaco et al., 2006, Bhattacharya et al., 2012). Hip fractures 
are by far the commonest site of fracture in these patients (Genever et al., 2005, Wielinski et 
al., 2005). In individuals above the age of 60 years, the incidence of hip fractures in PD 
patients was shown to be six times higher than in controls without the disease (Walker et al., 
2013). 
Falls are a significant risk factor for fractures in PD. Low bone mineral density is reported in 
PD patients, (Van den Bos et al., 2013a, Schneider et al., 2008, Sato, 1997, Taggart and 
Crawford, 1995) and increases the risk of fractures (Schneider et al., 2008). A recent meta-
analysis of studies relating to osteoporosis and bone mineral density in PD pooled results 
from15 studies and reported lower bone mineral density in PD patients compared to the 
general population (OR 1.18, 95% CI 1.09-1.27; p=0,036) (Zhao et al., 2013). Bone density 
has also been shown to correlate inversely with disease duration and H&Y stage(Di Monaco 
et al., 2006), which may also explain the increased risk of fracture with advancing disease. 
Low vitamin D levels, weight loss, and immobility (Van den Bos et al., 2013a, Sato, 1997) in 
PD may explain why PD patients develop low mineral bone density and osteoporosis. 
Pneumonia 
Pneumonia is also another common reason for hospitalisation in PD. A retrospective study to 
assess the reasons for PD admissions to an Australian large teaching hospital reported 761 PD 
admissions over a 5 year period (Temlett and Thompson, 2006). Among the admissions where 
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PD was recorded as a secondary diagnosis (n=645), 12% had pneumonia recorded as the 
primary reason for admission (Temlett and Thompson, 2006). Similar figures were reported 
in a UK study where 11% of the PD admissions were due to pneumonia (Woodford and 
Walker, 2005). Another large retrospective study which evaluated reasons for non-elective 
PD admissions in England using the Hospital Episodes statistics (HES) data showed that 14% 
of the 232 905 non-elective PD admissions were for pneumonia (Low et al., 2015). 
Various non-motor and motor features of PD increase the predisposition to lower respiratory 
infections. Swallowing and the cough reflex provide important protective mechanisms for 
preventing aspiration and consequently, respiratory tract infection (Melo and Monteiro, 
2013). In PD, up to 35% of patients complain of swallowing difficulties and this correlates 
with disease severity (D'Amelio et al., 2006, Kalf et al., 2012). Several potential mechanisms 
for how dysphagia develops in PD have been proposed. Firstly, akinesia and rigidity of the 
pharyngeal muscles as a direct consequence of dopaminergic neuron degeneration in the 
substantia nigra has been put forward as the main explanation for swallowing in PD (Mu et 
al., 2012). Since PD dysphagia does not respond to dopaminergic therapy, it is likely that 
other mechanisms contribute to dysphagia in PD (Melo and Monteiro, 2013). Histochemical 
and histological studies of pharyngeal muscles of autopsied PD patients and controls found 
evidence of muscle fibre denervation, atrophy, and abnormal distribution of fibre type in PD 
patients compared to controls (Mu et al., 2013b). When PD patients with dysphagia were 
compared to their unaffected PD counterparts, those with dysphagia were found to have more 
atrophied myofibrils (Mu et al., 2012). Peripheral denervation due to alpha-synuclein 
deposition may also contribute to the pathophysiology of dysphagia in PD (Mu et al., 2012). 
Alpha-synuclein deposition has been demonstrated in the sympathetic ganglia, 
gastrointestinal tract enteric plexus, vagus nerve (Beach et al., 2010, Braak et al., 2006, Mu 
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et al., 2013b), and in both sensory and motor nerves of the pharyngeal musculature. (Mu et 
al., 2013a). 
Swallowing problems result in pooling of saliva which further increases the risk of aspiration 
pneumonia (Nobrega et al., 2008, Chou et al., 2007). PD patients also experience silent 
aspiration and laryngeal penetration which contribute to the risk of respiratory tract infections 
(Nobrega et al., 2008, Rodrigues et al., 2011). Airway penetration has also been demonstrated 
in 22% of PD patients without any swallowing complaints (Monteiro et al., 2014). 
The cough reflex aids in the removal of mucus and other foreign bodies from the airways and 
impairment of this reflex may contribute to the risk of respiratory infections in several 
conditions including PD (Ebihara et al., 2003, Hammond, 2001). Cough efficacy is also 
impaired in PD patients with both early and advanced disease when compared to controls, 
(Ebihara et al., 2003) which may contribute to the high risk of respiratory tract infection in 
PD. Respiratory dysfunction in PD is frequent but patients are often asymptomatic (Sabaté M 
et al., 1996, Pal et al., 2007). An association between swallowing impairment and respiratory 
dysfunction has been reported (Monteiro et al., 2014). Coordination of the respiratory cycle 
and swallowing is important in facilitating safe swallowing (Gross et al., 2008). In a normal 
state, the sequence of events between swallowing and respiration starts with inspiration 
followed by deglutition apnoea, then post-swallow expiration, and this is thought to form a 
protective mechanism which prevents airway aspiration (Selley et al., 1989, Martin-Harris et 
al., 2003). When compared to healthy controls, PD patients were reported to swallow during 
inhalation and were more likely to inhale after swallowing increasing the risk of aspiration 
(Gross et al., 2008). 
Urinary tract infection (UTI) 
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Urinary dysfunction is a key non-motor manifestation of PD, occurring in up to 39% of PD 
patients (Campos-Sousa et al., 2003). Symptoms range from urinary incontinence, urgency, 
nocturia, and frequency with the latter two symptoms being the most commonly reported 
(Campos-Sousa et al., 2003). Urinary dysfunction especially detrusor hyperactivity in PD may 
be related to the loss of inhibitory effect on the micturition reflex which occurs as a result of 
dopaminergic neurons in the substantia nigra (Cersosimo et al., 2013, Yeo et al., 2012). 
Presence of alpha-synuclein in the autonomic ganglia, is another plausible pathogenic 
mechanism for these symptoms in PD (Beach et al., 2010). Urinary incontinence in PD may 
be exacerbated by mobility problems in advanced disease. One study showed that urinary 
incontinence was associated with an increased risk of hospitalisation and admission to nursing 
homes (Thom et al., 1997). The association persisted after adjusting for age and the presence 
of several comorbid conditions (Thom et al., 1997). UTI is amongst the commonest reasons 
why PD patients attend the emergency department, occurring in up to 20% (Tan et al., 1998, 
Guneysel, 2008), and is a frequent complication in those who are hospitalised (Martignoni et 
al., 2004). With progression of motor disability, PD patients become increasingly immobile 
which can lead to urinary stasis, bacterial proliferation and UTI (Rogers et al., 2008). The link 
between poor mobility and UTIs was shown in a retrospective study which explored the risk 
factors for hospitalisation for UTI (Rogers et al., 2008). Authors assessed records of 408 192 
elderly subjects who were admitted to skilled nursing facilities in five states in the USA.  89 
538 were eventually admitted to hospital and of these patients, 4.4% (n= 3 961) were admitted 
for urinary tract infections (Rogers et al., 2008). Ability to walk conferred a significant 
reduction in hospitalisation due to UTI: 69% reduction in risk of hospitalisation in those who 
walked independently, and 45% in those who required either supervision or limited assistance 
(Rogers et al., 2008). In this study the presence of other chronic medical conditions including 
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PD, dementia, diabetes mellitus, renal failure and stroke, and indwelling catheters were some 
of the factors that were associated with an increased risk for hospitalisation for UTI (Rogers 
et al., 2008).  
Problems related to blood pressure (postural hypotension and syncope) 
Postural hypotension is a common non-motor symptom in PD occurring in up to 
approximately 30% of patients (Velseboer et al., 2011). The frequency of symptomatic 
orthostatic hypotension (OH) increases with advancing disease and disease duration and age 
(Ha et al., 2011). Postural hypotension may occur as a result of sympathetic denervation in 
PD. Dopaminergic medication may also exacerbate OH and in the elderly patients, multiple 
comorbidities and use of other medications such as antihypertensives and diuretics can also 
exacerbate OH (Mussi et al., 2009). Patients with OH complain of dizziness, light headedness, 
fatigue, and even syncope on standing up from a supine or sitting position (Ha et al., 2011, 
Jamnadas-Khoda et al., 2009) due to central nervous system hypoperfusion (Mussi et al., 
2009). Postural hypotension is associated with an increased risk of falls and consequently, 
serious injures such as fractures and head trauma ((Lahrmann et al., 2006). Up to 50% of 
patients with OH do not have symptoms and this may also increase the risk of falls (Jamnadas-
Khoda et al., 2009)(Jamnadas-Khoda et al., 2009), which may lead to hospitalisation in PD.  
Neuropsychiatric symptoms 
Anxiety, depression, psychosis, and cognitive impairment are common in PD, with up to 71% 
of patients reporting at least one symptom (Riedel et al., 2010). The majority of these 
symptoms can be managed in the outpatient department, but when severe and carers are 
unable to cope, hospitalisation may be warranted.  Klein et al. (2009) showed that amongst 
143 PD patients who contributed to 243 admissions to a neurological unit, 24% of the 
admissions were due to psychosis (Klein et al., 2009). Medication-related psychosis was the 
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most significant factor contributing to repeated admissions (Klein et al., 2009). In a survey of 
National Parkinson Foundation (NPF) centres, up to 63% of the international centres and 49% 
of US NPF centres reported that that would admit patients for behavioural management (Chou 
et al., 2011). 
Other reasons for PD hospitalisation 
10-37% of PD hospital admissions are primarily for management of motor symptoms of PD 
(Tan et al., 1998, Temlett and Thompson, 2006, Klein et al., 2009). Infection of deep brain 
stimulation leads, battery replacement and adjustment of DBS settings also increase the risk 
of hospitalisation in PD (Hassan et al., 2013). Gastrointestinal, cardiovascular disorders, 
(Temlett and Thompson, 2006, Woodford and Walker, 2005) and cerebrovascular 
emergencies (Guneysel, 2008) also lead to hospitalisation in PD. Marakoff et al. (2011) 
showed that PD patients who had gastrointestinal disorders were 1.42 times more likely to 
visit the emergency rooms and higher total health care costs compared to those without these 
symptoms (Makaroff et al., 2011)(Makaroff et al., 2011). A small proportion of PD patients 
are admitted electively for DBS surgery, rehabilitation, and confirmation of diagnosis (Chou 
et al., 2011).  
1.8.3. PD hospitalization outcome 
 
When patients with PD present to the emergency department and are hospitalised, the 
outcome is often poor. Patients have prolonged hospital stays up to 1.19 times longer than 
controls (Guttman et al., 2003). Another study estimated that PD patients spend 2 more days 
longer in hospital per year (Huse et al., 2005). They are often discharged to rehabilitation 
units and a high rate of institutionalisation has been reported (Parashos and O'Brien, 2002, 
Tan et al., 1998). This adds to the huge burden of care associated with the condition and also 
66 
 
impairs the quality of life. Low et al. (2015) reported high mortality in PD patients during 
hospitalisation when compared to controls (OR 2.46, 95% CI 2.42, 2.49; p<0.00001 (Low et 
al., 2015). 
In hospital, PD patients are often looked after by teams other than their own PD specialists, 
(Gerlach et al., 2011b, Martignoni et al., 2004) which may have an impact on the inpatient 
PD care patients receive. This is compounded by the fact that in some hospitals PD experts 
are unaware or are not informed about PD admissions (Gerlach et al., 2011a). Out of 51 
National Parkinson foundation (NPF) centres taking part in an online survey to evaluate 
practises and opinions on hospital admission of PD patients, only 25% had mechanisms in 
place to notify neurologists about PD patient‘s admission (Chou et al., 2011). In another study, 
a PD nurse specialist was involved in only 2% of the 59 PD admissions to a surgical ward 
(Derry et al., 2010). Similarly, in The Netherlands, PD nurse specialists were involved in only 
2.2% of the admissions (Gerlach et al., 2013). 
Cheng et al. (2007) showed that involvement of specialists who have knowledge and 
experience in managing PD and its complications is associated with better adherence to PD 
quality of care indicators, when compared to non-movement disorders specialists (Cheng et 
al., 2007). Most NPF centres were not confident of the quality of care received by hospitalised 
PD patients (Chou et al., 2011). The same perception was held by patients and their caregivers 
in a New Zealand survey (Buetow et al., 2010). In a UK hospital audit, authors surveyed 
junior doctors and reported that, although a significant proportion of doctors knew the 
complications of omitting PD medications, only 25% were confident in changing PD 
medication formulation if this was needed (Sathyababu et al., 2012). In another hospital audit, 
only 25% of junior doctors knew medications that are contraindicated in PD (Magdalinou et 
al., 2007). This results in poor medication management when PD patients are admitted to 
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hospital. Suboptimal PD care during hospitalisation also results in several complications 
including worsening of motor symptoms, infections, prescription errors, (Gerlach et al., 2012, 
Gerlach et al., 2013, Mueller et al., 2009) poor surgical outcomes (Walker et al., 2013), and 
prolonged hospital stays (Huse et al., 2005). 
Prescription errors are common during hospitalisation and have been reported in between 17% 
and 74% of PD admissions (Gerlach et al., 2012, Gerlach et al., 2013, Derry et al., 2010, 
Magdalinou et al., 2007, Hou et al., 2012, Domingo-Echaburu et al., 2012).  These may 
include dose omissions, sudden medication withdrawal, incorrect dose timing, dosage or 
formulations, and use of medications which are contraindicated in PD (Gerlach et al., 2012, 
Gerlach et al., 2013, Derry et al., 2010, Domingo-Echaburu et al., 2012). Poor medication 
management is associated with worsening of motor symptoms (Gerlach et al., 2013, NICE 
guidelines [CG35], 2006) and has been shown to correlate with the amount of levodopa dose 
missed (Gerlach et al., 2013). PD medication errors also increase the risk of complications 
such as falls, confusion, and hallucinations (Magdalinou et al., 2007, Derry et al., 2010, 
Barber et al., 2001). Use of contraindicated medication such as anticholinergics can worsen 
cognition and cause confusion (Ehrt et al., 2009, Bédard et al., 1999). A serious life threating 
complication that can occur following abrupt withdrawal of PD medication is Neuroleptic 
Malignant Syndrome, otherwise known as Parkinson Hyperpyrexia Syndrome (Newman et 
al., 2009).  The syndrome is characterised by altered level of consciousness, fever, rigidity of 
muscle, dysautonomia, excessive sweating, and raised serum creatine kinase levels (Newman 
et al., 2009). Such potentially life threatening complications highlight the need for strict 
adherence to medication doses and timing when PD patients are hospitalised.  
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1.9. Aims 
The previous section highlighted a number of unmet needs in the management of PD. Firstly, 
the lack of neuroprotective treatments. Secondly, the need for a sensitive tool for use in 
identifying individuals with early or prodromal disease, which provides a window for use of 
potential neuroprotective therapies. The extensive scale of PD hospitalisations and poor 
inpatient outcomes has also been highlighted. As long as there is no cure for the disease, 
hospitalisation rates and associated costs are likely to grow exponentially with the aging of 
the population. Interventions to reduce these hospital admissions are therefore urgently 
required. 
The objectives of this project sought to address these pertinent issues and were fourfold:  
1. To systematically review literature for interventions aimed at reducing PD 
hospitalisation. 
2. To describe the extent of hospitalisation in both early and advanced PD patients who 
participated in a large PD oral medication trial in England (PD MED trial). To 
compare hospitalisation rate, admission duration, and time to first admission in 
patients treated with the three main groups of symptomatic treatments for early and 
late disease. 
3. To assess the accuracy of reporting PD hospital admissions using data from a large 
tertiary hospital in England and discuss the impact on PD resource allocation. 
4. To develop an MRI based biomarker for potential use as a diagnostic and prognostic 
marker in PD.
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CHAPTER 2: A SYSTEMATIC REVIEW OF INTERVENTIONS TO REDUCE 
HOSPITALISATION IN PARKINSON’S DISEASE 
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2.1. Background  
PD hospitalisation, its associated high morbidity, mortality, and costs, which are likely to rise 
in the coming decades due to the aging population and consequent increase in disease 
prevalence. Therefore, there is a need for interventions aimed at reducing PD hospital 
admissions. Such interventions should be cost-effective and focussed on reducing known risk 
factors for hospitalisation. Evidence based initiatives for reducing unplanned hospital 
admissions in other chronic conditions, are already in existence. These include use of acute 
clinics, multidisciplinary teams and patient education (Gibson et al., 2002, Thomas et al., 
2013, Viswanathan et al., 2015). It is uncertain if these measures are effective for patients 
with PD. The purpose of this study was to perform a systematic review of the available 
literature for effective interventions aimed at preventing unplanned hospital admissions in 
individuals with PD. 
2.2. Methods  
A search for publications from EMBASE, MEDLINE and CINAHL databases up to 
September 2014 was performed. Eligibility criteria included RCT evaluating effectiveness of 
intervention versus no intervention in reducing hospital admissions and/or emergency 
department visits in patients with PD. Index terms and free text terms for ‘Parkinson’s 
disease’, Parkinson⃰, ‘hospitalisation’, and hospital⃰ were used, but this yielded no relevant 
RCTs. The search criteria were therefore broadened to include other study types. This 
included all studies where a specific measure was employed and led to a reduction in number 
of hospital admissions or emergency department visits in PD. Interventions included those 
that have been used in other chronic diseases to reduce unplanned hospital admissions such 
as patient educational programmes, urgent assessment clinics, specialist’s clinics, and 
specialist nurses. Outcome measures included a reduction in either hospital admission, non-
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elective (unplanned) admissions, or emergency room visits. Study participants were 
individuals with PD of all disease stages and duration. No age restrictions were applied. 
Abstracts and title headings were screened by one person and only publications with full 
abstracts, published in the English language and addressing interventions to reduce hospital 
admissions in PD were included. 
2.3. Results  
7 610 abstracts obtained from the three data sources were screened (figure 6). Duplicates and 
publications addressing hospitalisation in conditions other than PD were excluded. 115 
articles and abstracts were assessed for eligibility. From these, 106 excluded articles discussed 
issues pertaining to PD hospitalisation such as frequency and reasons for admissions, inpatient 
care and medication errors, but did not assess the effect of specific interventions on reducing 
hospital admissions in PD. One RCT assessed the effectiveness of two dysphagia 
management techniques in reducing aspiration pneumonia and also measured hospitalisations 
as an adverse event. Nine retrospective studies reported a change in healthcare utilisation 
including the number of emergency visits and or  
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Figure 6: Flow diagram showing publications identified through database searching and reasons 
for inclusion and exclusion from the review. 
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hospitalisation after an intervention and these were included (table 3)(Klein et al., 2009, Willis 
et al., 2012, Grubb et al., 2012, Grubb et al., 2013, Delea et al., 2011, Wei et al., 2014, 
Kulkarni et al., 2008, Davis et al., 2010, Ney et al., 2013) . 
One RCT compared the incidence of pneumonia among 515 patients with dementia and PD 
who were randomised to either chin-down posture technique or two types of thickened fluids 
(nectar- and honey-thick consistencies) over a 3 month follow up period (Robbins et al., 
2008). There was no difference in the incidence of pneumonia (primary outcome measure) 
between the two interventions. When the two types of thickened fluids were compared the 
cumulative incidence for pneumonia was less in the nectar-thick fluid compared to honey-
thick fluid (0.08 and 0.15 respectively; HR 0.50 95% CI 0.23, 1.09; p=0.083), but the 
difference was not significant (Robbins et al., 2008). 
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Table 3: Proposed interventions for reducing Parkinson’s disease hospital admissions 
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Proposed intervention 
Author, year 
Study type Study Group Study intervention Outcome Effect of proposed intervention on hospitalisation 
and emergency room visits 
Dysphagia management       
Robbins et al (Robbins et 
al., 2008) 
 
Randomised 
Controlled 
Trial 
515 
(PD and 
dementia 
patients) 
Chin down posture 
versus honey/nectar thick 
fluid 
Pneumonia incidence, 
Hospitalisation measured as an 
adverse event 
No difference in serious adverse events (including 
hospitalisation) between the two intervention grroups 
Frequent Neurologist 
involvement 
     
Willis et al (Willis et al., 
2012) 
 
Retrospective 
cohort  
 
2 4929 
PD patients 
 
Neurologist versus no 
neurologist care 
 
PD-related and general medical 
related hospitalisation 
Neurologist care associated with ↓ hospitalisation for 
traumatic injury (HR 0.56, 95% CI 0.40-0.78), 
psychosis (HR 0.71, 95% CI 0.59-0.86) and urinary 
tract infection (HR 0.74 95% CI 0.63-0.87). 
Ney   
et al (Ney et al., 2013) 
Survey  
 
3 883 
Parkinsonism, 
multiple 
sclerosis, 
epilepsy, 
dementia. 
Neurologist ambulatory 
care 
Utilisation and cost of non-
ambulatory care : inpatient, 
emergency, and home care 
 
↓ in condition related emergency, inpatient, and 
homecare care events (OR 0.64, P=0.001) and costs ( 
53% ,p<0.001) 
Open acess clinic      
Klein et al (Klein et al., 
2009)  
Retrospective  143 
PD patients 
Open access clinie Mean number of 
hospitalisations per year, mean 
length of stay 
50% ↓ in average number of PD admissions over 2 
years : 36  to 18 
PD medication choice      
Grubb et al (Grubb et al., 
2012) 
 
Retrospective 
 
 
 
7 230 
PD patients 
 
 
Rasagiline versus 
dopamine agonists 
 
 
Number of hospitalisation, 
duration of stay and costs 
Fewer hospital admissions (OR 0.76, 95% CI 0.66-
0.86), shorter length of stay and lower costs in 
rasagiline group 
Grubb et al(Grubb et al., 
2013) 
Retrospective 3 864 
PD patients 
Rasagiline versus 
Selegiline 
 
Hospitalisation, emeregency 
room visits and falls 
Lower emergency room visits (OR 0.79; 95% CI, 0.68 
to 0.92), lower all hospital admissions (OR 0.82; 95% 
CI, 0.68 to 0.99), and lower number of falls in 
rasagiline group 
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PD Mediation Adherence 
Delea et al (Delea et al., 
2011) 
Retrospective 
 
1 215 
PD patients 
 
Adherence to 
levodopa/carbidopa/ 
entacopone  
 
All cause and PD- related 
hospitalisations, length of stay, 
emergency room and physicians 
visits, prescriptions and 
healthcare costs 
 
Satisfactory adherence versus non-adherence: mean 
number PD related admissions (0.15 vs 0.12 ,p<0.001), 
emergency visits (0.04vs 0.08, p=0.010), all cause 
hospitalisation (0.30 vs 0.53, p<0.001) 
 
Kulkarni et al 
2008(Kulkarni et al., 2008) 
Retrospective 
Longitudinal 
cohort 
 
104 PD 
patients 
 
PD medication 
adherence 
 
Medication adherence, PD 
related hospitalisations and 
emergency room visits. 
 
Suboptimal adherence associated with worsening 
motor symptoms: Odds for adherers (MPR>0.8) 
experiencing symptom worsening compared to non-
adherers was 67% less (OR 0.33 95% CI 0.13-0.85) 
 
Wei et al (Wei et al., 2014) 
 
 
 
Retrospective 
Crossectional 
study 
 
 
7 583 PD 
patients 
 
 
 
 
PD medication 
adherence 
 
 
 
Hospital visits, emergency room 
visits , skilled nursing facility, 
home health agency, physcians 
visit and health costs 
 
Prevalence and relative risk (low versus high adherers): 
hospitalisation 57% vs 47% and 1 versus 0.86 (95% CI 
0.81-0.90),  
Emergency room visits 68% vs 59% and 1 versus 
0.91,95% CI 0.86-0.96 
Davis et al (Davis et al., 
2010) 
Retrospective 3 119 
PD patients 
PD medication 
adherence 
Medication adherence, health care 
utilisation (including hospital 
admissions and emergency 
room visits), and costs 
Mean hospitalisation per annum, non-compliant versus 
compliant: 2.3 versus 1.8; p<0.005. Mean number of 
emergency departments visits were not significantly 
different 1.9 versus 1.8 
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The overall incidence of pneumonia in this study was low, but the authors could not 
attribute the low incidence to the interventions used in this study because no comparison 
group was included (Robbins et al., 2008). Hospitalisations were reported as an adverse 
event and 20% of participants had at least one hospital admission in each of the two 
intervention arms. The number of withdrawals due to adverse events, including 
hospitalisations, was higher in the thickened fluid group (4%) compared to chin down 
posture group (2%): 2% difference, 95% CI -0.4%, -5%; p=0.112)(Robbins et al., 2008). 
A retrospective cohort study among 24 929 Medicare recipients in the United States (US) 
evaluated the effect of frequent neurologist care on PD hospitalisation and reported a 
reduction in hospital admissions for traumatic injury (HR 0.56, 95% CI 0.40-0.78; 
p<0.001), psychosis (HR 0.71, 95% CI 0.59-0.86;p<0.001), and urinary tract infection 
(HR 0.74 95% CI 0.63-0.87; p<0.001) in patients who had frequent neurologist care 
compared to those who were not treated by a neurologist (Willis et al., 2012). Another 
US survey assessed the impact of neurologist care on healthcare costs and utilisation 
among 3 883 individuals with chronic neurological conditions including Parkinsonism 
and showed that respondents who had consulted a neurologist had a reduction in disease-
related home care, emergency, and inpatient care events compared to those with no 
neurologist involvement (OR 0.64, P=0.001) (Ney et al., 2013). In another retrospective 
study, PD patients with poor motor symptom control, medication-related complications, 
or neuropsychiatric symptoms were allowed to access an urgent neurology clinic without 
prior appointment. This resulted in a 50% reduction in PD admissions over a 2 year period 
(Klein et al., 2009). In addition there was a reduction in hospital length of stay from 11 
to 4.5 days (Klein et al., 2009).  
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Two retrospective studies reported fewer hospital admissions in PD patients treated with 
rasagiline when compared to dopamine agonists (Grubb et al., 2012) or selegiline (Grubb 
et al., 2013). Comparisons of the number, duration, and cost of hospital admissions for 7 
230 PD patients who were initially treated with either a dopamine agonist or rasagiline 
were compared using data from the Medicare Supplemental Database. The authors 
reported fewer hospital admissions (OR 0.76, 95% CI 0.66-0.86), shorter duration of stay 
(-0.38 day p< 0.0001), and reduced costs in rasagiline-treated patients compared to the 
DA group: $12 327 versus $16 525 respectively (Grubb et al., 2012). In a retrospective 
study involving 3 864 individuals with PD, Grubb et al showed that, rasagiline use was 
associated with lower emergency room visits (OR 0.79; 95% CI, 0.68 to 0.92) and all 
cause hospital admissions (OR 0.82; 95% CI, 0.68 to 0.99) compared to the selegiline-
treated group (Grubb et al., 2013). However, no difference was found in the odds of PD-
related hospital admissions and fractures (Grubb et al., 2013). 
Four retrospective studies assessed the frequency of medication adherence in PD and also 
measured hospitalisation as an outcome. In a retrospective historical cohort study which 
included 1 215 from a US health claim database, Delea et al. (2011) showed that patients 
with satisfactory levodopa/carbidopa/entacapone therapy compliance (proportion of days 
where a patient had medication supply ≥80%), had 49% fewer emergency room visits 
(p=0.010) and 39% less PD-related hospitalisations compared to the non-adherent group 
(p=0.001) (Delea et al., 2011). The number of all hospitalisations and overall PD-related 
costs were also lower in the group of patients with satisfactory treatment adherence (Delea 
et al., 2011). In another study of 104 PD patients, suboptimal adherence to PD medication 
was associated with worsening motor symptoms (Kulkarni et al., 2008). PD related 
hospitalisations and emergency room visits were used as an indicator of worsening motor 
symptoms, in addition to an increase PD medication dosage. Medication possession ratio 
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(MPR), a measure of medication adherence was defined as the proportion of days covered 
by a PD prescription: the numerator was the number of days covered by a PD prescription 
and the denominator was the number of days between prescription disbursements 
(Kulkarni et al., 2008). During the first year of follow up, the mean possession ratio, PD 
related emergency room visits, and hospitalisation were 0.52 ± 0.35, 0.07 ± 0.29, and 
0.91± 2.19 respectively. In the fifth year the MPR was lower 0.42 ± 0.37 with higher 
emergency room visits and hospitalisation: 0.18± 0.70 and 1.40± 3.74 (Kulkarni et al., 
2008). In a retrospective cross-sectional study, Wei et al. (2014) used Medicare 
administrative data for 7 583 patients with PD and found that those with a medication 
possession ratio of more than 90% had lower emergency room visits and hospitalisation 
rate than poor adherers (less 80% MPR) (Wei et al., 2014). Another US study evaluated 
the prevalence and cost of poor adherence to PD medication using retrospective 
administrative and claims data. The study included 3 119 participants who had a PD 
International Classification of Diseases (ICD) code recorded and were on PD medications 
during the study period. The mean number of hospitalisations over 12 months was 
significantly higher amongst individuals who were non-compliant with PD medication in 
comparison to the compliant group (2.3 versus 1.8; p<0.005) (Davis et al., 2010). 
However, there was no difference in the mean number of emergency room visits (Davis 
et al., 2010). Mean health costs were significantly higher in the non-adherent group 
(Davis et al., 2010). 
2.4. Discussion 
Hospitalisation in PD is a significant cost-driver (Findley et al., 2003) and patient 
outcome is often poor (Temlett and Thompson, 2006, Huse et al., 2005, Mueller et al., 
2009). This review highlights the lack of evidence-based interventions for reducing PD 
patient hospitalisation.  
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Of the few studies in this area, only one RCT of a specific intervention was found. This 
reported a low overall pneumonia incidence and no difference in the frequency of 
pneumonia when either chin-down posture or thickened fluids were used to manage 
dysphagia (Robbins et al., 2008). This study was limited by a short follow up period and 
the absence of a control group (Robbins et al., 2008). There was no difference in 
hospitalisation rates between the two interventions. Further, the cumulative pneumonia 
incidence was less when fluids with nectar compared to honey consistency were used 
(Robbins et al., 2008). This difference could have been a chance finding because the 
overall incidence of pneumonia in the study was low. Although speculative, the low 
pneumonia rates reported in the study suggests that chin-down posture and fluids of 
nectar/honey consistency may be useful interventions for pneumonia prevention.  
There were nine retrospective studies where hospitalisation rates and emergency room 
visits in PD were measured. These studies suggested that frequent neurologist 
consultation, open access clinics, and compliance with PD medication may reduce 
hospital admissions and emergency room attendance by PD patients. The cost 
effectiveness and the actual number and frequency of neurological consultations required 
to reduce PD hospitalisation is uncertain. Frequent consultations may provide 
opportunities for medication adjustments, earlier detection and management of 
complications which, in turn, reduces the need for hospitalisation (Willis et al., 2012). 
Open access clinics also provide similar opportunities for symptoms and complication 
management which potentially prevents hospital admissions (Klein et al., 2009). The 
effectiveness of open access clinics was based on a report from a single centre with no 
comparison group. An association between PD medication adherence and reduction in 
emergency room visits and PD-related hospital admissions was reported in four 
retrospective studies (Delea et al., 2011, Davis et al., 2010, Wei et al., 2014, Kulkarni et 
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al., 2008). Sub-optimal adherence to PD medication can have negative implications on 
motor outcomes and patient quality of life (Grosset et al., 2007). These findings imply 
that optimising PD symptom control through medication compliance possibly reduces 
hospital admissions for poor motor control. Interventions such as regular neurologist care 
and open access clinics may be difficult to implement in countries where some individuals 
have no health insurance. In addition, some patients may not be able to afford their PD 
prescriptions which may impact on medication adherence, motor symptom control, and 
therefore hospitalisation. A surprising finding was the association between rasagiline 
treatment and fewer hospital admissions reported in two retrospective studies (Grubb et 
al., 2013, Grubb et al., 2012). Dopamine agonists have superior symptomatic effects 
compared to monoamine oxidase inhibitor treatment (Caslake et al., 2009 ). However, 
dopamine agonist treatment is associated with more side effects (Caslake et al., 2009 ). 
This may account for the fewer hospitalisations in rasagiline group. The differences in 
emergency room visits between selegiline and rasagiline treated patients cannot be 
explained. These two studies were funded by the rasagiline manufacturer which may have 
led to bias. 
A major limitation of these studies is their retrospective design. Reliability of the reported 
results is dependent on the accuracy of the databases from which the data were extracted. 
It is also impossible to control for all confounding factors in such studies. Therefore, 
definitive conclusions regarding the effectiveness of the above interventions cannot be 
drawn based on this evidence. Nevertheless, these studies provide some insight into the 
interventions that require further evaluation. 
Falls, fractures, infections, cognitive, and motor decline have been identified as risk 
factors for unplanned hospital admissions in patients with PD (Hassan et al., 2013). 
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Implementing preventative measures for these complications may reduce the need for 
hospital admission. Falls in PD can occur as a result of postural instability, poor motor 
symptom control, and drug-related side effects (e.g. postural hypotension). Optimising 
motor symptom control and managing medication side effects may prevent falls and 
hence hospital admissions. Furthermore physiotherapy is thought to improve PD motor 
symptoms, mobility, and balance, (Tomlinson et al., 2013) which may also potentially 
reduce the risk of falls. A recent Cochrane review compared the effectiveness of 
physiotherapy interventions and no intervention in PD on outcomes such as gait, falls, 
and clinician-rated measures of impairment and disability. Health resource usage 
including hospitalisation was not reported as an outcome measure. Although there was a 
reported trend towards improvement in falls, there was no significant difference in the 
number of falls between the physiotherapy and non-intervention arms in 6 studies from 
which data could be abstracted (Tomlinson et al., 2013). The authors reported that the 
absence of a positive effect from physiotherapy could have been a result of short follow 
up periods, reliance on falls diaries, and the small number of participants in the included 
studies (Tomlinson et al., 2013).  Fracture prevention measures may reduce 
hospitalisation as shown in an Italian retrospective study which included 5,167 
postmenopausal women who were discharged from hospital with primary or secondary 
diagnosis of hip fracture (Tarantino et al., 2011). The study compared the effect of 
treatment or no treatment with fracture prevention medication on mortality, re-fracture 
rates, and costs of health resource use (including hospitalisation). For those who were 
treated with bisphosphonates, the effect of compliance with treatment on these outcome 
measures was also assessed (Tarantino et al., 2011). Only 34% of the included patients 
were exposed to fracture prevention treatments and 1 044 events (deaths and 
hospitalisation) were reported, and these were related to re-fractures (Tarantino et al., 
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2011). A significantly reduced incidence of death (-55%, p<0.001) and re-fracture related 
hospitalisations (-40% p<0.001) was reported when fracture prevention treatment was 
used (Tarantino et al., 2011). In those who were treated with bisphosphonates, adherence 
of <40% was associated with higher total costs including re-hospitalisation, compared to 
those with better adherence (Tarantino et al., 2011). It is uncertain if osteoporosis and 
fracture prevention measures translate into a reduction in hospitalisation rates in PD.  
Early speech and language therapy involvement in dysphagia management may 
potentially reduce the number of hospital admissions for aspiration pneumonia. To date, 
no studies have systematically assessed whether pneumonia, falls, and fracture prevention 
strategies discussed above can reduce the number of hospital admissions in PD.  
PD nurse specialists, where available, may play a crucial role in identifying PD patients 
in the community who are at high risk of hospitalisation. By working in liaison with other 
PD specialists in primary and secondary care, social services, palliative care and 
rehabilitation services, early treatment can be instituted in the patients’ home. Community 
PD nurse care has been shown to be cost neutral when compared to primary care 
physicians in a RCT (Jarman et al., 2002). However, effectiveness of this approach in 
reducing PD hospitalisation rates has not been assessed.   
 Interventions such as specialist clinics (multidisciplinary or nurse-led), (Thomas et al., 
2013) medication management, (Viswanathan et al., 2015) and patient self-management 
educational programmes (Gibson et al., 2002) have been shown to be effective in reducing 
unplanned admissions in other chronic conditions. The limited evidence available in PD 
suggests that specialist clinics and medication management may reduce hospitalisation 
and therefore these interventions require further evaluation. A PRISMA checklist would 
have highlighted some of the limitations of this study which include the inclusion of 
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positive studies which were predominantly retrospective and the lack of an assessment of 
risk of bias for the individual studies.  
This review has highlighted a gap in evidence-base for interventions that are effective in 
reducing PD hospital admissions. Proposed measures are based mainly on retrospective 
studies and none have been systematically assessed in PD. Nevertheless, these 
interventions merit further evaluation in well-designed prospective trials. In view of the 
health costs and morbidity associated with PD hospitalisation, it is imperative that PD 
experts and policy makers make a joint effort to find ways to reduce hospitalisation in PD 
as the search for disease modifying treatment continues.
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CHAPTER 3: FREQUENCY OF HOSPITALISATION IN PARKINSON’S 
DISEASE USING HOSPITAL EPISODES STATISTICS. 
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3.1. Background 
At present there is no good quality evidence for effective interventions which can mitigate 
hospitalisation in PD. There is a suggestion that controlling motor symptoms may 
potentially reduce healthcare utilisation in PD, but supporting evidence for this is poor. 
Other studies have demonstrated a difference in hospitalisation rates in individuals treated 
with different dopaminergic therapies, but these studies are limited by their retrospective 
nature (Grubb et al., 2012, Grubb et al., 2013). To date there are no randomised controlled 
trials which assessed the effect dopaminergic treatments on hospitalisation in PD.  
The aims of the present study were to compare hospitalisation rates and duration of 
admission for PD patients on the different classes of oral medications used for treating 
early and advanced PD. The patients took part in an open label randomised controlled 
trial of oral medications used for treating Parkinson’s disease (acronym PD MED): 
 PD MED EARLY: levodopa versus dopamine agonists versus MAOBI  
 PD MED LATER: dopamine agonists versus MAOBI versus COMTI 
The current study also sought to describe the demographic characteristics and patterns of 
hospitalisation of the PD MED participants.   
3.2. Methods 
The PD MED EARLY trial is the second largest oral medication trial conducted in 
patients with PD. The study evaluated the cost and clinical effectiveness of the three 
different classes of oral medications used for treatment of early PD: levodopa, dopamine 
agonists, and MAOBI inhibitors. Patients were initially drug naïve or treated for less than 
6 months (PD MED Collaborative Group, 2014). The study design and results for the PD 
MED EARLY trial were published elsewhere (PD MED Collaborative Group, 2014). 
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1 620 patients diagnosed with idiopathic PD based on the UKPD brain bank criteria, were 
recruited into the early disease trial (PD MED EARLY) and 500 patients to the later 
disease trial (PD MED LATER). There were 91 recruiting centres majority of which were 
in the UK: UK (89 centres), Russia (1 centre), and Czech Republic (1 centre) (PD MED 
Collaborative Group, 2014).  
PD MED EARLY showed a small benefit of levodopa over levodopa sparing treatments 
in patient-rated quality of life and this was sustained at 7 years follow up (PD MED 
Collaborative Group, 2014).  
In PD MED LATER, patients with advanced disease requiring adjunctive therapy were 
randomised to COMTI, dopamine agonists or MAOBI.  The PD MED LATER study 
results will be published in early 2017. Dopamine agonists’ superiority over COMTI and 
MAOBI in advanced disease was reported in systematic reviews (Stowe et al., 2011, 
Stowe et al., 2010, Caslake et al., 2009 ). It was therefore postulated that dopamine agonist 
treated patients would fare better than MAOBI and COMTI treated patients in terms of 
PD-related hospitalisations.  
Hospital Episodes Statistics (HES) data for study participants from English and Welsh 
PD MED study centres, were obtained from the Health and Social Care Information 
Centre (HSCIC). The HES data included inpatient episodes from 1st April 1999 to 31st 
March 2013. HES data were linked to the PD MED trial database on the following 
variables: patient PD MED trial number (unique identifier); month and year of birth; 
gender; first part of patient postal code. 
All HES inpatient episodes for PD MED study participants from England and Welsh 
centres, with exact matches on the first three variables (PD MED trial number, month and 
year of birth, and gender) , were included. An inpatient episode was defined as the time 
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a patient spent under the care of one consultant during a hospital admission (The NHS 
Information Centre for health and social care, 2010). A hospital admission or complete 
spell was composed of one or more finished consultant episodes. For purposes of this 
study, a hospital admission was defined as a complete inpatient spell. 
Duplicate episodes and other inpatient episodes which occurred prior to patient 
randomisation to the PD MED trial were excluded. First patient randomisation was on 9th 
November 2000, so admissions prior to this date were excluded. For patients who died 
during the study period, inpatient episodes recorded after the date of death were also 
excluded: these were considered as HES data errors. Hospital episodes for PD MED 
participants from Scottish centres were excluded as these are stored in a separate database 
from that of England and Wales. Hospitalisation data for non-UK PD MED participants 
were not available. 
Descriptive analyses were performed and summary tables produced for the following: 
baseline demographic characteristics including age, sex, disease duration, H&Y, and co-
morbidity. Hospitalisation data included the number of hospital admissions per patient 
during the study period, type of admission (elective or non-elective), admission duration, 
and primary reasons for admission using the ICD-10 codes. Zero bed days were defined 
as admissions where a patient was admitted and discharged within 24 hours (Low et al., 
2015). Primary diagnoses were divided into PD-related (complications of PD and its 
treatment; table 4) and other (all other primary diagnoses).  
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Table 4: List of PD-related primary diagnosis categories 
 
 
 
 
 
 
 
 
 
 
Table 4 above shows examples of some of the PD-related primary diagnoses which were included. 
All fractures, falls and injuries were included. (Non-traumatic subdural haemorrhages were 
excluded) 
 
 
 
 
 
 
PD-related categories Examples of included Primary diagnoses 
Parkinson's disease Parkinson’s disease 
Neuropsychiatric 
symptoms 
Disorientation 
Hallucinations 
Senility 
Restlessness and agitation 
Non motor symptoms Nausea and vomiting  
Constipation  
Somnolence 
Hyperhidrosis  
Malaise and fatigue 
Dysphagia  
Problems related to blood 
pressure 
Hypotension 
Dizziness 
Orthostatic hypotension  
Syncope and collapse 
Infections Urinary tract infection 
Pneumonia  
Falls, fractures, injuries Tendency to falls 
Fractures  
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Outcome measures included: number of admissions, time to first hospital admissions, 
time to the first PD-related event, and admission duration. The outcome measures were 
analysed by using the same two comparisons used for PD MED EARLY: levodopa versus 
levodopa-sparing (dopamine agonists and MAOBI arms combined), and dopamine 
agonist versus MAOBI. For PD MED LATER study comparisons were made between 
dopamine agonists versus combined COMTI and MAOBI then MAOBI versus COMTI. 
A negative binomial model was used to compare the number of admissions and the 
duration of admissions between the treatment arms. This model was used for the analysis, 
as this is an appropriate model for over-dispersed count data. Survival analysis was used 
to compare the risk of events (time to first admission and time to first PD-related 
admissions). 
All models were run without covariates and then including significant covariates. 
Covariates used include: H&Y stage (categorised as 1-1.5, 2, 2.5-5), disease duration 
(categorised as <0.5 years; ≥0.5 years), age (categorised as <70 years; ≥70 years), and 
gender. 
Data were presented as mean ± standard deviation (SD) or median (interquartile range - 
IQR) and 95% CI where appropriate. A significance level of 5% was used to assess for 
statistical evidence between groups. SAS software version 9.2 & 9.4 and Stata SE version 
14 were used for data analysis. 
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3.3. Results  
PD MED EARLY  
Patient demographics 
1 548 of the 1 620 who participated in the early disease PD MED trial were from English 
and Welsh study centers: mean age 70 ± 8.8 years, 65% male. 97% of the participants 
were above age 50 years. Mean disease duration was 7.8 ± 13.3 months at study entry 
(table 5).  
73% (n=1 128) of participants were admitted to hospital during the study period 1st April 
1999 to 31st March 2013: mean age 71± 8.5 years, 66% male, mean disease duration 7.1± 
13.1 months, and median follow up time was 5.7 (4.2-8.1) years, range 0-12.3 years. 
93% of the 1 128 patients had mild disease: H&Y stage 1 to 2.5 (table 5). Only 2% (n=23) 
of the patients were below age 50 years. 374 patients were on levodopa only, 431 on 
dopamine agonist and 323 on MAOBI.  
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Data cleaning  
Figure 7: Flow diagram showing all inpatient episodes from Hospital Episode Statistics 
(HES) data. 
 
Included and excluded episodes. DOB: Date of Birth, TNO: Trial number, HES: Hospital 
Episode Statistics 
 
 
 
 
 
All inpatient episodes from HES
31 March 1999- 31 March 2013 
14 068 episodes 
PD MED EARLY
10 542 episodes
Excluded
DOB mismatches 83 episodes
2 TNO mismatches 8 episodes 
2 678 inpatient episodes prior to randomisation
5 duplicate episodes
5 episodes after patient date of death
36 episodes prior to randomisation date
37 episodes at end of HES year
30 episodes from Scottish participants 
7 662 episodes
1 128 unique 
TNO
PD MED LATER
3 526 episodes
Excluded
TNO mismatches 6 episodes 
12 DOB mismatches
895 episodes prior to patient randomisation to 
PD MED LATER
4 duplicate episodes
15 unfinished episodes
3 episodes moved to PD MED EARLY
2591episodes
341  unique 
TNO
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Table 5: Baseline demographic data for PD MED EARLY patients from England and Wales 
and the subset of patients who had at least 1 admission 
 
Variable 
 
All early PD MED patients 
included in dataset 
Early PD MED Patients 
who had an admission 
Early PD MED Patients 
who did not have an 
admission 
 
N=1 548 N=1 128 N=420 
Mean Age(SD) 
70 (8.8) 71 (8.5) 67 (9.0) 
Age N (%)  
<50 39 (3) 23 (2) 16 (4) 
50-59 
144 (9) 83 (7) 61 (15) 
60-69 
499 (32) 339 (30) 160 (38) 
70-79 
685 (44) 528 (47) 157 (37) 
≥80 
181 (12) 155 (14) 26 (6) 
Sex N (%)  
Male 1 003 (65) 740 (66) 263 (63) 
Duration of PD in 
Months(Mean[SD]) 
 
7.8 (13.3) 
 
7.1 (13.1) 
 
9.7 (13.7) 
Hoehn & Yahr Stage  
 N (%) 
 
1 
 
468 (30) 
 
337 (30) 
 
131 (31) 
 
1.5 
 
314 (20) 
 
217 (19) 
 
97 (23) 
 
2 
 
442 (29) 
 
328 (29) 
 
114 (27) 
 
2.5 
 
223 (14) 
 
162 (14) 
 
61 (15) 
 
3 
 
97 (6) 
 
80 (7) 
 
17 (4) 
 
4-5 
 
4 (1) 
 
4 (1) 
 
0 (0) 
 
 
 
 
 
94 
 
Hospital admissions  
A total of 10 542 inpatient episodes were obtained from the HES data. After excluding 
duplicate records, inpatient episodes occurring before the PD MED randomisation and 
other HES data errors, 7 662 inpatient episodes were obtained (figure 7 above), and these 
were accounted for by 1 128 patients. These episodes made up 5 734 hospital admissions 
for the period 1st April 1999 to 31st March 2013.  5 725 were completed admissions and 
the remaining 9 admissions had no discharge date. 31st March was considered as the 
discharge date since data from 1st April 2013 onwards were not available: HES data years 
end on 31st March. The median (IQR) number of admissions per patient were: 4 (2-6), 
range 1-87 admissions (figure 8). Median duration of admission: 15 (2-54.5) days, range 
0-355 days. 49% (n=2 809) of the admissions were zero bed days. There were 3114 (54%) 
elective and 2 413 (42%) non-elective (emergency) admissions, 203 transfers between 
hospitals, and 1 maternity admission. The method of admission was not recorded for 3 
admissions.  
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Figure 8: Number of admissions per patient for PD MED EARLY patients who were 
hospitalised 
 
 
Elective admissions 
844 patients had 3 114 elective admissions: median number of admissions per patient was 
1(0-2), range 1 - 82 admissions.  Median duration of admissions was 0 (0-6) days (range 
0 - 355 days). 80% (n=2 481) of all elective admissions were zero bed days. Majority of 
zero bed day admissions were for reasons not related to PD: neoplasms (16%), disease of 
the eye and adnexa (12%), gastrointestinal disorders (11%), musculoskeletal and 
connective tissue disorders (7%), symptom, signs, laboratory and clinical findings not 
classified elsewhere (6%), cardiovascular and circulatory disorders (3%), and 
genitourinary disorders (4%). Only 7% (n=205) of all elective admissions had a PD-
related primary diagnosis on discharge. Of these PD was recorded as the primary 
discharge diagnosis in 75% of the admissions. 
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Non-elective admissions 
There were 2 413 non-elective admissions from 854 patients. 292 of these patients were 
on levodopa treatment only, 326 on a dopamine agonist and 236 on a MAOB inhibitor. 
The median number of admissions per patient was 1(0-2): range 1 - 20 admissions (figure 
9). 13% of non-elective admissions were zero bed days. Median duration of admissions 
was 6.0(1-16) days and range was 0 - 256 days. 42% (n=1 033) of all non-elective 
admissions had a PD-related primary diagnosis on discharge from hospital in 547 
patients. Table 6 and 7 show the commonest PD-related non PD-related reasons for 
admissions respectively. 
Figure 9:  Number of non-elective admissions per patient for PD MED EARLY patients who 
were hospitalised 
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Table 6: PD-related primary diagnoses (reasons for admission) for PD MED EARLY trial 
patients who had non-elective admissions 
 
Primary PD-related reason for admission Number of admissions  % 
Infections 324 29.8 
Fall/Fracture/Injuries 318 29.3 
Parkinson’s disease 184 16.9 
Problems related to blood pressure 132 12.2 
Neuropsychiatric disorders 64 5.9 
PD non-motor symptoms 62 5.7 
PD drugs adverse effects 2 0.2 
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Table 7: Non PD-related primary diagnoses (reasons for admission) for PD MED EARLY 
trial patients who had non-elective admissions. 
Diagnosis Category Frequency % 
Symptoms, signs, clinical and laboratory findings not classified elsewhere 429 32.3 
Cardiovascular and circulatory disorders 241 18.2 
Gastrointestinal disorders 131 9.9 
Musculoskeletal and connective tissue disorders 105 7.9 
Respiratory tract disorders 64 4.8 
Neoplasms 53 4.0 
Diseases of the nervous system 45 3.4 
Diseases of the skin and subcutaneous tissues 45 3.4 
Complications of surgical and medical care 44 3.3 
Genitourinary tract disorders 32 2.4 
Endocrine nutritional and metabolic disorders 28 2.1 
Infectious diseases 23 1.7 
Anaemia 19 1.4 
Mental and behaviour disorders 18 1.4 
Infectious diseases 17 1.3 
Poisoning by drugs medicaments and biological substances 12 0.9 
Diseases of the eye and adnexa 7 0.5 
Factors influencing health status and contact with health services 5 0.4 
Foreign bodies 3 0.2 
Burns and corrosions 2 0.2 
Toxic effects of nonmedicinal substances 2 0.2 
Disease of the ear and mastoid 1 0.1 
Disorders of immune mechanisms 1 0.1 
 
 
Hospital admissions by treatment arm. 
Elective and non-elective admissions 
When both elective and non-elective admissions for the 1 128 patients were considered, 
there was no difference in the number of admissions during the study period, between 
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the levodopa arm and the levodopa sparing arms (RR 0.90, 95% CI 0.81, 1.06), time to 
first admission, admission duration between the treatment arms (table 8). When 
considering the number of PD-related admissions only, no difference between levodopa 
and levodopa-sparing arms (RR 1.2, 95% CI 0.95, 1.40) was found.  
When dopamine agonist and MAOBI treatment arms were compared, no difference in 
rate of admissions was found (RR 1.0, 95% CI: 0.85, 1.18). The rate of PD-related 
admissions did not differ between these two arms (RR 0.9, 95% CI 0.75, 1.20). 
Table 8: Time to first admission, admission rates and duration for PD MED EARLY patients 
on levodopa versus levodopa sparing 
 LD alone LD-sparing 
N 505 845 
Number of admissions Mean (SD) 3.8 (5.96) 3.5 (4.32) 
Median (IQR) 2.0 (0.0-5.0) 2.0 (0.0-5.0) 
 N* 374 626 
Time to first admission (years) Mean (SD) 2.6 (2.28) 2.5 (2.1) 
 Range 0 – 12 0 – 9 
Total Admission Duration (per 
patient) (Days) 
Mean (SD) 40.7 (66.36) 42.9 (62.31) 
 Median(IQR) 15.0 (2.0-51.0) 17.5 (2.0-62.0) 
N 1915 2969 
Admission Duration (Days) Mean (SD) 8.0 (19.2) 9.0 (20.9) 
 Median(IQR) 1.0 (0.0-7.0) 1.0 (0.0-9.0) 
*Only including those patients who had an admission. Comparisons in this table exclude 
individuals who were randomised between the LD-sparing arms. Total admission duration was 
calculated as the sum of the duration of admissions for all patient divided by the number of 
patients. Admission duration was average admission duration for all the admissions in each 
group. 
 
Non-elective admissions  
Levodopa versus Levodopa sparing treatment 
Significant predictors for the number of non-elective admissions were: older age, H&Y 
stage, and disease duration at randomisation. A negative binomial model which 
included these predictors was used, but no difference in admissions rates between 
levodopa and levodopa-sparing treatment was found (RR 1.0; 95% CI; 0.84, 1.14). 
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Similarly, there was no difference in the time to the first admission (HR: 1.1 95% CI; 
0.9-1.2; figure 10), and mean admission duration (RR 1.1; 95% CI 0.91, 1.23; table 9), 
between levodopa and levodopa sparing treatment. When assessing PD-related 
admissions only, no difference in both admission rate (RR 1.0, 95% C.I 0.81, 1.22) or 
time to first PD-related admissions (HR 1.0 95% CI 0.9, 1.3; figure 11), between 
levodopa and levodopa-sparing arms, was found. Admissions duration between these 
treatments did not differ (RR 1.2; 95% CI 0.93, 1.47). Furthermore, time to the first fall, 
fracture or injury related admission was no different when these treatment arms were 
compared (HR 1.1; 95% CI 0.8, 1.4; figure 11). 
Table 9: Time to first admission, admission rates and duration for PD MED EARLY patients 
who had non-elective admissions (levodopa versus levodopa sparing arms) 
 LD alone LD-sparing 
N 505 845 
Number of admissions Mean (SD) 1.6 (2.28) 1.6 (2.22) 
Median (IQR) 1.0 (0.0-2.0) 1.0 (0.0-2.0) 
 N* 292 489 
Time to first  
admission (years) 
Mean (SD) 3.6 (2.56) 3.2 (2.21) 
Range 0 – 12 0 – 10 
Total Admission Duration 
(per  
patient) 
Mean (SD) 40.2 (56.20) 39.0 (49.17) 
Median 
(IQR) 
20.0 (5.0-55.0) 21.0 (7.0-58.0) 
N 831 1366 
Admission Duration (days) Mean (SD) 14.1 (24.14) 14.0 (21.72) 
 Median 
(IQR) 
6.0 (1.0-18.0) 6.0 (1.0-17.0) 
 
Table 9 above, * Only including those patients who had an admission. Comparisons in this table 
exclude individuals who were randomised between the LD-sparing arms. Total admission 
duration was calculated as the sum of the duration of admissions for all patient divided by the 
number of patients. Admission duration was average admission duration for all the admissions 
in each group. 
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Figure 10: Time to first admission (levodopa versus levodopa-sparing) for PD MED EARLY 
patients who had non-elective admissions 
 
 
 
Figure 11: Time to first PD-related admission (levodopa versus levodopa-sparing) for PD 
MED EARLY patients who had non-elective admissions 
 
 
 
 
There were 227 (17%) patients who had a fall/fracture/injury related admission. There 
was no difference in the time to first fall related admission (see figure 12) 
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Figure 12:  Time to first fall/fracture/injury related admission (levodopa versus levodopa-
sparing) for PD MED EARLY patients who had non-elective admissions 
 
 
Dopamine agonist versus MAOBI 
When comparing dopamine agonist versus MAOBI arms, there was no difference in the 
rate of admissions (RR 1.1; 95% CI 0.89, 1.31), admission duration (RR 1.1; 95% CI 
0.92, 1.43), time to first admission (figure 13), and time to first PD-related event (figure 
14). 
Figure 13: Time to first admission (dopamine agonist versus MAOBI) for PD MED EARLY 
patients who had non-elective admissions 
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Figure 14: Time to first PD-related admission (dopamine agonists versus MAOBI) for PD 
MED EARLY patients who had non-elective admissions 
 
There were 129 (15%) of patients who had a fall/fracture/injury related admission. 
There was no difference in the time to fall-related admission between the arms (see 
figure 15). 
Figure 15: Time to first fall/fracture/injury related admission (dopamine agonists vs MAOBI) 
for PD MED EARLY patients who had non-elective admissions 
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PD MED LATER   
Patient Demographics 
486 of patients from the PD MED LATER were included from England and Wales: 
mean age 73±8.2 years mean disease duration 5.6±3.9 years. 341 (70%) of these 
patients: mean age 73±8.1 years, 63% male and mean disease duration 5.7 ±4.1 years, 
were admitted during the study period. 42% of the patients who were admitted had 
H&Y stage 3 or more (table 10). 
Table 10: Baseline demographic data for all PD MED LATER patients from England and 
Wales and the subset who had at least 1 admission 
Variable All PD MED patients 
included in dataset 
Patients who had an 
admission 
  N=486 N=341 
Mean Age (SD) 73 (8.2) 73 (8.1) 
Age (%) <50 5 (1) 3 (1) 
50-59 31 (7) 19 (6) 
60-69 103 (21) 63 (18) 
70-79 254 (52) 179 (52) 
≥80 93 (19) 77 (23) 
Sex (%) Male 306 (63) 215 (63) 
Duration of PD in years(SD) 5.6 (3.9) 5.7 (4.1) 
Hoehn & Yahr N 
(%)                     
1 19 (4) 12 (3) 
1.5 36 (7) 18 (5) 
2 142 (29) 102 (30) 
2.5 98 (20) 67 (20) 
3 153 (32) 112 (33) 
4-5 38 (8) 30 (9) 
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Hospital admissions 
2 591 inpatient episodes making up 1 854 spells/admissions were obtained for the 341 
patients. Of these patients, only two patients had taken part in early disease trial 
randomisation. The number of admissions per patient ranged from 1-40, median (IQR) 
4(2-7) (figure 16). 38% (n=700) of these admissions had zero days duration, and the 
range was 0-434 days. Majority of the admissions were non-elective: 59% (n=1 017) 
and 41% (n=764) were elective. There were 73 transfers between hospitals. 
Figure 16: Number of admissions per patient for the PD MED LATER patients who were 
hospitalised 
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Elective admissions 
There were 764 elective admissions from 229 patients. Median number of admissions per 
patient was 2 (1-4) and range 1 - 39 admissions. 549 (72%) were zero bed days, median 
admission duration 0 (0-1), range 0- 320 days. Of the 764 elective admissions, 9% (n=68) 
had a primary diagnosis coded as PD-related of which 81% were coded as PD (table 11). 
Of the patients who had PD-related elective admissions, 6 (14%) were on dopamine 
agonists, 17 (41%) MAOBI, and 19 (45%) on COMTI. 
Table 11:  PD-related primary diagnoses (reasons for admission) for PD MED LATER who 
had elective admissions 
Primary reason for admission Number of admissions % 
Parkinson’s disease 55 81 
PD non motor symptoms 2 2.9 
Neuropsychiatric disorders 2 2.9 
Injuries 1 1.5 
Infections 6 8.8 
Fractures 2 2.9 
 
Non-elective admissions 
There were 1 017 non-elective admissions from 304 patients: 62 (27%) were on dopamine 
agonists; 69 (31%) MAOBI, and 96 (42%) on COMTI. Median number of admission per 
patient was 3(1-4), mean 3.3 ±2.7 (figure 17), range 1 - 15 admissions. 91 (30%) of the 
304 patients had one non-elective admission and the rest had more than 1 non-elective 
admission. 150 (15%) of the admissions were zero bed days, median admission duration 
6 (1-17) days and range 0 - 131 days. Of all 1 017 non-elective spells, 532 (53%) had the 
primary diagnosis coded as a PD-related diagnosis (table 12) 
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Figure 17: Number of admissions per patient for the PD MED LATER patients who had non-
elective admissions 
 
 
Table 12:  PD-related primary diagnoses (reasons for admission) for PD MED LATER 
patients who had non-elective admissions 
Primary PD-related reason for admission Number of admissions  % 
Fall/Fracture/Injuries 141 26.5 
Parkinson’s disease 120 22.5 
Infections 176 33.1 
Problems related to blood pressure 53 10.0 
Neuropsychiatric disorders 35 6.6 
PD non-motor symptoms 6 1.1 
Other 1 0.2 
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Hospital admissions by treatment arm. 
Non-elective admissions 
Dopamine agonist versus MAOBI and COMTI 
When dopamine agonists, and combined MAOBI and COMTI were compared there was 
no difference in the rate of admissions (RR 1.0; 95% CI 0.78, 1.38), admission duration 
(RR 1.0 95% CI; 0.81, 1.20), or time to first non-elective admissions (HR 1.1, 95% CI 
0.8, 1.4): table 13, figure 18.  
Table 13: Time to first admission, admission rates and duration for PD MED LATER trial 
patients who had non-elective admissions (levodopa versus levodopa sparing arms) 
 DA MAOBI and 
COMTI 
N 140 216 
Number of admissions Mean (SD) 2.2 (2.96) 2.2 (2.69) 
Median (IQR) 1.0 (0.0-3.0) 1.0 (0.0-4.0) 
 N* 86 138 
Time to first  
admission (years) 
Mean (SD) 2.6 (2.24) 2.6 (1.99) 
Range 0.01 – 11.40 0.02 – 8.91 
Total Admission Duration 
(per  
patient) 
Mean (SD) 50.0 (55.2) 49.9 (57.0) 
Median 
(IQR) 
32.5 (8.0-73.0) 33.0 (9.0-74.0) 
N 302 483 
Admission Duration (days) Mean (SD) 14.2 (20.93) 14.3 (21.20) 
 Median 
(IQR) 
6.0 (1.0-17.0) 6.0 (1.0-17.0) 
*Only including those patients who had an admission. The comparisons in this table exclude 
individuals who were randomised between the MAOBI vs COMTI arms. Total admission 
duration was calculated as the sum of the duration of admissions for all patient divided by the 
number of patients. Admission duration was average admission duration for all the admissions 
in each group. 
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Figure 18: Time to first admission (dopamine agonists versus COMTI and MAOBI) for PD 
MED LATER patients who had non-elective admissions 
 
DDI: dopamine degradation inhibitor (MAOBI and COMTI) 
 
When comparing the number of PD-related non-elective admissions, no difference in 
rate of admissions was found between the two groups (RR 1.1; 95% CI 0.79, 1.53). 
After including H&Y stage, disease duration, gender and institutionalisation into a 
negative binomial model, there was no difference between dopamine agonists versus 
COMTI and MAOBI groups (RR 1.2, 95% CI 0.84, 1.60). For PD-related admission 
duration, a negative binomial regression model without covariates found no difference 
between the dopamine agonists and combined COMTI and MAOBI arms (RR 0.9 95% 
CI 0.73, 1.22). PD duration was the only significant covariate and when included, this 
did not change the inferences. Similarly, including patient admission duration as a 
random effect did not alter the results (RR 0.9, 95% CI 0.65, 1.17). There was no 
difference in the time to the first PD-related admission (figure 19). 
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Figure 19: Time to first PD-related admission (dopamine agonists versus COMTI and 
MAOBI) for PD MED LATER patients who had non-elective admissions 
 
DDI: dopamine degradation inhibitor (MAOBI and COMTI) 
 
There were 70 (20%) patients who had a fall/fracture/injury related admission. There 
was no difference in the time to first fall related admission between the dopamine 
agonist compared COMTI and MAOBI groups (figure 20). 
Figure 20: Time to first fall/fracture/injury related admission (dopamine agonists versus 
COMTI and MAOBI) for PD MED LATER patients who had non-elective admissions 
 
DDI: dopamine degradation inhibitor (MAOBI and COMTI) 
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MAOBI versus COMTI 
There was no difference in rate of admissions (RR 1.1; 95% CI 0.85, 1.52; table 14) and 
the time to first admission: HR 1.1, 95% CI 0.8, 1.4 (figure 21) between the MAOBI 
and COMTI groups. 
Table 14: Time to first admission, admission rate and duration for PD MED LATER patients 
who had non-elective admissions (MAOBI versus COMTI) 
 MAOBI COMTI 
N 144 141 
Number of admissions Mean (SD) 2.0 (2.38) 2.3 (2.78) 
Median (IQR) 1.0 (0.0-3.0) 1.0 (0.0-3.0) 
 N* 95 91 
Time to first  
admission (years) 
Mean (SD) 2.7 (1.92) 2.4 (2.42) 
Range 0 – 10 0 – 9 
Total Admission Duration 
(per  
Mean (SD) 36.6 (44.31) 51.3 (59.41) 
patient) Median(IQR) 18.0 (6.0-54.0) 36.0 (9.0-72.0) 
N 285 318 
Admission Duration (days) Mean (SD) 12.2 (18.56) 14.7 (22.01) 
 Median 
(IQR) 
6.0 (1.0-15.0) 6.0 (1.0-19.0) 
*Only including those patients who had an admission. The comparisons in this table exclude 
individuals who were randomised between the DA versus MAOBI and COMTI arms. Total 
admission duration was calculated as the sum of the duration of admissions for all patient 
divided by the number of patients. Admission duration was average admission duration for all 
the admissions in each group. 
 
When the admission duration was assessed using a negative binomial regression model 
adjusting for age, gender and institutionalisation, there was some evidence that patients 
in the COMTI arm had longer admissions (RR 1.2; 95% CI 0.99, 1.58). After including 
an offset for years in the trial, however, strong evidence of a difference between the 
arms in admission duration (RR 1.5; 95% CI 1.15, 1.97) was obtained. When similar 
analysis as that performed when comparing dopamine agonist versus COMTI and 
MAOBI was used, and adjusting for significant covariates, there was no evidence of a 
difference in admission duration (RR 1.2; 95% CI 0.92,1.63) between the COMTI and 
MAOBI treatment arms.  
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Figure 21: Time to first admission (MAOBI vs COMTI) for Later PD MED patients who had 
non-elective admissions 
 
When comparing PD-related non-elective admission rate without adjusting for 
covariates, the admission rate ratio was 1.2 (95% CI 0.87, 1.78). Including the only 
significant predictors in the model (institutionalisation), did not change the inferences 
on admission rates (RR 1.2; 95% CI 0.84, 1.70). In addition, no difference between the 
arms in time to first PD-related admission was found (figure 22). For PD-related 
admission duration, no difference between the MAOBI versus COMTI arm (RR 1.2; 
95% CI 0.92, 1.67) was found. There were no significant predictors for admission 
duration. Fitting a model with total admission duration per patient showed some 
evidence that the patients in the COMTI arm spent longer time in hospital (RR 1.5; 95% 
CI 1.0, 2.3). 58 (20%) of patients who had a fall/fracture/injury related emergency 
admission. There was no difference in the time to the first fall/fracture/injury-related 
admission, between the arms (figure 23). 
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Figure 22: Time to first PD-related admission (MAOBI vs COMTI) for PD MED LATER 
patients who had non-elective admissions 
 
 
 
Figure 23: Time to first fall/fracture/injury related admission (MAOBI vs COMTI) for PD 
MED LATER patients who had non-elective admissions 
 
3.4. Discussion  
This study assessed hospitalisation patterns in two large cohorts of PD patients with early 
and later stage disease. 73% and 70% from the PD MED EARLY and LATER study, 
respectively, were admitted to hospital at least once during the study period. Prospective 
hospitalisation data from HES was used in conjunction with PD MED data, which 
allowed comparisons of hospital admission rates by randomised treatment arm. To our 
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knowledge, this is the first study to assess PD hospitalisation by treatment class in a 
prospective and randomised fashion. PD MED was a large study which included a real 
world population and therefore results of this study can be generalised to the PD 
population seen in routine clinical practice.  Another strength of this study is its large 
sample size and availability of treatment, disease duration, and disease severity data from 
the PD MED database, which allowed comparisons to be made. These data were also used 
to control for potential confounders. Furthermore, all included patients had a PD 
diagnosis confirmed by a movement disorders specialist and based on the UK PD Brain 
Bank Criteria. Evaluating hospitalisation by treatment option may also provide insight 
into strategies that may be useful for preventing hospitalisation in PD 
The high rate of hospitalisation demonstrated here is comparable to that reported in a 
study in Ontario which compared hospitalisation between 15 306 patients with 
Parkinsonism and 30 612 age and gender-matched counterparts without Parkinsonism 
(Guttman et al., 2004). Similar to the current study, Guttman et al. (2004) assessed both 
elective and non-elective admissions and showed that 68.4% of the Parkinsonism patients 
were admitted over the 6 year study period (Guttman et al., 2004). Nevertheless, their 
study included all patients with Parkinsonism as study authors could not validate the 
diagnosis of included patients (Guttman et al., 2004). The current study only included 
patients with a diagnosis of idiopathic PD. The admission rate reported in our study is 
therefore more likely to reflect the correct PD hospitalisation frequency. 
There were no differences in hospitalisation rates, length of stay, and time to first 
admission, between levodopa and levodopa sparing arms. No difference was found when 
dopamine agonist and MAOBI arms were compared. In PD MED LATER trial cohort, 
no differences were found between the different adjunctive therapies. Since poor control 
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of motor symptoms and motor complications of treatment in later disease may lead to 
problems such as falls and fractures, the time to admission for these complications was 
also compared. But no difference in the time to admissions for falls and fractures was 
observed, when the treatment arms compared. These findings contrast with previous 
retrospective reports which demonstrated fewer emergency admissions and shorter length 
of stay in PD patients treated with rasagiline compared to dopamine agonists (Grubb et 
al., 2012).  
There are a two plausible explanations for the lack of a difference in hospitalisation rates 
and duration between the treatment groups. Firstly, the current study showed that patient 
age, disease duration, and severity were significant predictors of hospitalisation. These 
factors were shown to be associated with an increased risk of falls (Wood et al., 2002, 
Allcock et al., 2009, Wielinski et al., 2005), low mineral density(Di Monaco et al., 2006), 
and dysphagia (D'Amelio et al., 2006), all of which increase the risk of hospitalisation in 
PD. Since age, disease duration and severity are not amenable to symptomatic treatments, 
therapy is unlikely to influence hospitalisation rates in PD. Secondly, addressing motor 
aspects of PD alone without addressing critical non-motor factors such as dementia, 
anxiety, and depression is unlikely to be effective in reducing admissions in PD. A more 
comprehensive approach which covers the management of both motor and non-motor 
aspects of the disease may be required.   
Repeat hospital admissions were common among the PD MED patients who were 
included in this study. For example, from the group of patients who had non-elective 
admissions, 63% and 70% (PD MED EARLY and LATER, respectively) had repeat 
hospital admissions during the study period. Hassan et al. (2013) also reported high rates 
of repeat hospital encounters in 51% of PD patients ( (Hassan et al., 2013). These results 
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demonstrate substantial utilisation of health resources by PD patients across all disease 
stages.   
As expected, the majority of the elective or planned admissions were of short duration: 
80% and 72% of elective admissions in EARLY and LATER PD MED groups, 
respectively, were zero bed days. 
Considering non-elective admissions, there was no difference in the median duration of 
stay between the PD MED EARLY and the LATER cohort. This observation was 
unexpected since patients with more advanced disease are more likely to develop 
complications during hospital admissions which can prolong length of stay. In addition 
in advanced disease, treatment regiments are complicated, therefore treatment errors are 
more likely to occur resulting in longer duration of hospital stay. The commonest reasons 
for non-elective admission in both groups were the same: falls fractures, infections and 
motor symptoms (primary diagnosis: PD). This provides an explanation for the similar 
lengths of stay. 
The admission duration reported in this study is similar to what has been previously 
reported in other UK studies which assessed emergency admissions only. A recent study 
in England used HES data to evaluate the cost of PD hospitalisation and also assessed 
other aspects of hospitalisation including length of stay, reasons for admissions and 
mortality (Low et al., 2015). The study reported mean lengths of stay which ranged from 
5-17 days among PD patients of different age groups (Low et al., 2015). Another 
retrospective study assessed the reasons for PD emergency admissions to a district general 
hospital in England and reported a mean length of stay of 21 days among the 120 PD 
patients (Woodford and Walker, 2005). Furthermore, a prospective study reported a mean 
duration of stay of 12 days during emergency admissions to a general hospital in northern 
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Italy over a 1 year period (Martignoni et al., 2004). In Turkey, a small retrospective study 
including 66 PD patients admitted to emergency department reported a mean duration of 
12 ± 7 days. A number of factors may influence length of stay during. Low et al. (2015) 
showed an increasing length of stay with patient age in PD patients (Low et al., 2015). 
Differences in healthcare systems, hospital reimbursements, hospital bed availability, and 
social care structures may also influence length of stay, therefore direct comparisons of 
duration of admissions between countries may not be accurate. 
Although the current study did not have a control group of people without PD, there is 
clear evidence that PD patients stay in hospital longer than non-PD controls (Lubomski 
et al., 2015, Low et al., 2015, Guttman et al., 2004). Low et al. (2015) showed that PD 
patients stayed in hospital 7 days longer than controls (Low et al., 2015). A large 
retrospective Australian study compared demographic details and hospitalisation aspects 
of PD and non-PD patients and reported a median length of stay 7 (3-13) in PD patients 
and 1 (1-7) days in those without PD (p<0.001) (Lubomski et al., 2015). Similarly, 
Guttman et al. (2003) reported 1.19 times longer length of stay in PD patients compared 
to controls (Guttman et al., 2003). Several reasons including deterioration in PD motor 
symptoms, account for the prolonged admissions during PD hospitalisation. Gerlach et 
al. (2012) showed that 20% of PD patients who were admitted to hospital reported a 
deterioration in motor symptoms and a further third develop complications such as 
confusion and infections (Gerlach et al., 2012). The risk of motor deterioration was 
associated with poor PD medication management (Gerlach et al., 2012, Gerlach et al., 
2013). Magdalinou et al. (2007) performed a case note review of 35 patients admitted to 
hospital and reported prescription errors and a lack of awareness by junior doctors of the 
available formulations of PD medication, which resulted in complications (Magdalinou 
et al., 2007). An association between PD medication errors and prolonged length of stay 
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was also demonstrated in a recent cross-sectional study (Martinez-Ramirez et al., 2015). 
The authors reviewed records for 212 PD patients who had 339 admissions and showed 
that those who had missed/delayed doses and had dopamine blockers prescribed stayed 
in hospital for longer periods than those who did not have similar prescription errors 
(Martinez-Ramirez et al., 2015). 
Infections, falls, fractures, and injuries were the commonest reasons for non-elective 
admissions in both PD MED EARLY and LATER groups, which is consistent with 
previous reports. There were more PD-related non-elective admissions in the later than 
the early disease group, which is expected: 59% and 45%, respectively. Disease and 
medication related complications such as postural instability, hypotension, falls, 
fractures, and neuropsychiatric symptoms occur more frequently in later stages of the 
disease leading to frequent hospital admissions for these complications. Nevertheless, 
patients with early disease were also admitted to hospital for these complications. Falls, 
infections, and fractures are also an early disease phenomenon, albeit less frequent.  
Walker et al. (2013) assessed the incidence of hip fractures in people with PD compared 
with non-PD controls. 72% of the PD patients who had hip fractures were reported to 
have mild to moderate PD (H&Y stages 1-3) (Walker et al., 2013). Low mineral bone 
density, a known significant risk factor for fractures, (Schneider et al., 2008) has been 
demonstrated in patients with early PD (Van den Bos et al., 2013b). Another study 
reported falls in 23% of patients with early PD (Voss et al., 2012). Dysphagia, silent 
aspiration, and impaired cough efficacy are thought to contribute to the increased risk of 
respiratory tract infection in PD and these abnormalities have been demonstrated in both 
early and advanced disease (Potulska et al., 2003, Ebihara et al., 2003) which may explain 
the high number of infections leading to admissions in the current study. Occurrence of 
these complications in early disease suggests that similar strategies may be employed 
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across all disease stages to reduce hospitalisation in PD. Targeting patients with early 
disease may prevent future hospitalisation. Such interventions may include osteoporosis 
prevention for fractures, falls management, and screening for dysphagia to reduce the risk 
of aspiration pneumonia. The effectiveness of these preventative strategies should be 
examined in further studies.  
Some patients were admitted to hospital for management of motor symptoms (primary 
diagnosis code PD), these only contributed to a small proportion of non-elective 
admissions: 7% and 12% in early and later PD MED, respectively. Since the majority of 
the admissions were for reasons other than management of motor symptoms, this 
observation may also explain the lack of a difference in hospitalisation between patients 
on the different oral treatments for PD motor symptoms.  
There are a number of limitations to this study. Firstly, there was a possible under-
estimation of PD admissions. Incomplete episodes at the beginning or end of the study 
period were excluded which probably resulted in an under estimation of the number and 
duration of admissions. Evaluation of coding of PD admissions at a tertiary hospital in 
England showed significant underreporting of PD admissions on the Secondary Uses 
Services database which is linked to HES (chapter 4). This suggests that the extent of PD 
hospitalisation may be even higher than reported in the current study. Finally, hospital 
admissions to private hospitals are not included in HES which may have resulted in 
underestimation of PD hospitalisation, but this only contributes to a small proportion of 
hospital admissions in the UK. 
In conclusion, this study demonstrated a high rate of hospitalisation in patients with early 
and advanced PD. Although available symptomatic treatments are effective in controlling 
motor symptoms, they had no differential effect in reducing hospitalisation rates and 
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length of stay in PD. Addressing motor aspects of the disease alone may not be sufficient 
to reduce the burden of hospitalisation in PD. Disease related complications which are 
frequently encountered in advanced disease, contributed to a large proportion of non-
elective admissions in both groups of PD patients. Therefore, screening and early 
management of these complications in addition to addressing motor and non-motor 
aspects of the disease may prevent unplanned admissions in PD and reduce the associated 
costs. These prevention strategies should be introduced earlier in the course of the disease. 
Future studies should evaluate the effectiveness of preventative interventions that address 
both motor and non-motor aspect of the disease.  
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CHAPTER 4: UNDER-REPORTING OF PARKINSON’S DISEASE HOSPITAL 
ADMISSIONS 
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4.2. Background 
Hospitalisation in PD is associated with a substantial economic burden (Low et al., 2015). 
It is crucial that metrics relating to hospital episodes are accurate. These data form part 
of the Secondary Uses Services (SUS) database in England which is used for hospital 
reimbursements and health care planning (Payne, 2013). In this study, the number and 
characteristics of PD admissions to a large Birmingham hospital were estimated and the 
coding accuracy of the admissions was also assessed. 
4.3. Methods  
This service evaluation was approved and registered with the University Hospital 
Birmingham (UHB) audit department. The hospital is a large tertiary centre in the UK’s 
second largest city, with a capacity of 1 213 inpatient beds, and providing secondary care 
services to an estimated 800 000 patients per year (University Hospital Birmingham NHS 
foundation Trust, 2013). The hospital also has a large catchment area beyond the West 
Midlands and is the regional centre for functional surgery in PD(University Hospital 
Birmingham NHS foundation Trust, 2013). Data extraction was performed by the UHB 
informatics department and data were stored in a secure SQL server. 
The SUS database is a database where all data pertaining to health resource use in NHS 
trusts in England are stored (Payne, 2013). The SUS was searched for PD admissions 
during the period 1st July 2009 to 30th June 2013. Admissions where PD was recorded 
as a primary or secondary diagnosis were identified from this database using the ICD-10, 
codes G20 and F023 for PD and PD dementia, respectively, based on the discharge date. 
The UHB electronic inpatient Prescribing Information and Communications System 
(PICS) database, stores information on medications prescribed during hospital 
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admissions. The PICS database was searched for all admissions where PD medications 
were prescribed during the study period.  
Quality assurance checks on the data were performed. Firstly, since PD is less prevalent 
in younger age groups (Pringsheim et al., 2014), all patient records for admissions 
identified from SUS and PICS, where the patient age was under 40 years, were reviewed, 
and those with diagnoses other than PD were excluded. Secondly, since dopaminergic 
drugs used for treating PD are also used in other conditions, a sample of 20 medical 
records for patient admissions identified from PICS database search were reviewed, to 
ascertain if they had PD. Of the 20 records, 55% (n=11) had PD and were all on levodopa, 
35% (n=7) were on low dose non-ergot dopamine agonists for restless legs syndrome or 
cabergoline for pituitary adenomas, and the remaining 2 patients had normal pressure 
hydrocephalus and dystonia. Patient records for all admissions obtained from the PICS 
database, where bromocriptine, cabergoline and low dose non-ergot dopamine agonists 
were prescribed (pramipexole <1.05mg, ropinirole <6mg/day, rotigotine <6mg/day) were 
reviewed, and excluded admissions for patients with other diagnoses. Case notes for 
patients contributing to the remaining admissions identified by the PICS search were also 
reviewed and admissions for those who did not have PD were also excluded. 
For all admissions identified in the SUS database using G20 and F023 ICD-10 codes, and 
the PICS database, patient hospital numbers were obtained. A supplementary search of 
the two databases was then undertaken using these patient hospital numbers to identify 
any additional hospital admissions missed by the SUS and PICS criteria, but still 
occurring in the evaluation period. 
To estimate the number of PD patients who were admitted to hospital, data from the 
electronic search of SUS and PICS databases were used and capture-recapture methods 
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were applied to estimate the number of patients missed by both searches (Hook and Rega, 
1995). This is a recognised method for estimating population sizes or disease occurrence 
and assumes that the available data sources do not identify the entire population being 
studied (Brittain and Böhning, 2008). Chao’s lower bound method which provides a 
reliable estimation of the total population size was used (Brittain and Böhning, 2008).  
The same capture-recapture analysis was also applied to the number of PD admissions 
that were identified after electronic searches of SUS and PICS. Admissions obtained from 
the supplementary search using hospital numbers were not included in the capture-
recapture analysis, as this was not an independent source of admissions. 
Assessing the coding error rate 
The coding error rate was ascertained as the proportion of PD admissions not recorded in 
the SUS database. The denominator was the sum of all admissions identified by the three 
searches (PICS, SUS, and hospital number search) described above and the numerator 
was the number of PD admissions not appearing in the SUS database. Descriptive 
analyses of the type of patients (age, gender) and information on the admission (e.g. 
number of admissions per patient during the study period, length of stay, and reasons for 
admissions) were performed. 
4.4. Results 
Exclusions 
2 300 possible PD admissions were identified from SUS and PICS databases over the 4 
year period.  16 admissions for patients below the age of 40 years who had diagnoses 
other than PD (dopa-responsive dystonia, pituitary tumours, and drug-induced 
Parkinsonism) were excluded (figure 24). After reviewing case notes for patients who had 
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admissions identified from the PICS database, 285 admissions for patients who did not 
have PD were also excluded.  
Figure 24: PD admissions identified from SUS, PICS databases search 
 
 
Numbers of patients 
997 patients were identified from SUS (656 of these were in both PICS and SUS, and 341 
patients in SUS only), and 71 patients were identified from PICS only (figure 25). 
Therefore, in total, the PICS and SUS database identified 1 068 PD patients as having 
been admitted during the 4 year study period: median age (IQR) was 75 (67-82) years and 
59% were male. Capture-recapture methods estimated that the number of patients missed 
by both databases was 59, meaning that over the 4 year period an estimated 1 127 PD 
patients, 95% CI 1 107 to 1 146, were admitted to UHB. Therefore, the SUS database 
missed an estimated 130 PD patients (range: 110-149 missed patients). 
PD admissions with either a PD diagnosis (ICD-10 F02.3, 
G20) or on PD medications (N=2 300)
Total admissions (N=1 999)
Elective admissions 
(N= 742)
Emergency admissions 
(N=1 257)
Admissions excluded
1) Admissions for patients aged< 40yrs without PD 
(N=16)
2) PICS only admissions with diagnoses other than PD 
(N=285)
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Figure 25: The number of Parkinson’s disease patients by method of ascertainment 
 
Figure 25 above shows the number of PD patients obtained by searching the PICS, SUS 
databases. The capture recapture method estimated that 59 patients were not recorded in these 
two databases. 
Numbers of admissions  
SUS database identified 1 811 admissions during the study period. Of these, 1 053 
admissions appeared in both databases (PICS and SUS), and 758 admissions were in SUS 
only. 188 admissions were in PICS only. Therefore, in total, 1 999 admissions were 
identified from the two databases. Capture-recapture methods estimated that the number 
of admissions missed by the SUS and PICS searches was 212, meaning that over the 4 
year period, there were an estimated 2 211 PD admissions, 95% CI 2 169 to 2 252, to 
UHB. 
A supplementary search of both databases using the patient hospital numbers of the 1 068 
patients obtained from initial SUS and PICS searches, identified an additional 479 PD 
PICS: PD 
medication 
71      656         
SUS:
ICD-10 codes
341
Capture 
recapture 
estimate   
59
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admissions during the study period. For these admissions, no PD ICD-10 code was 
recorded on SUS and no PD medications were prescribed on PICS (table 15). Therefore, 
when the three search criteria (SUS, PICS and hospital numbers) were combined, a total 
of 2 478 PD admissions were identified during the study period. 
Table 15: Number of Parkinson’s disease admissions by data source 
 Admissions 
Data Source Total Elective Non-Elective 
SUS 1 811 700 1 111 
PICS only 188 42 146 
Hospital number search 479 324 155 
Total 2 478 1 066 1 412 
 
Coding errors 
The admissions coding error rate was calculated using data from the three sources: 1 811 
PD admissions from SUS database, 188 from PICS database only, and 479 admissions 
from the hospital number supplementary search. Therefore, 27% (667 not recorded on 
SUS/2 478) of these admissions were not coded as having PD on discharge from hospital, 
and were therefore not recorded in the SUS database during the study period. 
Capture-recapture methods estimated that there were 2 211 admissions of PD patients. 
There were 1 811 admissions recorded on SUS, which gives an estimated coding error 
rate of 18% (400 admissions not recorded on SUS/2 211 admissions). 
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Non-elective admissions 
Of the 2 478 admissions identified during the study period, there were 1 412 (57%) non-
elective admissions in 747 patients: median age 79 (71-85) years and 57% were male. 
60% (n=451 patients) were admitted only once during the study period and 40% had 
repeat hospital admissions (range 2-18 admissions). Median length of hospital stay was 6 
(1-18) days. 45% of the admissions were under the general medical team, 21% geriatric 
medicine, 7% general surgery, 5% trauma and orthopaedics, 5% accident and emergency, 
4% neurosurgery, and only 1% were admitted to the neurology ward. Infections (20 %), 
and falls, fractures and injuries (15%) were the commonest reason for non-elective 
admission (Table 16). 
Elective admissions 
There were 1 066 elective admissions in 502 patients during the 4 year study period: 
median age 71 (63-79) years and 64% were male. Median length of stay was 0 (0-1) days. 
The majority of elective admissions were to neurosurgery (24%), nephrology (19%), 
neurology (9%), general surgery (9%), cardiology (6%), and ophthalmology (4%). The 
commonest reasons for elective admission included PD (20 %), genitourinary disorders 
(20%), neoplasms (13 %), musculoskeletal disorders (11 %), central nervous system and 
disorders of sense organs (7%), gastrointestinal disorders (7%) and PD surgery (6 %). 
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Table 16: Commonest primary reasons for non-elective and elective admissions 
 
4.5. Discussion  
This study showed a significant under-coding of PD on discharge from hospital. 8% 
(n=188) of all admissions were identified by the prescription database only, implying that 
although PD medications were prescribed, PD diagnosis was not coded on discharge so 
these admissions were not found in the SUS database. Another 19% of PD admissions 
were identified based on searching both PICS and SUS databases using hospital numbers 
of patients previously identified using PD and PD dementia ICD-10 codes and PD 
medication, suggesting further underestimation of PD admissions by SUS. In total, 27% 
of PD admissions were not recorded on the SUS database during the study period. 
  Total Elective Non-Elective 
Age  Median:75 
IQR:67-82 
Median:71IQR:63-
79 
Median:79 
IQR:71-85 
  Range:40-101 Range:40-94 Range:44-101 
Cause of 
Admission 
Infections 186 11.6% 0 0 186 17.2% 
 Cardiovascular and 
circulatory disorders 
155 9.7% 48 8.6% 115 10.6% 
 Falls fractures  112 7.0% 4 0.7% 109 10.0% 
 Gastrointestinal disorders 102 6.4% 34 6.1% 76 7.0% 
 Other injuries  75 4.7% 1 0.2% 74 6.8% 
 PD  218 13.6% 164 29.4% 64 5.9% 
 PD mental health symptoms 65 4.1% 1 0.2% 64 5.9% 
 Problems related to blood 
pressure 
61 3.8% 1 0.2% 61 5.6% 
 Musculoskeletal and 
connective tissue disorders  
102 6.4% 48 8.6% 56 5.1% 
 Central nervous system and 
disorders of sense organs 
86 5.4% 42 7.5% 44 4.0% 
 Genitourinary tract 
disorders 
51 3.2% 13 2.3% 41 3.8% 
 Respiratory tract disorders 38 2.4% 0 0.0% 38 3.5% 
 PD gastrointestinal 30 1.9% 2 0.4% 28 2.6% 
 Endocrine disorders 32 2.0% 7 1.3% 25 2.3% 
 Neoplasms 108 6.7% 89 15.9% 23 2.1% 
 Complication of device 
implants or prosthesis 
medical and surgical 
procedure 
30 1.9% 11 2.0% 21 1.9% 
 PD surgery  71 4.4% 58 10.4% 16 1.5% 
 Other infectious disease 12 0.7% 0 0.0% 12 1.1% 
 PD other NMS 12 0.7% 0 0.0% 12 1.1% 
 Dermatological disorders 16 1.0% 9 1.6% 7 0.6% 
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Capture-recapture methods showed slightly lower estimates for PD under-coding on SUS 
(18%), which indicates that the method is not always reliable when used to estimate 
populations. However, the method also showed that PICS and SUS searches 
underestimated the number of PD patients admitted during this period by 59 patients, 
suggesting that the capture-recapture coding error rate is higher than 18%. The methods 
used for ascertaining admissions in the present study were exhaustive, so our estimate for 
under-reporting of PD admissions on SUS is likely to be accurate.  
Under-coding of other chronic conditions as secondary diagnoses has also been reported 
when hospital inpatient data were used (Whitston et al., 2012, Anwar et al., 2011). Anwar 
et al. (2011) reported 41% under-coding of diabetes admissions when Scottish inpatient 
hospital data were compared with the Scottish National Diabetes register (Anwar et al., 
2011). In another study in England, an estimated 9% of diabetes hospital admissions were 
not coded when HES data were compared with data from the English National Diabetes 
audit (Whitston et al., 2012). Although these studies showed a wide disparity in diabetes 
under-coding, results suggest that improvements in diagnosis coding are required. This is 
crucial since resource allocation (Payne, 2013), performance metrics used for comparing 
NHS trusts, and hospital reimbursement (Department of Health, 2013) are derived from 
inpatient data. A recent audit of accident and emergency and inpatient care data of NHS 
trusts in England (2012/13) conducted by the Audit Commission reported a mean coding 
error rate of 11% for all primary diagnoses and 15% for secondary diagnoses for inpatient 
spells (Department of Health, 2013).  
When compared to these previous figures, the present study showed a much higher coding 
error rate. Several reasons may account for the difference in coding error rates. Firstly, 
the current study was disease-specific whereas the NHS audit reported an overall coding 
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error rate for several hospitals and all diagnoses. Coding accuracy for PD is likely to vary 
across different hospitals, as occurs with other chronic conditions (Anwar et al., 2011, 
Whitston et al., 2012). The majority of admissions in the current study (57%) were non-
elective and infections, falls, fractures, and injuries were the commonest primary reasons 
for admissions. Since PD was a secondary diagnosis during these admissions, it was less 
likely to be recorded. Lastly, 78% of non-elective admissions were recorded under teams 
other than neurological or geriatric teams, which may account for the high PD under-
coding. Although no comparison of coding error differences between different admitting 
specialties was performed, it is likely that teams which are familiar with PD management 
are more likely to record the disease on discharge. This requires further verification in the 
future.  
The high under-reporting of PD admissions shown in our study questions the quality and 
usefulness of SUS data for PD healthcare planning. The financial implications of such 
errors on individual hospital trusts are likely to be substantial as previously shown 
(Nouraei et al., 2009, Razik et al., 2013). A recent study to evaluate the reasons, rate, and 
cost of PD hospitalisation in England reported expenditure of £907 million on PD 
admissions over a 4 year period (Low et al., 2015). If 27% of PD admissions are not 
recorded on the SUS database as shown in the present study, then the NHS expenditure 
on PD admissions is underestimated by approximately £61 million annually. 
The English NHS audit in 2012/13 found that coding inaccuracies for inpatient spells 
were mainly due to poor recording of secondary diagnosis codes by coders, (Department 
of Health, 2013) who are not medically trained. In addition, discharge summaries which 
contained inadequate and inaccurate information were used to obtain information for 
coding (Department of Health, 2013). Coders also relied on poorly documented medical 
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notes for extracting data, which led to coding errors (Department of Health, 2013). In 
other studies, lack of involvement and awareness of the importance of coding by medical 
staff were some of the key factors contributing to coding errors (Razik et al., 2013, Pillai 
A and Medford A.R, 2013)..  
A number of recommendations aimed at tackling these potential sources of coding errors 
can be proposed. These include dissemination of information regarding the importance 
of accurate and legible handwritten medical documentation on all wards and in the 
doctor’s mess. Coding of neurological diagnoses for patients who attend the neurology 
outpatients department has also been proposed. Senior clinicians who review patients in 
these clinics are more likely to record accurate neurological diagnoses. Our hospital uses 
electronic outpatient records and these are linked to the inpatient prescribing database 
which is also available to coders for use during coding. This may improve coding of 
neurological diagnoses when patients are discharged from hospital. The effect of this 
intervention on inpatient coding of neurological diagnoses will be assessed in the future. 
If results show an improvement in the coding error rate, this intervention will be trialled 
in other departments. Further training of coders is also required. 
Limitations of this study include its reliance on retrospective data which may lead to 
inclusion of admissions for patients without PD. This potential problem was addressed 
by excluding admissions from the PICS database where small doses of dopamine agonists 
were prescribed for conditions such as restless legs syndrome and pituitary adenomas. 
Case notes of all patients who were identified by the PICS database only were reviewed 
and non-PD cases were excluded. Admissions identified from SUS database only but 
having no PD medications prescription may reflect prescription errors which are common 
when PD patients are hospitalised (Derry et al., 2010). It is also plausible that a proportion 
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of these could have been incorrectly coded as having PD. For example patients with other 
types of Parkinsonism not requiring dopaminergic medication may have been coded as 
having PD. Patients with early PD, who have mild motor symptoms, which do not require 
treatment could potentially account for a small proportion of these patients. 
If under-reporting of PD admissions on the SUS database is repeated nationally, the NHS 
expenditure on PD admissions in England is underestimated by approximately £61 
million annually. If such coding errors are not addressed, these figures will continue to 
rise with increasing life expectancy, and thus PD prevalence, in coming decades. The 
NHS should take urgent action to implement measures to improve coding accuracy to 
improve healthcare planning and hospital reimbursement. 
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CHAPTER 5: DEVELOPMENT OF A MAGNETIC RESONANCE IMAGING 
(MRI) SENSITIVE PROBE FOR IMAGING IN PARKINSON’S DISEASE 
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5.1. Background 
Dopamine metabolism 
The monoamine dopamine (3,4hydroxyphenylethyl-amine) was discovered by Arvid 
Carlsson in the 1950s (Carlsson, 2003). The neurotransmitter plays a crucial role in many 
processes including movement, cognition, learning, appetite, mood, and also in peripheral 
sympathetic nervous system (Beaulieu and Gainetdinov, 2011). A large proportion of 
dopaminergic neurons in the brain are found in the substantia nigra and ventral 
tegmentum area of the midbrain. These neurons have three major projections to the 
striatum, limbic and prefrontal cortical regions (Bjorklund and Dunnett, 2007). 
Degeneration of the substantia nigra dopaminergic neurons is the main mechanism by 
which the motor syndrome of PD develops. Understanding the processes involved in 
dopamine synthesis, release, storage and uptake at the presynaptic terminal is crucial for 
a number of reasons. Firstly, it may provide insights into processes that lead to the 
degeneration of dopaminergic neurons. For example, impaired dopamine metabolism 
may lead to production of toxic oxidative species which have been implicated in the 
pathogenesis of the dopaminergic neuron degeneration (Meiser et al., 2013). Secondly, 
current PD treatments exert their action by either binding to the dopamine receptors or by 
inhibiting various enzymes that are involved in dopamine degradation. Further, ligands 
that are currently used in imaging the dopaminergic system bind to various targets 
involved in dopamine metabolism (figure 2).  
Dopamine synthesis and degradation 
The initial step in dopamine biosynthesis involves conversion of tyrosine to 
dihydroxyphenylalanine ( levodopa) by the enzyme tyrosine hydroxylase (TH), a process 
regulated by the cofactor tetrahydropterin (Elsworth and Roth, 1997, Meiser et al., 2013). 
Levodopa is then decarboxylated by aromatic amino acid decarboxylase (AADC) to form 
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dopamine which is in turn transported actively from the cytoplasm into storage vesicles, 
(Elsworth and Roth, 1997) by the vesicular monoamine transporter 2 (VMAT2) (Meiser 
et al., 2013). Dopamine is pumped via a proton gradient into the vesicles and can reach 
very high vesicular concentrations (estimate 0.1M) compared to the cytoplasmic 
concentration (Elsworth and Roth, 1997). This prevents formation of oxygen reactive 
products from dopamine oxidation in the cytoplasm (Meiser et al., 2013). Dopamine then 
exerts its functions by binding to and activating its receptors (D1-5) on the post synaptic 
terminal (Beaulieu and Gainetdinov, 2011).  Dopaminergic neurotransmission is 
regulated by dopamine auto-receptors (D2-like), which are present on presynaptic 
terminal, and these receptors inhibit dopamine synthesis and release, and also slows down 
the firing rate (Elsworth and Roth, 1997). These D2 auto-receptors also potentially 
regulate dopamine transporter (DAT) by increasing its surface expression thus increasing 
dopamine uptake (Eriksen et al., 2010). DAT and other monoamine transported such 
serotonin transporter (SERT) and noradrenaline transporter (NET) belong to a family of 
transporters called solute carriers 6 (SLC6) which transport monoamines using a sodium 
transmembrane gradient and chloride co- transport (Eriksen et al., 2010). Once in the 
cytoplasm, dopamine is either actively transported back into storage vesicles for further 
release or metabolised by the enzyme monoamine oxidase (MAO) to form 3,4 
dihydroylphenylacetic acid ( DOPAC)  (Elsworth and Roth, 1997, Meiser et al., 2013). 
The remaining dopamine in the cytoplasm is degraded by monoamine oxidase and 
catechol-O-methyl transferase (COMT) to form homovallinic acid (HVA) by glial cells 
(Meiser et al., 2013). Figure 26 below illustrates the dopamine metabolism discussed 
above. 
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Figure 26: Dopamine synthesis and degradation 
 
Figure obtained from Eisenhofer and Reichmann 2012: Dopamine synthesis, storage, release, 
uptake, and degradation. Enzymes involved in dopamine synthesis: TH, tyrosine 
hydroxylase and AADC, aromatic acid decarboxylase, Transporter for dopamine storage: 
VMAT2 (not shown) is found the storage vesicles. Reuptake transporters: DAT, dopamine 
transporter; EMT, extracellular monoamine transporter. Receptors: D1, dopamine D1 receptor; 
D2 dopamine D2 receptor.  Degradation enzymes: MAO, monoamine oxidase; COMT, 
catechol-O-methyltransferase. Degradation products: DOPAC, dihydroxyphenylacetic acid; 
HVA, homovanillic acid; MTY, 3-methoxytyramine.  
Figure obtained from Eisenhofer G, Reichmann H (2012) Dopaminergic Neurotransmission in 
Primer on the Autonomic Nervous System (Third Edition), Paton D, Robertson I, Biaggioni G, 
Burnstock PA, Low JFR, eds. Academic Press, San Diego, pp. 63-65, with permission from 
Elsevier 
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5.2 Aims 
MRI has several advantages over radionuclide imaging in PD, including availability, 
lower costs, and no exposure to radiation. But its use as a diagnostic tool in PD is limited 
by low sensitivity (Brooks, 2010). Nevertheless,  as highlighted in Chapter 1, small 
research studies have shown that when various MRI modalities such as diffusion tensor 
imaging, susceptibility imaging, and high field strength are combined, MRI gives high 
sensitivity and specificity for differentiating brains of individuals with PD from healthy 
control brains,(Peran et al., 2010)  atypical forms of the disease, (Prodoehl et al., 2013) 
and may also have a role in assessing disease severity and progression (Zhang et al., 2010, 
Ulla et al., 2013). This suggests that with further developments, MRI has potential utility 
as a diagnostic and prognostic biomarker. 
The main objective of this study was to determine the feasibility of using two types of 
MRI sensitive probes (lanthanide and 19F based) for imaging dopaminergic cells in PD. 
These probes may be used in the future in conjunction with other MRI techniques such 
as DTI, high field strength and SWI to increase the sensitivity of the tool and this project 
forms the initial stage in its development. 
5.3. Materials and methods 
Lanthanide probes 
Lanthanides are a group of rare earth metals, used as molecular probes and contrast agents 
by utilising their fluorescent and magnetic properties (Heffern et al., 2014). MRI contrast 
agents used in clinical practice are based on the lanthanide, gadolinium which has 
magnetic properties. Europium has fluorescent properties and its long stokes shift 
(difference between excitation and emission wavelengths) is utilised in fluorescence 
microscopy studies to abrogate the influence of cellular auto-fluorescence by use of 
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interference filters (Diamandis and Morton, 1988, Murphy and Davidson, 2012). For 
purposes of this study europium based compounds were used for fluorescence 
microscopy. Since europium and gadolinium are isoelectric, when a lead compound is 
obtained, europium will be replaced with gadolinium to form a probe which will then be 
tested in small animals using magnetic resonance imaging.  
DAT ligands used in clinical practice are cocaine analogues which bind to surface DAT 
with very high affinities. The hypothesis for this study was that the lanthanide based probe 
would be taken up by dopaminergic terminals via DAT or neutral amino acid transporters 
in a similar fashion as PET ligands. This approach potentially allows intracellular 
accumulation of the substrates in sufficiently high amounts to allow visualisation by 
fluorescence microscopy and also by MRI in subsequent studies. Hence, compounds that 
are DAT or neutral amino acid transporter substrates, instead of those that only bind to 
surface DAT, were synthesised.  
Given that dopamine and levodopa are actively pumped into the dopaminergic terminals 
via DAT and neutral amino acid transporter respectively,(Camargo et al., 2014) probes 
which are potential DAT or ADCC substrates were synthesised by conjugating europium 
to either dopamine or levodopa. Feasibility of using the europium probes was 
demonstrated in a previous pilot study in our laboratory (unpublished). In the current 
study cellular uptake of europium compounds by PC12 cells was assessed using 
fluorescence microscopy.   
Europium-dopamine (MT172, MT630) and Europium-L dopa (MT519) conjugates, were 
synthesised at the Oxford Chemistry Research Laboratory courtesy of Dr Manuel 
Tropiano and Professor Stephen Faulkner. The chemical structures and fluorescence 
spectra of the compounds MT172, MT630, and MT519 are shown in figure 27 below. As 
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preluded above, the europium compounds characteristically have long stoke shifts: 
excitation wavelength is in the ultraviolet to blue range and emission within the visible 
(red) range of the electromagnetic spectra. Each compound was diluted with 
physiological saline (PSS) to make a stock solution of concentration 10mM and stored in 
100µL aliquots at -200 C. On the day of the experiments the compounds were thawed and 
diluted further with PSS to make 30µM, 100 µM, and 300µM solutions for the 
experiments and warmed to 370C.  
PC12 Cells 
PC12 cells were obtained as a gift from Professor Ann Logan’s laboratory at the 
University of Birmingham.  The cells were used for these experiments for several reasons. 
Firstly, the cell line has been used broadly in PD. Greene and Tischler (1976) 
demonstrated that the large quantities of cells could be produced and maintained easily 
(Greene L.A and Tischler A.S, 1976), which is a useful property for screening studies. 
Furthermore, PC12 cells possess the machinery required to produce dopamine and also 
contain energy dependent transporter mechanisms for uptake of monoamines into the 
cells (Greene and Rein, 1977, Kadota et al., 1996).These properties are essential for 
cellular uptake of potential DAT or ADCC substrates, which were used in this project. 
Maintaining undifferentiated PC12 cells 
Undifferentiated PC12 cells were grown in Roswell Park Memorial Institute (RPMI) 
1640 (+glutamax) culture media (Thermofisher: Life technologies), using established 
protocols (Elobi, 2014). RPMI culture media was supplemented with horse serum 10%, 
foetal calf serum 5% and 1% penicillin/streptomycin (50µg/ml) to make the complete 
growth media and stored at 4oC. Cells were grown in  25cm2 flasks, in an incubator with 
5% CO2 and 95% humidified air at 37 
0C. Cell culture media change was performed every 
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two days. All media preparation and change was performed in a sterile fume cupboard, 
cleaned with 70% ethanol prior to use. Cells were transferred from the tissue culture flask 
to a falcon tube and gently pipetted to separate the cells. 10µL of the cell suspension was 
mixed with an equal volume of tryptan blue and cells were counted using a 
haemocytometer. The cell suspension was centrifuged at 800 revolutions per minute 
(RPM) for 5 minutes. The supernatant was discarded and the cell pellet dislodged by 
adding fresh growth media. The cell density was adjusted by adding the required volume 
of fresh media to maintain a maximum cell density of 500 000 cells per ml and transferred 
to the tissue culture flask which was stored in the incubator. 
Culture media for differentiating PC12 cells 
Dulbecco’s Modified Eagle Media (DMEM) (1X) (+Glutamax) (Gibco® life 
technologies) was used for differentiating PC12 cells. This was supplemented with 1% 
horse serum, 1% penicillin/streptomycin and 100ng/ml nerve growth factor (NGF) 2.5S 
(Sigma-Aldrich®, UK). The differentiation media was changed daily for 7 days using the 
protocol described by Greene and Tischler (Greene L.A and Tischler A.S, 1976). Cell 
differentiation was monitored daily using an inverted microscope.  
Physiological Salt solution (PSS) 
One litre of PSS was made up by adding 0.368g EDTA( 1mM), 4.766g HEPES (20mM), 
0.373g KCl (5mM), 7.592g NaCl (130mM), 0.901g glucose(5mM), 1.3mls MgCl (from 
1mM stock solution yielding 1.3mM), and 1.8mls CaCl (1.8mM) to 500mL distilled 
water, then and made up to 1000mls. The PH was adjusted to 7.4 using 1M NaOH (Elobi, 
2014). 
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Cover slips for plating PC12 cells 
13mm2 cover slips were used for plating cells. The cover slips were sterilised with 70% 
ethanol and left to dry in a sterile fume cupboard. Poly-L-lysine* sigma cat number P4707 
(0.01%) was diluted 1:1 with sterile filtered water. Cover slips were soaked in the diluted 
poly-l-lysine for 5 minutes and then allowed to air dry for 2 hours. Prior to an experiment, 
cells were seeded onto coverslips at density of 50 000cells per coverslip and placed in an 
incubator for one hour to allow the cells to attach before adding fresh culture media: 
RPMI or DMEM based culture media for undifferentiated and differentiated PC12 cells 
respectively. For undifferentiated cells, coverslips with cells were kept at 370C in the 
incubator overnight and used for cellular uptake experiments the following day. For 
differentiated PC12 cells, differentiation media was changed daily for 7 days. 
Experiments for differentiated PC12 cells were performed from day 7 onwards.  
Neurotransmitter Transporter Uptake Assay (NTUA): positive control 
The NTUA assay kit contains a fluorescent monoamine transporter substrate for the 
dopamine transporter DAT, Noradrenaline transporter (NET) and serotonin transporter 
(SERT) (Molecular devices, UK part number R8173). The substrate is pumped into the 
cells via any of these three monoamine transporters.(Jorgensen et al., 2008) The kit also 
contains a dye which quenches extracellular fluorescence and therefore aids in reducing 
any background signal.(Jorgensen et al., 2008)  NTUA was diluted with 10mls of 
physiological saline (PSS) and aliquots were stored at -200C. On the day of experiments 
NTUA was thawed, diluted further with PSS (1:10), and pre-warmed to 370C. 
Cellular uptake of lanthanide compounds by PC12 using fluorescence microscopy 
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PC12 cells were plated onto coverslips pre-coated with poly-L-lysine as described above. 
For the cellular uptake experiments, a coverslip with cells was placed in a heated organ 
bath attached to an epifluorescence microscope (Olympus BX51W1 purchased from 
Olympus, Southend, UK). The cells were perfused with pre-warmed PSS (370C) for 20 
minutes at flow rate of 0.6ml/min. After the PSS perfusion, cells were continuously 
exposed to either NTUA (positive control) or europium based compounds (MT172, 
MT630, or MT519) for 60 minutes. This was followed by a further drug washout with 
PSS for 20 minutes. For the NTUA cellular uptake experiments, PC12 cells and NTUA 
were excited with a 405nm light emitting diode (LED) source and a fluorescein 
Isothiocyanate (FITC) emission filter (519nm) was used.  
Figure 27: Chemical structure and molecular weight of Europium complexes. 
 
 
For cellular uptake of europium conjugates, excitation wavelengths, 405nm and 365nm 
from an LED light source (Cairn imaging, Kent, UK) and Qdot 605nm emission filters 
(Chroma Technology Corp, USA) were used. In subsequent experiments a mercury arc 
lamp light source was used with a 390nm excitation filter. Bright field and fluorescent 
Images were taken at time 0 then at 10minute intervals throughout the experiment using 
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an Orca-ER Hamamatsu digital camera (Hamamatsu photonics, UK), attached to the 
epifluorescence microscope. The following camera settings were used, bright field: 
exposure time 150ms, gain 0, offset=0 and fluorescent images: exposure time 5sec, gain 
255, offset 0. Organ bath temperature was maintained between 29 and 34 0C. 
The change in PC12 cell fluorescence (negative control) over time was also assessed 
using methods similar to those for cellular uptake experiments.  
Statistical analysis 
Image analysis was performed using image J software version (1.38e/Java1.5). A region 
of interest (ROI) was created around an individual PC12 cell (figure 28). The ROI was 
automatically fitted onto subsequent images of each cell on the image stack. Since the 
distribution of the fluorescent vesicles was uneven, with some regions of the cells having 
significantly higher pixel intensity than others (figure 28), the median, instead of mean 
cell fluorescence was used, since the median would be more representative of such data. 
The same principle was applied when measuring the background fluorescence. Median 
fluorescence (median pixel intensity) was measured in each ROI. Another ROI of exactly 
the same size as the cell, was drawn adjacent to the cell and the median fluorescence of 
this region was considered as the background fluorescence. Fluorescence was expressed 
in arbitrary units (au). Corrected median fluorescence for each cell was calculated by 
subtracting the median background fluorescence from the median cell fluorescence 
(figure 28). The mean fluorescence of all cells in each experiment was calculated for all 
time points: 0, 10, 20, 30, 40, 50 and 60 minutes. Data were analysed using GraphPad 
Prism 6.Ink. The mean fluorescence was plotted against time and the rate of uptake (slope 
of the graph) in au.min-1 was calculated. Data were represented as mean ± SEM. 
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Comparisons between groups were performed using Student t-test or Mann-Whitney U 
test accordingly. 
 
Figure 28: Regions of interest for cell and background fluorescence 
 
 
The areas marked in yellow represent the regions of interest. Pixel intensity in region of Interest 
(1) represents background fluorescence and (2): cell fluorescence, scale bar 50µm.  
5.4. Results 
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PC12 cells developed branchlike extensions (neurites), which increased in number and 
length with time, when cells were maintained in DMEM based media supplemented 
with NGF (figure 29). 
Cell Auto-fluorescence 
When PC12 cells were washed with PSS over 60minutes a decline in cellular 
fluorescence over time was observed: rate of decline -0.09 ±0.005 au.min-1 (figure 30). 
5.4.2.1 Cellular uptake of neurotransmitter transporter uptake assay (NTUA) by 
PC12 cells using fluorescence microscopy 
 
There was a time dependent NTUA cellular accumulation (increase in cellular 
fluorescence) in both differentiated (figure 31) and undifferentiated PC12 cells (figure 
32), when 405nm excitation wavelength and 519nm emission filter were used. Rate of 
NTUA uptake was 0.27± 0.02 au.min-1 and 0.33±0.01 au.min-1, in differentiated and 
undifferentiated cells respectively.  
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Figure 29: PC12 differentiation from day 1 to day 7 in NGF enriched DMEM culture media. 
 
Figure 29 above shows PC12 cells grown in NGF-enriched media. Neurite number and length 
increased from day 2 onwards. 
Figure 30: Change in undifferentiated PC12 cell auto fluorescence over time 
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Figure 30 above, data points represent mean change in PC12 cell fluorescence ±SEM, when 
cells were washed with PSS over 60minutes 
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Figure 31: NTUA cellular uptake by differentiated PC12 cells 
 
1 0 2 0 3 0 4 0 5 0 6 0 7 0 8 0
- 1 0
0
1 0
2 0
3 0
t i m e  ( m i n u t e s )
F
l
u
o
r
e
s
c
e
n
c
e
 
(
a
r
b
i
t
r
a
r
y
 
u
n
i
t
s
)
       
b) 
     
 
 
 
 
 
 
 
 
 
Figure 31a) Data points represent mean change in PC12 cellular fluorescence ± SEM when 
exposed to NTUA over 70minutes. Results shown are for 3 experiments. b) Images showing 
increase in cell fluorescence with time when cells were exposed to NTUA: images shown for 
time 0, 20, 40, and 60 minutes. Scale bar 20µm. 
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Figure 32: NTUA cellular uptake by undifferentiated PC12 cells 
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Figure 32 (a) showing a time dependent increase in mean PC12 cellular fluorescence ± SEM 
when cells were exposed to NTUA over 60 minutes. Results shown are for 1 experiment.  b) 
Images showing increase in PC12 cell fluorescence, images taken attime 0, 30 and 60 minutes. 
Scale bar 20µm. 
 
5.4.2.2 Cellular uptake of europium conjugates by PC12 cells  
 
Cellular fluorescence gradually decreased with time when both differentiated and 
undifferentiated PC12 cells were exposed to 30µM MT519, MT630 and MT172: figure 
33-35. 
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Figure 33: MT519 (30µM) cellular uptake by differentiated PC12 cells 
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Data points represent mean change in PC12 cell fluorescence ±SEM when cells were exposed to 
MT519, results for 5 experiments shown. 
 
The rate of change in fluorescence when differentiated PC12 cells were exposed to 
MT519 was 0.01 ± 0.01 au.min-1 (95% CI -0.013 to 0.003). 
Figure 34: MT630 (30µM) uptake by differentiated and undifferentiated PC12 cells  
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Figure 34 above: data points represent mean change in cell fluorescence ±SEM, when cells were 
exposed to MT630. Negative values indicate a fall in fluorescence over time. Results for e 4 
experiments shown, each represented by a different colour.  
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When differentiated and undifferentiated PC12 cells were exposed to MT630 (30µM), 
cellular fluorescence declined with time (figure 34). Rates of change in fluorescence for 
each of the 4 experiments are shown in table 17. 
Table 17: MT630 (30µM) uptake by differentiated and undifferentiated PC12 cells 
 MT630 uptake 
by PC12 cells 
Experiment 1 
Differentiated cells 
Experiment 2 
Differentiated cells 
Experiment 3 
Differentiated 
cells 
Experiment 4 
Undifferentiated 
cells 
Excitation/ 
emission λ (nm) 
365/605 365/605 405/605 405/605 
Rate of change in 
cell fluorescence 
au.min-1±SEM 
-0.01 ± 0.01 
 
-0.10 ± 0.004 
 
-0.003± 0.02 
 
-0.31 ± 0.03 
 
 
95% CI 
-0.032 to 0.015 
 
-0.11 to -0.09 
 
-0.05 to 0.04 
 
-0.39 to -0.23 
 
Table 17 shows rate of change in cell fluorescence when cells were exposed to MT630. Negative 
values indicate a fall in fluorescence over time. λ (nm) represents the excitation and emission 
wavelengths used for each experiment. 
Figure 35: MT172 uptake by undifferentiated and differentiated PC12 cells  
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Figure 35 shows change in fluorescence during MT172 exposure only. Data points represent 
mean ±SEM for cells from 4 experiments. Negative values indicate a fall in fluorescence over 
time 
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Similarly, with MT172 30µM and 100µM exposure, the change in PC12 cell fluorescence 
was assessed, and a decline in cellular fluorescence with time was observed (figure 35). 
The rate of change in cellular fluorescence for these experiments is shown in the table 18. 
Table 18: MT172 (30µM and 100µM) uptake by differentiated and undifferentiated PC12 
cells 
MT172 uptake by 
PC12 cells 
Experiment 1 
Differentiated cells 
Experiment 2 
Differentiated  
Experiment 3 
undifferentiated 
cells 
Experiment 4 
Undifferentiated 
cells 
MT172 
concentration 
30µM 30µM 30µM 100µM 
Excitation/ 
emission λ (nm) 
405/605 365/605 405/605 405/605 
Rate of uptake  
au.min-1±SEM 
-0.56 ± 0.042 
 
-1.8 ± 0.30 
 
0.098 ± 0.026 
 
-0.39 ± 0.037 
 
 
95% CI au.min-1 
-0.66 to -0.46 
 
-2.5 to -1.0 
 
0.035 to 0.16 
 
-0.48 to -0.30 
 
Table 18 shows rate of change in cell fluorescence when PC12 cells were exposed to MT172. 
Negative values indicate a fall in fluorescence over time. λ (nm) represents the excitation and 
emission wavelengths used for each experiment. 
5.4.2.3 Verifying MT172 and MT630 fluorescence signal 
Results of the experiments described above demonstrated a decline in cellular 
fluorescence over time when the cells were exposed 30µM and 100µM of the europium 
conjugates: MT159, MT630, and MT172. This finding was similar to that seen in the 
negative control experiments where cells were washed with PSS only. There are two 
possible explanations for this finding. Firstly it is possible that the method used for 
detecting the fluorescence signal had low sensitivity and hence could not detect minimal 
cellular accumulation of these compounds over time. However, the same protocol was 
used to assess NTUA uptake and demonstrated an increase in cellular fluorescence over 
time. Secondly, it is possible that the europium conjugates used in these experiments had 
a weak fluorescence signal which could not be detected at the concentration used in this 
study. To explore the latter point, further tests were performed to determine the minimum 
concentration at which the fluorescence signal could be detected and the optimum 
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conditions (concentration of the compound, excitation and emission wavelengths) at 
which the fluorescence signal could be detected. 
Methods  
To ascertain which one of the europium conjugates provided the strongest luminescence, 
10mM solutions of MT172, MT630, and MT611 were each placed in empty capillary 
tubes. MT611is a europium complex with a strong fluorescence signal, and was used as 
a positive control. All compounds were excited using available acousto-optical tuneable 
filters (excitation wavelengths): 365nm, 370nm and 405nm, 450nm and 650nm, on a 
confocal microscope. A 605nm emission filter was used.  All three compounds produced 
a fluorescent signal when excited at the following wavelengths, 365nm, 370nm and 
405nm. MT611 (positive control) had the brightest fluorescent signal at all excitation 
wavelengths used (figure 36, 37). Of the two europium conjugates (MT630 and MT172), 
MT172 had a brighter fluorescence signal and therefore was used for further tests (figure 
36).  
The minimum concentration at which the fluorescence signal could be detected was also 
assessed by placing MT172 and MT611 solutions in capillary tubes: concentration 100 
µM, 300 µM, 500 µM and 1mM. 390nm/605nm (emission/excitation wavelengths) were 
used since this produced a strong fluorescent signal from both compounds. An empty 
capillary tube was used as a negative control. For each compound, corrected fluorescence 
was calculated. Several regions of interest within the capillary tube with the compound 
were marked out using image J and the mean pixel intensity for these regions were 
calculated. The mean background fluorescence (obtained by drawing several regions of 
interest in an area outside the capillary tube and finding the mean pixel intensity for these 
regions) was also measured. Corrected fluorescence for each compound equated to the 
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mean compound fluorescence minus the mean background fluorescence. The minimum 
concentration above which the fluorescence could be detected (x intercept at which the 
fluorescence was zero) was also determined using linear regression. Both MT172 and 
MT611 were fluorescent as demonstrated before and the fluorescent signal increased with 
increasing concentration (figure 37).  
The MT172 concentration above which a fluorescence signal could be detected was 
greater than 190 µM (x intercept where y=0) for MT172, this suggested that the 
fluorescence detection threshold in capillary had to be greater than 190µM. Since the 
MT172 fluorescence signal was visible in the capillary tube at a concentration 300µM 
(figure 37), further MT172 cellular uptake studies were therefore carried out using this 
300µM.   
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Figure 36: Images for 10mM MT172, MT611, and MT630 fluorescence signal in capillary 
tubes 
 
Figure 36 above shows fluorescence signal for MT611 and MT630 placed in capillary tubes and 
excited at various wavelengths: 365nm, 370nm, 405nm. Emission wavelength used 
was605nm.Scale bar 1 000µm 
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Figure 37: MT172 and MT611 fluorescence in capillary tubes at different concentrations 
a) 
 
 
b) 
5 0 0 1 0 0 0 1 5 0 0
- 2 0
0
2 0
4 0
6 0
8 0
M T 1 7 2  a n d  M T 6 1 1  f l u o r e s c e n c e  s i g n a l  a t  v a r i o u s  c o n c e n t r a t i o n s
c o n c e n t r a t i o n  ( µ M )
F
l
u
o
r
e
s
c
e
n
c
e
 
(
a
r
b
i
t
r
a
r
y
 
u
n
i
t
s
)
M T 1 7 2
M T 6 1 1
 
Figure 37 a) Top row shows MT172 fluorescence signal in capillary tubes, bottom row 
MT611 in capillary tubes at different concentrations: Columns from left to right: 0µM, 
300 µM, 500 µM, and 1mM. Capillary tubes with compounds were excited at 390nm and 
a 605nm emission filter was used. Scale bar 1000µm. (b) Fluorescence signal (y axis) in 
the capillary tubes plotted against concentration (x axis), for MT172 and MT611 
 
5.4.2.4 MT172 (300µM) cellular uptake by PC12 cells. 
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When MT172 (300µM) cellular uptake was assessed: excitation/emission (390/605nm)   
a time dependent increase in cellular fluorescence in undifferentiated cells was seen 
(figure 38a, b). The cellular fluorescence peaked at 40 minutes. There was minimal 
decrease in fluorescence during drug washout with PSS (time 60-80 minutes) (figure 
38b). Mean rate of increase in fluorescence during MT172 exposure to undifferentiated 
cells (3 experiments) was 0.73±0.24 au.min-1 (95% CI 0.11 to1.35). For subsequent 
experiments cells were therefore exposed to MT172 for a maximum time of 60minutes. 
The rates of change in cell fluorescence for the three MT172 cellular uptake experiments 
are shown in table 19. When 300µM MT172 cellular uptake was assessed in differentiated 
PC12 cells (n=3 experiments) (figure 39a), the mean rate of uptake for all cells in the 
experiments was 0.78± 0.15 au.min-1 (95% CI 0.41 to 1.42). Table 20 shows the rates of 
300µM MT172 uptake by differentiated PC12 cells in the 3 experiments. Cellular 
fluorescence continued to increase during drug washout, shown in figure 39b. 
Table 19: Rate of MT172 300µM uptake by undifferentiated PC12 cells 
Undifferentiated PC12 cells Experiment 1 Experiment 2 Experiment 3 
Rate of uptake au.min-1± SEM 0.47 ± 0.07 
 
1.39 ± 0.45 
 
1.30 ± 0.17 
 
95% Confidence Interval 
au.min-1 
0.30 to 0.63 
 
0.29 to 2.49 
 
0.89 to 1.71 
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Figure 38: MT172 (300 µ M) uptake by undifferentiated PC12 cells  
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Figure 38 above. Data points represent mean change in cell fluorescence +SEM, when cells were 
exposed to MT172 300µM and excited at390nm, emission  605nm,a) results for individual 
experiments b) Results for 3 experiments combined.  
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Figure 39: MT172 (300 µ M) uptake by differentiated PC12 cells 
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Figure 39 above .Data points represent mean change in PC12 cell fluorescence ± SEM, when cells 
were exposed to MT172 300µM over 60minutes.Results for 3 experiments shown 
 
Table 20: Rate of MT172 300µM uptake by differentiated PC12 cells 
Differentiated PC12 cells Experiment 1 Experiment 2 Experiment 3 
Rate of uptake au.min-1± 
SEM 
1.66 ± 0.38 
 
0.14 ± 0.15 
 
-0.36 ± 0.38 
 
95% Confidence Intervals 
au.min-1 
0.72 to 2.59 
 
-0.23 to 0.50 
 
-1.28 to 0.56 
 
Table 20 shows the rate of change of cell fluorescence for differentiated PC12 cells. Cells were 
exposed to MT172 300µM during each experiment. Negative values indicate a fall in fluorescence 
over time. 
 
MT172 cellular uptake by undifferentiated (n=3) and differentiated (n=3) PC12 cells were 
compared using unpaired t-test and showed no significant difference in the rate of increase 
in cellular fluorescence between the two groups (mean difference -0.5 ± 0.67 au.min-1, p= 
0.38; figure 40). 
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Figure 40: Mean rate of MT172 300µM uptake, comparison between differentiated and 
undifferentiated PC12 cells 
 
Figure 40. Compares the mean rate of change in cell fluorescence for the undifferentiated PC12 
cell experiments (n=3) and differentiated PC12 cell experiments (n=3).  
5.4.2.5 Modified cellular uptake protocol: to determine if MT172 cellular uptake by 
PC12 cells is mediated by dopamine transporter (DAT) or noradrenaline 
transporter (NET) 
 
Methods  
Further tests were performed to determine if the observed MT172 cellular uptake was 
mediated by the monoamine transporters DAT or NET. Given the variability in MT172 
cellular uptake between experiments (figure 38 and 39), the method used for cellular 
uptake was modified in an attempt to improve consistency of results between 
experiments. A two stage protocol was devised. Cells were washed with PSS prior to 
starting the experiment as before in order to reduce auto-fluorescence. Stage 1: PC12 cells 
were exposed to 300µM MT172 for 60 minutes followed by a 40 minute MT172 washout 
using PSS. Stage 2: second MT172 exposure for a further 60 minutes (figure 41). Fewer 
images were taken during MT172 exposure to reduce photo-bleaching. Images were taken 
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at times 0minutes (A: start of MT172 perfusion). Since previous experiments showed a 
minimal fall in fluorescence after drug washout with PSS for 20 minutes (figure 38b), 
which suggested an equilibrium was reached, for this modified protocol, further images 
were taken at time 80 minutes (time point B: 60 minutes MT172 exposure then 20 minutes 
PSS washout), and 180 minutes (time point D). Another image was taken at time 100 
minutes (C: after a further 20 minutes PSS perfusion, this was considered as the baseline 
image for the second MT172 exposure). 390/605nm filters were used. If the protocol is 
robust then rate of MT172 cellular uptake in stages 1 and 2 would be equal (slope AB= 
slope CD), and the protocol would be used to assess for MT172 uptake in the absence and 
presence of DAT or NET blockers. GBR 12909, a DAT blocker was purchased from 
Tocris Biosciences, Bristol UK. GBR stock solution was stored at 20 0 C in 1mM aliquots. 
This was diluted with PSS to make 1µM solution for the experiments. Desipramine, a 
NET inhibitor which also inhibits SERT, was stored in 10mM aliquots and diluted with 
PSS to 1µM solution for the experiments. A previous study in our laboratory showed that 
GBR 1µM and desipramine 1µM could inhibit NTUA uptake by PC12 cells (Elobi, 2014). 
For experiments to assess if MT172 cellular uptake was mediated by DAT or NET, cells 
were perfused with 300µM MT172 during stage 1 (Stage 1: AB), followed by PSS for 20 
minutes. GBR 1µM and desipramine 1µM perfusion was started from 80 minutes 
onwards. Cells were then exposed to a second MT172 perfusion for a further 60 minutes 
(stage 2) Fluorescence images were taken at time 0, 80,100, and 180 minutes as described 
above.  NTUA was used as a positive control. Corrected median fluorescence for each 
cell was calculated as described before. The rates of NTUA/MT172 uptake slope (AB) 
and (CD) were compared for each cell using Wilcoxon matched-pairs signed rank test. 
Mann Whitney U test was used to compare the rate of MT172 cellular uptake before and 
after exposure to GBR and desipramine.  
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Figure 41: Modified cellular uptake protocol: 2 stages 
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The sketch above illustrates the two staged protocol (NB, this is not ‘real data’) 
• AB:MT172 first exposure, baseline images taken at time(point A)=0 minute, peak fluorescence images 
taken after 20 minute PSS wash time (point B)=80 minute  
• BC: Further MT172 washout with PSS for 20 minute 
• CD: Second MT172 exposure, baseline fluorescence image (point C), time =100 minute and peak 
fluorescence image taken after 20 minute washout with PSS (point D) time=180 minute 
 
Results 
NTUA uptake by PC12 cells using a modified (two stage) protocol.  
NTUA uptake by undifferentiated PC12 cells was assessed using the two staged protocol 
described above. Results for 20 cells were analysed (figure 42a). There was a linear 
increase in fluorescence during NTUA exposure: AB, CD on figure 42a. Median (IQR) 
rate of uptake for first NTUA exposure (slope AB) was 2.2 (0.99-3.59) au.min-1, and 2.4 
(0.06-3.92) au.min-1 for the second exposure (slope CD). NTUA washout (BC) was 
associated with a reduction in fluorescence. When the rates of NTUA cellular uptake for 
each of the 20 cells were compared, there was no significant difference between the two 
stages: median difference was -0.09, p=0.48 (figure 42b). 
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Figure 42: NTUA uptake by undifferentiated PC12 cells, using the modified 2 staged cellular 
uptake protocol 
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Figure 42(a) above data points represent mean change in cell fluorescence ±SEM when cells were 
exposed to NTUA during stages 1 and 2. BC represents a drop in cell fluorescence when cells 
were washed with PSS. Results shown are for 20 cells. (b) Comparing rate of increase in cell 
fluorescence (NTUA uptake) for stage 1 versus stage 2. Results shown are for 20 cells. 
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5.4.2.6 300µM MT172 cellular uptake by undifferentiated PC12 cells using the 
modified two stage protocol 
Four experiments were performed and data for 40 cells were analysed. The rate of MT172 
300µM uptake was weak in stage 1 and 2, median (IQR) rate of uptake 0.08 (-0.11-0.14) 
au.min-1 and 0.05 (-0.45-0.092) au.min-1 respectively. There was no difference in the rate 
of MT172 cellular uptake between the 2 stages, median difference -0.02 au.min-1, p= 0.28 
(figure 43). 
Figure 43: Rate of MT172 300µM cellular uptake by undifferentiated PC12 cells using a 
modified protocol stages 1 versus stage 2 
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Figure 43 compares the rate of increase in cell fluorescence for each cell during stage 1 and 
stage 2 MT172 exposure: results for 40 cells shown. There was no significant difference 
between the 2 stages. 
 
MT172 (300µM) cellular uptake by undifferentiated PC12 cells in the absence and 
presence of GBR and desipramine using 2 staged uptake protocol 
In total five experiments were performed, data for 50 cells were analysed. Median (IQR) 
MT172 rate of uptake for stage 1 was and 2 were 0.06 (-0.07-0.15) au.min-1 and 0.04 (-
0.28-0.09) au.min-1 respectively. There was no difference in MT172 cellular uptake 
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before and after adding GBR and desipramine, median difference -0.01 au.min-1, p=0.06 
(figure 44). 
Figure 44: Comparing MT172 (300µM) cellular uptake rate by undifferentiated PC12 cells 
before and after GBR and desipramine (1µM) exposure, results for 50cells. 
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Figure 44 shows rate of change in cell fluorescence when exposed to MT172 in the absence and 
presence of GBR and Desipramine. Results for 50 cells shown. There was no significant 
difference between the 2 stages. 
 
5.5. Discussion 
This novel study sought to assess the feasibility of labelling dopaminergic cells using 
lanthanide based probes with the ultimate aim of using the compounds as MRI based 
contrast agents for labelling dopaminergic neurons in PD in the future. The project also 
optimised a protocol for use in screening other potential probes in the future. 
PC12 cells were grown and differentiated using Green and Tischler’s protocol (Greene 
L.A and Tischler A.S, 1976). Cell differentiation resulted in neurite growth, as previously 
reported (Greene L.A and Tischler A.S, 1976). Background cell fluorescence, can 
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interfere with the signal from potential probes. This a recognised problem in fluorescence 
microscopy, which is thought to arise from metabolites including NADH and flavins 
(Aubin, 1979). Culture media used for maintaining cells also contain vitamins such as 
riboflavin which may also contribute to the auto-fluorescence. In the current study, cells 
were washed with PSS in order to remove excess culture media before exposing the cells 
to the probes. A reduction in cell auto-fluorescence over time was observed (figure 30). 
Use of NTUA as a fluorescent substrate for assessing monoamine transporter function 
has been validated before in HEK-293 and CHO-KI cell lines transfected with human 
DAT (Jorgensen et al., 2008). In this study NTUA was used to validate the cellular uptake 
protocol that will be used for screening future lanthanide probes using PC12 cells. The 
current study showed a time dependent NTUA accumulation in PC12 cells. A previous 
study in our laboratory reported similar findings and also demonstrated NTUA uptake 
inhibition by desipramine and GBR, (Elobi, 2014) confirming DAT and NET expression 
by PC12 cells. 
The current study showed no evidence of cellular uptake of the europium based 
compounds at low concentrations. Another pilot study in our group (unpublished) 
demonstrated 30µM MT172 uptake by PC12 cells.  The current study could not replicate 
these results even when MT172 100µM was assessed using the same FITC filter set used 
in the pilot study. In fact, a decrease in fluorescence with time was seen when cells were 
exposed to MT172 100µM. Excitation and emission wavelengths of compounds that 
contribute to auto-fluorescence was reported to be in the range 365-440nm and 520nm 
respectively (Aubin, 1979). FITC band-pass filters with an emission wavelength of 
519nm may allow transmission of short wavelengths including auto-fluorescence. It is 
therefore plausible that the apparent europium conjugate accumulation reported in the 
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pilot study may have been due to auto-fluorescence. There is one potential explanation 
for the discordant results. The methodology of the current and pilot studies differed 
slightly. Cells were washed with PSS for 20 minutes prior to perfusing them with 
europium conjugates. This removed any excess culture media which could have 
contributed to auto-fluorescence, and hence observed reduction in fluorescence with time. 
Given that FITC emission is short (green: 519nm) and can block the europium emission 
(red: 615nm), the FITC filters were substituted with 390nm/605nm filter set, but no 
cellular uptake of the europium conjugates was demonstrated at concentrations less than 
100µM. This observation implied that the lanthanide conjugates used in this study had a 
weak fluorescence signal which could not be detected at these low concentrations.  
When experiments were repeated using a higher concentration (MT172 300µM), a time 
dependent increase in MT172 uptake by both differentiated and undifferentiated PC12 
cells was seen. Furthermore, there was no difference in the rate of MT172 cellular uptake, 
when differentiated and undifferentiated PC12 cells were compared. The latter finding 
was unexpected. Differentiated (NGF treated) PC12 cells were shown to have a higher 
DAT protein expression than undifferentiated cells (Kadota et al., 1996). The reverse was 
true for the noradrenaline transporter. DAT expression was also demonstrated on the 
neurite extensions of differentiated PC12 cells in one study (Kadota et al., 1996).  In the 
same study, Kadota et al. (1996) also compared, the rate of dopamine uptake in NGF 
treated and untreated cells and reported a higher rate of dopamine uptake in the earlier 
group (Kadota et al., 1996). If MT172 uptake was mediated via the dopamine transporter, 
then a higher rate of uptake should have been observed in differentiated PC12 cells. This 
finding implies that MT172 transport may be mediated by mechanisms other than DAT. 
Study results also showed variability in rate of MT172 cellular uptake between 
experiments (table 19 and 20). This may have arisen from a non-uniform field of 
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illumination from a failing mercury arc lamp light source.  This light source was used for 
the initial set of experiments because of time constraints, but was replaced with a new arc 
lamp for later studies. This is not ideal as definitive conclusions cannot be drawn from 
the results of these experiments. . Another plausible explanation is the use of cells at 
different passages which may result in variable responses. It is also possible that as the 
number of passages increases, the behaviour of the tumour cell line becomes 
unpredictable, which may account for the variable MT172 uptake.  
The cellular uptake protocol was therefore modified in order to improve the consistency 
of results between experiments. But when the modified protocol was used, the rate of 
NTUA uptake was more than twice and MT172 cellular uptake was significantly less than 
that observed in earlier experiments. This again demonstrated the unpredictable 
behaviour of the cells. There was no difference in the rate of NTUA uptake between stage 
1 and 2, implying that that the cellular uptake protocol was robust and could be used to 
compare the rate of MT172 cellular uptake in the presence of the absence of transporter 
blockers, within the same experiment. Nevertheless, when MT172 cellular uptake was 
assessed before and after GBR and desipramine exposure, there was no difference in the 
rate of uptake. These data suggested that MT172 cellular uptake shown in this study was 
not mediated via DAT or NET. MT172 uptake observed in this study was by a non-
specific mechanism, probably diffusion due to a concentration gradient. Support for this 
conclusion comes from results of earlier experiments which showed similar rates of 
uptake between undifferentiated and differentiated PC12 cells. Lanthanide complexes are 
reported to be taken up across the cell membranes by a method called macropinocytosis 
(New et al., 2010). The present study showed that tagging europium complexes with 
either dopamine or levodopa did not result in specific uptake via monoamine transporters.  
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The modified cellular uptake method has several limitations. It was difficult to maintain 
the organ bath temperature above 29 0 C during the long experiments. Previous reports 
have demonstrated that fluorescent substrate uptake via monoamine transporters is 
temperature dependent (Jorgensen et al., 2008). Suboptimal temperatures in this study 
could have impeded any energy dependent MT172 cellular uptake. Nevertheless, NTUA 
uptake was still demonstrated when the modified protocol was used, which confirms the 
notion that MT172 uptake was nonspecific and not monoamine transporter mediated. 
NTUA results also confirms the robustness of the modified protocol when used for 
screening probes with greater luminescence. Another drawback was the long duration of 
the experiments, which showed that this protocol is not suitable for high throughput 
screening. Future experiments should address these problems. Increasing the perfusion 
rate of compounds during experiments and use of controlled temperature chambers may 
reduce the heat loss and therefore help optimise the temperature during the experiments. 
Use of automated methods such as FLIPR tetra was considered but plate readers with 
suitable excitation and emission wavelengths appropriate for the long stoke shifts were 
not available. Future studies should also consider using methods other than fluorescence 
microscopy to assess cellular uptake of these compounds. This may include inductively 
coupled plasma spectrometry (ICP-MS).This sensitive technique has been used in other 
studies to quantify cellular uptake of compounds at single cell level (Zheng et al., 2015). 
This may be useful for future cell based work before proceeding to testing these 
compounds in animals. Rational drug design using methods such as methods such as 3D 
x-ray crystallography, (Mandal et al., 2009) should also be considered in the synthesis of 
other europium complexes to improve specificity for DAT. 
 A human cell line will be used in future studies, to counteract the problems of 
unpredictable behaviour which can arise from using a tumour cell line.  
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CHAPTER 6: HUMAN DOPAMINERGIC CELL LINE (LUHMES) IN THE 
DEVELOPMENTS OF AN MRI SENSITIVE PROBE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
171 
 
6.1. Background 
LUHMES cell line  
Lund Human Mesencephalon Cells (LUHMES) were developed at Lund University by 
immortalising human mesencephalic cells with a v-myc retroviral vector  (Lotharius et 
al., 2002). Cell proliferation can be halted by exposing cells to tetracycline which blocks 
v-myc and cause the cells to exit the cell cycle (Lotharius et al., 2002). The cells can then 
differentiate into mature dopaminergic neurons after addition of glial derived 
neurotrophic factor (GDNF) and dibutyrl cyclic AMP to the culture media (Scholz et al., 
2011). Differentiated LUHMES cells were shown to express mature dopaminergic neuron 
markers including DAT, VMAT2, D2, and tyrosine hydroxylase at varying levels 
depending on the stage of differentiation (Scholz et al., 2011). This cell line was 
considered to be ideal for the current project for several reasons. Firstly, LUHMES are a 
human cell line, therefore behavior is likely to be closer to that of primary dopaminergic 
neurons, when compared to a tumor cell line such as PC12 cells. Secondly, Scholz et al. 
(2011) demonstrated the ease of maintaining the cells, differentiation into mature 
dopaminergic neurons (Scholz et al., 2011). The same authors also confirmed the ability 
of these cells to take up dopamine (Scholz et al., 2011), which is an essential requirement 
for this project. The cell line has also been used in other PD studies to demonstrate 
cytotoxicity after MPP+ exposure and alpha-synuclein overexpression (Zhang et al., 
2014).   
The current study sought to validate dopamine transporter activity in LUHMES cells by 
assessing NTUA cellular uptake using fluorescence microscopy. The second objective 
was to optimise an assay method using the LUHMEs cell line which can then be used for 
screening fluorescent DAT substrates in the future. 
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6.2. Materials  
 LUHMES cells 
Cells were purchased from LGC standards, UK, and maintained using the protocol 
provided by LGC standards. Cells were grown in DMEM: F12 media , LGC standards, 
UK (stored at 40C) supplemented with 1% N2 supplement (Gibco-Invitrogen,  100X stock 
stored at -200C) and basic recombinant human fibroblast growth factor (BFGF) 40ng/ml, 
purchased from Gibco-Inivtrogen , and stored at -200C. Cells were grown in tissue culture 
flasks pre-coated with poly-l-ornithine 50µg/ml (Sigma-Aldrich, UK) followed by 
fibronectin 1µg/ml (Sigma- Aldrich, UK) (Scholz et al., 2011). Cells in culture media 
were placed in a humidified, 5% CO2 incubator at 37
0C and the growth media was 
replaced every 2-3 days. Materials for subculturing protocol (LGC standards, UK) which 
included Dulbecco’s phosphate buffered saline (D-PBS) (University of Birmingham IBR 
stores), DMEM: F12 growth media, and 0.025% Trypsin-EDTA, were pre-warmed in a 
370C water bath. The old culture media was removed and cells were briefly washed with 
10mls of D-PBS. 0.025% Trypsin- 0.1g/L-EDTA was used to detach cells for 3minutes, 
then 6ml of DMEM: F12 growth media supplemented with N2 supplement only, was 
added to the tissue culture flask. The cell suspension was transferred to a falcon tube and 
centrifuged at 190g for 7 minutes. The supernatant was removed, cells re-suspended in 
fresh growth media (including N2 supplement and bFGF), and transferred to another pre-
coated tissue culture flasks. 
Differentiating LUHMES cells 
Differentiating media (Lotharius et al., 2002) was made up by supplementing 
DMEM:F12 with 1X N2 supplement, 1µg/ml tetracycline (Sigma- Aldrich, UK, diluted 
with sterile water to make 0.1mg/ml stock, stored at -20 0C) 1mM, cyclic AMP (Sigma- 
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Aldrich, UK), diluted with sterile water to make 10mM stock solution stored at -200C), 
and 2ng/ml recombinant human glial derived neurotrophic factor (GDNF): R&D systems 
cat number 212GD-010, reconstituted with 0.1% BSA to make 0.1mg/ml stock solution, 
and stored at -200C.  The differentiation protocol was adapted from that used by Scholz 
et al. (2011) (Scholz et al., 2011). 1x 10 6 cells were cultured in complete growth media 
(DMEM: F12, N2 supplement and bFGF) in a 25cm 2 tissue culture flask for 24 hours, 
then the growth media was replaced with differentiation media. After 2 days, cells were 
detached using 0.025% Trypsin-EDTA and seeded onto poly-l-ornithine and fibronectin 
coated coverslips at a cell density of 50 000cells per coverslip and fresh differentiation 
media was added. The coverslips with plated cells were kept in a 37 0C, 5% CO2 
humidified incubator. The culture media was replaced every 2 days. Experiments were 
performed form day 5 onwards. NTUA was prepared as described in chapter 5. 
6.3. Methods 
LUHMES cells were differentiated to mature dopaminergic neurons as described above. 
On the day of experiments, coverslips with plated cells were placed in an organ bath 
attached to an epifluorescence microscope. The previous study with PC12 cells showed 
that auto fluorescence can potentially interfere with detection of probe fluorescence. The 
results of the two stage NTUA PC12 cellular uptake protocol also showed a time 
dependent increase in fluorescence in both stage 1 and 2. The same two stage protocol 
was applied for the LUHMES experiments. Differentiated LUHMES were washed with 
pre-warmed PBS for 20 minutes prior to the NTUA uptake experiments to remove excess 
culture media. NTUA perfusion was run for 60 minutes. After exposing the differentiated 
LUHMES cells to NTUA for 60 minutes, DAT and NET blockers GBR and desipramine 
(1µM) were applied for 20 minutes, followed by a second NTUA exposure for a further 
60 minutes. NTUA and the cells were excited at 405nm and a 519nm emission filter was 
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used. Results of the two stage protocol (figure 49a) showed a fall in fluorescence during 
the second NTUA exposure. Further experiments were therefore carried out without the 
transporter blockers to verify if the fall in NTUA uptake during stage 2 was secondary to 
inhibition of the monoamine transporters by GBR and desipramine. For all experiments, 
fluorescent and bright field images were taken at time 0 minutes (start of NTUA 
exposure) then at 10 minute intervals thought the experiment. The following camera 
settings were used: bright field (exposure 150ms, gain 0, and offset 0), fluorescence 
(exposure 5 seconds, gain 255, offset 0). Image analysis was performed using image J 
version (1.38e/Java1.5). Median cell fluorescence (arbitrary units) was measured in each 
region of interest and mean cellular fluorescence for the cells calculated. Linear 
regression was used to calculate the NTUA transport rate. T-test or Mann U Whitney 
were used to compare transport rates before and after addition of GBR and desipramine. 
Graph pad prism software version 6 was used for statistical analysis. 
6.4. Results 
Large numbers of LUHMES cells were generated within a few days (figure 45). When 
LUHMES cells were grown in differentiation media, proliferation stopped and from day 
2 onwards progressive neurite extension was seen. These increased in number and 
length to form a dense network of neurites as demonstrated in figure 46 below. 
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Figure 45: Images of undifferentiated LUHMES cells from day 0 to 5 in growth media. 
 
Figure 46: LUHMES cells grown in differentiation media from day 1 to day 5 
 
Figure 46 above: images showing an increase in number and length of LUHMES neurite 
network during cell differentiation from day 0 to 6,  
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6.4.1. NTUA cellular uptake by LUHMES cells 
NTUA (1:100) cellular uptake was assessed and this showed a minimal increase in signal 
over time: 0.37±0.02 au.min-1 (figure 47). 
Figure 47: NTUA (1:100 dilution) cellular uptake by differentiated LUHMES 
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Figure 47 above, data points represent mean change in cell fluorescence +SEM, when 
LUHMES cells were exposed to NTUA 1:100 dilution 
Experiments were therefore performed with a higher NTUA concentration (1:10 
dilution). Figure 48 below shows NTUA intracellular accumulation and also in neurite 
extensions of differentiated LUHMES at time 40 minutes after starting NTUA perfusion. 
There was a time dependent increase in LUHMES cellular fluorescence upon NTUA 
exposure during stage 1, followed by a fall in cell fluorescence during the second NTUA 
exposure (figure 49 below). The rate of increase in cell fluorescence (NTUA uptake) 
during stage 1 was 2.5±0.2 au.min-1 and NTUA 2 was -0.7 ±0.2 au.min-1(figure 49a and 
49b). The difference between the rate of NTUA uptake between the 2 stages was 
statistically significant (p<0.0001). 
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Figure 48: NTUA accumulation by differentiated LUHMES cells using confocal microscopy 
(images taken using confocal microscopy) 
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Figure 49: NTUA cellular uptake differentiated LUHMES before and after GBR/DES 
perfusion (a, b), results for 5 experiments 
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Figure 49 above: data points represent mean change in cell fluorescence +SEM, when 
LUHMES cells were exposed to NTUA only (blue), NTUA and blockers GBR and desipramine 
(red) 
The two stage NTUA uptake was repeated to ascertain if the fall in fluorescence during 
NTUA stage 2 demonstrated above was due to transporter inhibition by GBR and DES. 
Cells were exposed to NTUA, then washed with PBS for 20 minutes, followed by the 
second NTUA exposure for a further 60 minutes. 
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Figure 50: NTUA cellular uptake by LUHMES cells, 2 stages: results for 4 control 
experiments 
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Figure 50 above: data points represent mean change in cell fluorescence +SEM, for 4 experiments 
when LUHMES cells were exposed to NTUA during stage 1 (blue), and NTUA stage 2 (red) 
 
Similar to the previous results, the two stage NTUA cellular uptake control experiment 
showed a fall in cellular fluorescence during second stage NTUA exposure (figure 50 
above). The rate of uptake in stage1 was 2.5± 0.18 au.min-1 and in stage2 was -1.3± 0.19 
au.min-1.  
Effect of PBS supplemented with glucose, Calcium (Ca) and Magnesium (Mg) 
Ca and Mg free PBS was used in the previous section. Further tests were performed to 
assess the effect of using different buffer constituents on stage 2 NTUA cellular uptake. 
Supplementing PBS with Ca (0.8mM), Mg (0.56mM) and glucose (1g/L) did not alter the 
rate of change in cellular fluorescence when differentiated LUHMEs cells were exposed 
to NTUA. However, this led to loss of cell viability, as demonstrated in the images below 
(figure 51a). There was a fall in fluorescence (NTUA uptake) during the stage 2. The rate 
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of uptake for stage 1 was 2.12 ±0.18 au.min-1 and for NTUA stage 2 was -1.19± 0.14 
au.min-1.Changes in cell structure were visualised during the experiments. Supplementing 
PBS buffer with glucose only, had a similar effect on cell viability (figure 51b). 
Figure 51: Images showing effect of supplementing PBS buffer with calcium and magnesium 
and glucose on cell viability 
a) Calcium and magnesium 
 
b) Glucose only 
 
Image (a) calcium and magnesium and (b) glucose only. Scale bar 100µm. 
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Figure 52: NTUA uptake by differentiated LUHMES 2 stages using PBS supplemented with 
calcium and magnesium, results for 4 experiments 
 
5 0 1 0 0 1 5 0
- 5 0
0
5 0
1 0 0
1 5 0
2 0 0
t i m e  ( m i n u t e s )
F
l
u
o
r
e
s
c
e
n
c
e
 
(
a
r
b
i
t
r
a
r
y
 
u
n
i
t
s
)
N T U A  u p t a k e  s t a g e  1 N T U A  u p t a k e  s t a g e  2
T i m e  6 0 - 8 0 m i n u t e s  o n  t h e  g r a p h  r e p r e s e n t s  N T U A  w a s h o u t  P B S
 
Figure 52: data points represent mean change in cell fluorescence +SEM, when LUHMES cells 
were exposed to NTUA during stage 1(blue) and stage 2(red) using PBS buffer supplemented 
with calcium and magnesium. 
When results for experiments using calcium and magnesium free PBS were compared 
with PBS supplemented with calcium and Magnesium using Mann Whitney U test there 
was no significant difference in the rate of NTUA uptake during the first NTUA stage 
p=0.14 (figure 53). 
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Figure 53: NTUA uptake by differentiated LUHMES using PBS calcium and magnesium 
free compared to PBS supplemented with magnesium and calcium 
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NTUA uptake (1 stage only): Is NTUA uptake mediated by monoamine transporter 
blockers? 
Since all the experiments showed a consistent increase in cellular fluorescence for the 
first 60 minutes of NTUA exposure which egressed during stage 2, subsequent 
experiments were carried out for a maximum of 60 minutes (one stage protocol). To 
validate if DAT was responsible for NTUA uptake by differentiated LUHMES cells, cells 
were incubated with GBR 1µM (DAT blocker) for 15-60 minutes before the experiments 
then to both NTUA and GBR1µM for 60 minutes. Results showed an increase in cell 
fluorescence signal with time (rate of uptake 1.52± 0.21 au.min-1, figure 54a). 
Considering that NTUA uptake could not be supressed by GBR 1µM only, and that 
NTUA is also a NET substrate, further cellular uptake experiments were performed in the 
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presence of both GBR and desipramine. Results also demonstrated a time dependent 
increase in fluorescence, rate of uptake: 3.05±0.18 au.min-1 (figure 54b). Similarly, when 
NTUA uptake was assessed in the presence of NET, DAT, and SERT (fluoxetine 1µM) 
blockers, NTUA cellular uptake was not suppressed (rate of NTUA uptake 2.38±0.122 
au.min-1; figure 54c). 
Figure 54: NTUA cellular uptake by differentiated LUHMES in the presence of GBR, 
desipramine and fluoxetine 
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Figure 54 above: data points represent mean change in cell fluorescence +SEM, when 
LUHMES cells were exposed to NTUA only (blue), NTUA in the presence blockers (red) (a) 
GBR 1µM, (b) GBR and desipramine (1µM) (c) GBR, desipramine and fluoxetine 1µM 
 
Effect of increasing GBR concentration 
Increasing the GBR concentration to 10µM did not suppress NTUA uptake by 
differentiated LUHMES cells (rate of uptake 2.1±0.26 au.min-1 ; figure 55). 
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Figure 55: Effect of increasing GBR concentration on NTUA cellular uptake by LUHMES 
cells [DES (1µM) and GBR (10µM)] 
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Figure 55 above: data points represent mean change in cell fluorescence +SEM, when LUHMES 
cells were exposed to NTUA only (blue), NTUA in the presence of GBR 10µM (red) 
Effect of temperature on transporter rate 
The effect of temperature on transporter function was also considered as a possible reason 
for the lack of NTUA uptake inhibition by the transporter blockers. When a lower 
perfusion flow rate was used, the temperature during the experiments was suboptimal 
(29-300C). Attempts were made to increase the bath temperature in order to optimise 
effect of the monoamine transporter blockers. This was done by increasing the flow rate 
of NTUA into the organ bath. Increasing the perfusion pump rate from 6RPM to 15RPM 
resulted in an increase in the organ bath temperature to 34 degrees which was maintained 
throughout the experiments. There was no change in the rate of change in fluorescence 
(2.0 ± 0.28 au.min-1). NTUA uptake in the presence of the blockers was then repeated at 
this temperature, but this did not alter the results.  
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NTUA uptake by Differentiated LUHMES cell neurite extensions. 
Data analysis for NTUA uptake by LUHMES neurites was also performed. The analysis 
was performed for both control experiments (NTUA uptake only) and experiments with 
DAT and NET blockers. Results are shown in figure 56 below.  
Figure 56: NTUA uptake by LUHMES neurites with and without desipramine and GBR 
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Figure 56 above: data points represent mean change in neurite fluorescence +SEM, when 
LUHMES cells were exposed to NTUA only (blue), NTUA in the presence of GBR 1µM and 
desipramine (red) 
There was an increase in NTUA accumulation over time in both the control and 
experiments with blockers. But the rate of change increase in cell fluorescence in the 
presence of blockers was lower. The difference in NTUA uptake by the LUHMES 
terminals in the absence and presence of GBR and DES was statistically significant with 
a mean rate of uptake for control experiments without blockers 0.79 (95% CI 0.63, 0.94) 
au.min-1 and after addition of blockers mean rate of uptake was 0.48 (95% CI 0.23, 0.74) 
au.min-1 p=0.041(figure 57). 
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Figure 57: NTUA uptake by differentiated LUHMES terminals with and without (control) 
GBR and desipramine 
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6.5 Discussion 
LUHMES cells were easy to maintain and large number of cells were obtained within a 
short space of time as shown previously. The cells were differentiated into post mitotic 
neurons using methods described in previous reports (Scholz et al., 2011).  
 The current study demonstrated a time dependent increase in LUHMES cell fluorescence 
during NTUA exposure. Control experiments demonstrated similar rates of increase in 
cell fluorescence (NTUA accumulation) which suggests uniform differentiation of 
LUHMES cells. In addition to intracellular accumulation, NTUA was also seen to 
accumulate in varicosities along the neurites. This is consistent with previous reports 
which showed DAT expression on the cell bodies and also neurite extensions of 
dopaminergic neurons (Eriksen et al., 2009).  
The two stage modified NTUA uptake protocol showed a fall in fluorescence during the 
second NTUA exposure. This contrasts the previous findings in PC12 cell experiments 
where NTUA uptake was demonstrated in both stages of the experiments. Several reasons 
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may explain these results. Firstly the cell lines are likely to have different saturation 
kinetics. Secondly, initial experiments were performed using calcium and magnesium and 
glucose free PBS buffer which may not have provided the necessary salts and energy 
requirements for neuronal function during the long experiments. This potential problem 
was addressed by supplementing PBS with glucose, calcium, and magnesium. However, 
this did not improve the rate of NTUA uptake during stage 2. Addition of glucose, Ca, 
and Mg to the buffer impaired cell viability, probably related to excitotoxicity as a result 
of sudden changes in ion influx into the cells. 
Thirdly, photo-toxicity due to prolonged cell exposure to UV light during the long 
experiments is another possible explanation. Lastly, photo-bleaching from prolonged UV 
light exposure during NTUA stage 2 could have led to the fall in fluorescence, but this is, 
unlikely because a similar phenomenon was not seen in PC12 cells. 
Only one previous study has assessed dopamine uptake and release by LUHMES cells. 
Scholz et al reported (3H) dopamine uptake which was inhibited by GBR 12909 (Scholz 
et al., 2011). The current study sought to assess the DAT function using a fluorescence 
DAT substrate NTUA. In contrast to Scholz et al. (2011) study, which showed inhibition 
of DAT substrate uptake, incubating the cells with GBR did not inhibit NTUA cellular 
uptake. Given that other studies have shown that, in addition to DAT, dopamine reuptake 
in substantia nigra may also be via SERT and NET, (Kelly et al., 1985) and NTUA is a 
known substrate for the three monoamine transporters, NTUA uptake was assessed in the 
presence of various combinations of monoamine transport blockers: GBR, desipramine, 
and fluoxetine. Surprisingly, this did not alter the results, as NTUA uptake was still 
demonstrated. Furthermore, there was no significant change in the rate of increase in cell 
fluorescence in the presence of the transporter blockers. The effect of adjusting the 
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temperature and incubating the cells with the blockers for longer periods was also 
assessed. Temperature changes have been shown to correlate the DAT function (Xie et 
al., 2000). Xie et al. (2000) demonstrated that cellular uptake of DAT substrates including 
(3H)DA and (3H)MPP+,,
 a rat mesencephalic cell line and a human DAT transfected 
neuroblastoma cell line, was greater at higher temperatures (Xie et al., 2000). In this 
study, the authors showed that an increase in temperature by only 30C significantly 
increased DAT substrate uptake (Xie et al., 2000). To investigate the effect of increasing 
temperature on transporter rate and effect of GBR on NTUA uptake, bath temperature 
was increased to 34 0C in the current study, but this did not alter the rate of NTUA uptake 
by differentiated LUHMES cells. Similarly, when the studies with blockers were repeated 
at a higher temperature there was no suppression of NTUA uptake. Likewise, incubating 
the cells with the blockers for longer periods prior to NTUA exposure and increasing the 
concentration of GBR did not suppress NTUA uptake. Monoamine blockers used in this 
study have been shown to have high potencies for inhibiting their respective transporters 
(GBR IC50 for DAT 14nM, (Dutta et al., 1998); fluoxetine pIC50 7.8 for (3H) 5HT 
uptake; desipramine pIC50 for (3H) noradrenaline uptake 9.1: IC50 of approximately 
1nM (Mantovani et al., 2009). Much higher concentration (1µM) and for GBR 10 µM 
were used to ensure complete blockade of the monoamine transporters. GBR and 
desipramine 1µM was also used in a previous study in our laboratory and this suppressed 
NTUA uptake in PC12 cells (Elobi, 2014).   
Inability of the GBR, desipramine, and fluoxetine to suppress NTUA uptake in the current 
study, suggest that NTUA cellular uptake in this cell line was probably passive and not 
mediated by monoamine transporters.  Alternatively, it is also plausible that GBR affinity 
for DAT in LUHMES cells and rats phaechromocytoma (PC12 cells) DAT differ. 
Although speculative, another explanation for non-specific NTUA accumulation is that 
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the concentration (1:10) used in this study was too high. Support for this comes from a 
study which sought to assess whether methamphetamine induced dopaminergic neuron 
toxicity was DAT mediated (Xie et al., 2000). The authors tested for cellular uptake of 
methamphetamine at different concentrations and found that, cocaine (a DAT inhibitor) 
only blocked uptake when methamphetamine 10µM or less was used but not at higher 
concentration (Xie et al., 2000). The authors concluded that methamphetamine cellular 
uptake was DAT mediated at lower concentration and passive at higher concentration 
(Xie et al., 2000). To verify this hypothesis, future studies should reassess NTUA uptake 
inhibition by GBR using a lower concentration (1:100) or consider using higher GBR 
concentration than those used in this study. Lastly, it is also feasible that NTUA caused 
excitotoxicity to the LUHMES cells leading to formation of fluorescent substrates which 
was observed as a rise in cell fluorescence, this also requires verification in future studies. 
Animal studies have shown different DAT densities in various brain regions (Coulter et 
al., 1995). It is possible that DAT density in LUHMES cell bodies and neurites is 
different. This was investigated by examining the rate of NTUA uptake by LUHMES 
varicosities and neurite extensions. Data analysis showed a time dependent uptake NTUA 
uptake in the LUHMES terminals. NTUA uptake was significantly lower in the presence 
of GBR and desipramine, probably reflecting DAT dependent NTUA uptake in the 
neurites. This finding is consistent with results of previous reports which demonstrated 
higher dopamine clearance and release in the striatum when compared to the substantia 
nigra, implying a higher DAT density in striatal dopaminergic terminals  (Hoffman et al., 
1998). Inability of  GBR and desipramine to completely block NTUA uptake by the 
neurites suggests that the compound (NTUA),may be a substrate of other amino acid 
transporters present on the neurites. This requires further evaluation in future 
experiments. 
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Limitations to this study include the non-physiological conditions during the study. 
Suboptimal temperatures and the use of glucose and amino acid free buffer which could 
potentially interfere with dopamine transporter function. Increasing the bath temperature 
did not change the results. Use of more physiological media for future experiments, for 
example artificial CSF should be considered. However, some amino acids such as 
riboflavin can interfere with the fluorescence signal. Scholz et al. (2011) showed that 
electrophysiological properties of LUHMES cells lagged behind other differentiation 
markers and uniform properties were only demonstrated when day 10-12 differentiated 
cells were assessed (Scholz et al., 2011). Differentiating LUHMES cells for longer 
periods prior to experiments should also be considered in future studies.  
In summary, this study showed that LUHMES cells can be reliably differentiated to form 
a uniform population of cells. NTUA uptake by the LUHMES cell bodies was non-
specific in the cell bodies but GBR sensitive uptake was demonstrated in the neurites 
which provide further evidence for functioning dopamine uptake machinery in this cell 
line. Future work using a lower NTUA concentration is required to verify the utility of 
this cell line for screening other fluorescent DAT substrates.
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CHAPTER 7: DEVELOPMENT OF A 19F MAGNETIC RESONANCE 
IMAGING PROBE 
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7.1. Background 
In MRI, images are produced by measuring the signal from hydrogen ions/protons (1H) 
of water soft tissues (Amiri et al., 2015). This is dependent on the concentration of 1H and 
its surrounding environment ( (Armstrong and Keevil, 1991). Contrast agents are used to 
alter 1H relaxation times in various tissues, which enhances the contrast of the tissue of 
interest from its surroundings (Amiri et al., 2015).  However, increased vascular 
permeability or haemorrhage due to the underlying disease process may reduce specificity 
of a contrast agent in labelling the area of interest (Amiri et al., 2015). Use of fluorine 
MRI may counteract this problem.  
The potential use of 19F fluorine isotope (19F) in MRI was first described in the 1970s 
(Knight et al., 2011). Fluorine naturally occurs as a stable 19F isotope (100% natural 
abundance) and it also has a similar sensitivity and resonance frequency to that of the 
proton (Ruiz-Cabello et al., 2011). The later characteristic feature allows the use of 19F 
imaging on the current 1H MRI scanners (Ruiz-Cabello et al., 2011). In addition, fluorine 
is barely detectable in the body, the only small amount that is present is tightly bound to 
bone matrix (Chen et al., 2010, Knight et al., 2011). This provides a very high contrast to 
noise ratio and specificity as there is no interference from background signal on 19F MRI 
in vivo (Ruiz-Cabello et al., 2011). Another advantage is that fluorinating a compound 
for use as a tracer can be achieved by replacing hydrogen atoms with fluorine, which does 
not interfere which the chemical or biological effects of the compound (Knight et al., 
2011). But one drawback of using fluorine imaging is that high concentrations and 
therefore higher number of fluorine atoms per compound are required in order to obtain 
similar image quality as that produced with standard 1H MRI (Ruiz-Cabello et al., 2011). 
Molecules with few fluorine atoms have long longitudinal relaxation times thus low 
signal to noise ratio (Amiri et al., 2015). Longer acquisition/scanning times are therefore 
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required which has practical implication when it comes to clinical application (Amiri et 
al., 2015). To overcome this problem, perfluorocarbon (PFC) nanoparticles have been 
used in 19F MRI studies including for cell migration studies, vascular diseases, and to 
assess tissue hypoxia in tumours (Chen et al., 2010). These compounds can reach very 
high 19F atom concentration of up to 100M which can be detected by low field strength 
MRI of 1.5T used in clinical practice (Chen et al., 2010). But tolerability of compounds 
with high density of fluorine atoms, required to achieve such concentrations is unknown. 
Recent studies have also reported potential use of 19F MRI in proteinopathies such as 
Alzheimer disease (AD). For example, Higuchi et al. (2005) used a 19F amyloid tracer (E-
E) - 1- fluoro-2.5-bis (3-hydroxycarbonyl-4-hydroxy) styrylbenzene( FSB) to detect brain 
amyloid β plaques in vivo in amyloid precursor protein transgenic mice (Higuchi et al., 
2005). In another study, the authors used 19F curcumin derivatives to label brain amyloid 
β plaques using 7.0T MRI in an AD mouse model (Yanagisawa et al., 2011, Tooyama et 
al., 2016). The application of 19F tracers shown in these studies suggest that 19F imaging 
has potential for use in imaging in PD. 
The aim of this study was to develop a 19F based MRI probe for labelling nigrostriatal 
neurons in PD. 18F-fluorodopa is already in use as a PET probe for labelling dopaminergic 
neurones in PD. 19F 6- fluoro DL-DOPA is a non- radioactive fluorodopa ligand which is 
commercially available. As an initial step in the development of 19F probe in PD, cellular 
uptake of 19F 6- fluoro DL-DOPA by PC12 cells was assessed, using 19F- Nuclear 
Magnetic Resonance Imaging (NMR) spectroscopy. 
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7.2. Measurement of 19F 6-Fluoro DL-DOPA signal using Nuclear Magnetic 
Resonance (NMR) spectroscopy. 
7.2.1. Materials and Methods 
 
The study hypothesis was that 19F 6- fluoro DL-DOPA (figure 58) would be taken up by 
PC12 cells and metabolised to 19F 6- fluoro-dopamine which then accumulates in vesicles 
in a similar manner as dopamine. Firstly, the optimum concentration at which 19F 6- 
fluoro DL-DOPA could be detected by 19F NMR spectroscopy was determined. 
Figure 58: Chemical structure of 19F 6- fluoro DL-DOPA 
 
Molecular weight 296.09 
 
19F 6- fluoro DL-DOPA was purchased from Santa Cruz Biotechnology, Germany. The 
compound was diluted with sterile water to make a 10mM stock solution and stored in 
aliquots at -20 0C. For the experiments, 19F 6- fluoro DL-DOPA was diluted with PSS to 
make 10mM, 1mM, 100 µM and 30µM solutions which were then placed in 3mm NMR 
tubes (volume 200µL), for NMR spectroscopy. Data were collected on a Bruker DMX 
300 spectrometer equipped with a 7 T vertical wide-bore superconducting magnet 
operating at a fluorine resonance frequency of 282 MHz with a 30 mm RF bird cage coil. 
The following experimental conditions were applied (temperature 200C, Spectral width 
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(SWH) 100 000Hz, 900 pulse (P1) 10µs, time domain (TD) 16 384, acquisition time (AQ) 
0.819s, receiver gain (RG) 8 192, Dwell time (DW) 5µs, nucleus (NUC)- 19F, power level 
(PL1) 6db, field – 3 526 Hz, Pulse Program ZG, receiver gain (RG)= 8 192, DE 7.14 μs, 
and frequency of 19F nucleus (SF01) was 282.4Hz). The number of scans (NS) was 
gradually increased from 4 to 4 096 depending on the 19F signal obtained. 
7.2.2. Results 
 
When 19F 6- fluoro DL-DOPA 10mM was assessed, no signal was detected at NS=4. The 
number of transients was gradually increased from four to 4 096 scans. A small 19F signal 
was detected (-43parts per million: ppm) at NS=512 (figure 59). The intensity of peak 
increased with increasing number of transients (NS=4 096, figure 59e). Increasing the 
number of scans also increased the required scanning time. 19F 6- fluoro DL-DOPA 1mM, 
and 100µM solutions were also tested using similar settings but no signal was detected 
up to NS= 4 096 (figure 59 a and b). A small peak with marked background noise was 
seen with 19F 6- fluoro DL-DOPA 1mM after NS=16 000 (total scanning time of over 
8hours; figure 59c).  Shimming the 19F 6- fluoro DL-DOPA 10mM sample on tri-
fluoroacetic acid (TFA) 1mM also increased the size of the peak and allowed the number 
of scans to be reduced to 256 (figure 60), but showed marked background noise.   
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Figure 59: 19F 6- fluoro DL-DOPA 1mM and 10mM signal at various number of transients 
(NS) and spectral width (SWH) 100000Hz  
 
 
 
 
 (a) 1mM NS=512, (b) 1mM NS=4 095, and (c) 1mM NS=16 000, (d) 10mM, NS=512 (e) 10mM NS=4 
096. X axis (ppm): parts per million, y axis represents signal intensity (arbitrary units). 
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Figure 60:10mM 19F 6- fluoro DL-DOPA spectra after shimming with Tri-fluoroacetic acid 
                      .
 
7.3. 19F fluoro DL-DOPA cellular uptake by PC12 cells using 19F NMR 
spectroscopy 
7.3.1. Methods 
Given that no 19F signal was detected at 100µM concentration, 19F 6- fluoro DL-DOPA 
300µM was therefore used for the cellular uptake experiments. It was postulated that 19F 
6- fluoro DL-DOPA 300 µM would accumulate in PC12 vesicles and reach a detectable 
concentration greater than 1mM. To assess for cytotoxicity of 300µM 19F 6- fluoro DL-
DOPA, cells were incubated with the compound for 2 hours then cell viability was 
assessed by examining morphology of the cells using microscopy. 40 x106 PC12 cells 
were incubated with 300µM 19F-fluoroDopa for 2 hours in a 5% CO2 incubator at 37
0C. 
After the 2 hour incubation, there were no obvious morphological changes to the cells 
when visualised using light microscopy. 19F-fluoro DL-DOPA and PC12 cell suspension 
was transferred into a falcon tube and centrifuged at 800 RPM for 5 minutes. The 
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supernatant was removed and the cell pellet was gently washed with PSS to remove 
excess extracellular 19F-fluoro DL-DOPA. The cell pellet was then re-suspended in 2mls 
of PSS and transferred into 10mm NMR tubes (Norrell Select Series S300 purchased from 
Sigma-Aldrich catalogue number NORS3007-5EA) for NMR spectroscopy. 
Experimental conditions were set as before and number of scans was gradually increased 
until a 19F-fluoroDopa was detected. Tri-fluoroacetic acid (TFA) shimming sample was 
also used as the reference. 
7.3.2. Results. 
No 19F-fluoro DL-DOPA signal was detected when the number of scans was increased 
from 512 to 4 096. In total 3 samples were assessed. Results for 1 024 and 2 048 scans 
are shown below shown (figure 61). Results remained negative even when the samples 
were shimmed on trifluoroacetic acid (TFA). Figure 62 shows the TFA signal only. 
 
Figure 61:19F-fluoroDL-DOPA 300µM cellular uptake by undifferentiated PC12 cells 
.  
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Figure 62: Trifluoroacetic acid (TFA) 1mM signal 
 
Effect of increasing the number of fluorine atoms on the 19F NMR signal. 
Given that increasing the number of fluorine atoms can increase the 19F NMR signal, we 
sought to confirm this by comparing 10mM fluoxetine HCL signal with that of 10mM 19F 
6- fluoro DL-DOPA. Fluoxetine HCL contains three fluorine atoms, and was purchased 
from LKT laboratories Inc., UK cat No F4780. 10mM solution was made by diluting 
fluoxetine with PSS and placed in 3mm NMR tubes (volume 200µM). Scan settings 
NS=256, TD 32 768 SWH 20 000Hz, RG 256, P1 28 µs. PL16dB, field 1359. 3 samples 
were scanned, with and without TFA reference. Figures 63 and 64 show sharp fluoxetine 
peaks at NS= 256 with and without TFA, at -90ppm. 
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Figure 63: Fluoxetine 10mM NMR signal 
 
Fluoxetine signal at -90ppm 
 
Figure 64: Fluoxetine 10mM NMR signal with Trifluoroacetic acid (TFA) reference 
 
Fluoxetine signal at -90ppm 
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7.4. 2, 3, 5, 6-Tetrafluorotyrosine cellular uptake by LUHMES cells using NMR 
spectroscopy 
Earlier experiments showed that increasing the number of fluorine atoms and 
concentration of the compound increase the 19F signal intensity. Poly- fluorinated 
compounds have also been used in previous studies demonstrating a strong 19F signal 
(Chen et al., 2010). Since poly-fluorinated 19F fluorodopa was not available 
commercially, an alternative was sought for the initial study. Tyrosine is a levodopa 
precursor. Both amino acids are substrates of neutral amino acid transporters (Camargo 
et al., 2014).  6- (18F) fluoro- L-meta-tyrosine analogue has been evaluated for imaging 
of the striatal dopaminergic neurons in animal studies and was shown to produce images 
with high contrast (DeJesus et al., 1997). 2, 3, 5, 6-Tetrafluorotyrosine is commercially 
available and was therefore purchased from Manchester organics, UK, catalogue number 
C15374 (chemical structure shown in figure 62 below). If 2, 3, 5, 6-tetrafluorotyrosine 
signal and cellular uptake of the compound can be demonstrated by NMR spectroscopy , 
then poly- fluorinated 19F fluorodopa will be synthesised locally at the University of 
Birmingham with a plan to repeat the cellular uptake experiments and subsequently 
further testing in small animals, if results are positive.  
Figure 65: 2, 3, 5, 6-Tetrafluorotyrosine chemical structure 
HO
F
F
F F
OH
O
NH2
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7.4.1. Methods 
 
2, 3, 5, 6-Tetrafluorotyrosine was dissolved in water to form 10mM stock solution which 
was stored at -200C. The compound was diluted to make 300µM, 1mM, and 10mM 
solutions for NMR spectroscopy as previously described. The following settings were 
used for TFA: TD = 16 384, NS = 16, SWH = 100 000 Hz, RG = 16. For 2, 3, 5, 6-
Tetrafluorotyrosine: SWH 100 000h=Hz, NS 2048 and RG 819216384 Number of scans 
= 2 048, Dummy Scans = 2, Spectral Width = 100 000 Hz, acquisition time = 0.0819 s, 
RG = 8192. 
For cellular uptake experiments, the stock solution was diluted with D-PBS to make 
300µM solution. LUHMES cells were plated onto poly-L-ornithine and fibronectin 
coated multiwall plates and differentiated into mature dopaminergic cells using 
previously described methods. Experiments were performed from day 5 of differentiation 
onwards. On the day of the experiment, the differentiation media was removed from the 
wells and the cell layer was briefly washed with pre-warmed D-PBS. 2mls of 300µM 2, 
3, 5, 6-Tetrafluorotyrosine were added to each well with cells and incubated at 370C for 
1 hour. D-PBS only was also added to two wells and culture media only was added to an 
equal number of wells for control experiments. After incubation for 1 hour, cells were 
viewed under the microscopy to assess for viability. The 2, 3, 5, 6-Tetrafluorotyrosine, 
PBS, and culture media were removed from the wells and the cell layer was washed with 
PBS twice. 400µM of celLytic M (Sigma, catalogue number C2978) was added to each 
well and cells were incubated on a shaker for 15 minutes. A cell scraper was used to 
ensure that all cells were removed from the plates. The cells were transferred to Eppendorf 
tubes and centrifuged for 15 minutes at 15 000g. The supernatant was removed and 
transferred into NMR tubes for spectroscopy. 
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7.4.2. Results 
 
No signal was seen when 2, 3, 5, 6-Tetrafluorotyrosine 1mM and 300µM were assessed. 
When 10mM 2, 3, 5, 6-Tetrafluorotyrosine was assessed, small peaks (figure 66) at40ppm 
and -54ppm were seen.  
Figure 66: NMR signal for 1mM TFA and 10mM 2, 3, 5, 6-Tetrafluorotyrosine 
 
 
Due to the unavailability of time slots for using the local NMR spectrometer at the 
University of Birmingham, samples for cellular uptake of 10mM 2, 3, 5, 6-
Tetrafluorotyrosine by LUHMES cells were sent to the University of Warwick for further 
experiments. Formal report showed that after two attempts, ‘it was possible to detect the 
highest concentration (10mM), but were not overburdened by the signal’. The 
recommendation from the University of Warwick was that future work, would therefore 
need to be done with the upper end of the concentration scale. 
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7.5. Discussion 
This study confirmed the feasibility of detecting 19F fluoro DL-DOPA signal using NMR 
spectroscopy. At lower concentrations, greater number of transients (NS= 16 000 scans 
for 1mM) and thus longer scanning time (8hrs) were required to detect a signal. Such long 
scanning times are not practical for imaging in clinical practice. As expected, at higher 
concentration (10mM) fewer scans (NS=512) were required and a sharp 19F fluoro DL-
DOPA signal intensity was detected. Shimming is a method used in MRI and 
spectroscopy to increase the homogeneity of the magnetic field around sample and thus 
increase the signal (Bothwell and Griffin, 2011). In this experiment TFA was used as the 
shimming sample and this increased the 19F fluoro DL-DOPA signal and also reduced the 
scanning time.  
PC12 cells can concentrate dopamine in vesicles to 110mM (Kozminski et al., 1998), 
which exceeds the 10mM concentration detected by NMR spectroscopy. 18F fluorodopa 
is already in use as a PET ligand and can be taken up by dopaminergic neurons. 
Substituting 18F with 19F is unlikely to interfere with metabolism or cellular uptake of 
fluoro DL-DOPA by PC12 cells. The 19F fluoro DL-DOPA cellular uptake experiments, 
did not detect a signal, despite increasing the number of scans.19F is known to be 
hydrophobic and its mobility and thus ability to produce a signal is influenced by the 
surrounding environment (Tooyama et al., 2016). If 19F fluoro DL-DOPA was taken up 
by the PC12 cells and converted to fluoro DL-dopamine, it is plausible that the latter was 
trapped in intracellular vesicles, reducing its mobility, hence reducing the NMR signal. 
But the most likely explanation is that the concentration used for these experiments was 
too low to produce a meaningful NMR signal.  
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A large number of PC12 cells (40 x106) was used in-order to increase the volume fraction 
thus concentration of 19F fluoro DL-DOPA, but this caused the cells to settle at the bottom 
of the NMR tube, which can also cause an indistinct NMR spectra (Rangus, 2007). To 
counteract this problem, cell lysis methods were used for the 2, 3, 5, 6-Tetrafluorotyrosine 
cellular uptake experiments. This study also showed that increasing the number of 
fluorine atoms by using fluoxetine increased the signal intensity and reduced the signal 
to noise ratio. Surprisingly 2, 3, 5, 6-Tetrafluorotyrosine which has a four fluorine atoms 
showed a small signal at 10mM concentration. Only one experiment was performed at 
this concentration. The low signal maybe due to insoluble particles in the solution which 
can broaden the spectra (Rangus, 2007). It is unlikely that the low signal was related to 
sensitivity of the NMR spectrometer because a stronger signal was obtained from 19F 6- 
fluoro DL-DOPA which contains one fluorine atom per molecule. 
Tooyama et al. (2016) showed the feasibility of labelling amyloid β plaques in AD mouse 
model using a probe containing only three 19F fluorine atoms (Tooyama et al., 2016). In 
another study, the same authors also used another amyloid probe with six   19F atoms. 
Although higher signal intensities were seen when solutions of the probe with six atoms 
were compared to the probe with three 19F atoms, no 19F signal was detected in the mice 
brains after intravenous injection, of the probe with six fluorine atoms (Yanagisawa et al., 
2014). The study authors demonstrated that increasing the hydrophilicity of a probe by 
increasing the number of polyethylene glycol chains (PEG) increased the 19F signal 
(Yanagisawa et al., 2014). Nevertheless, when number of PEG chains exceeded seven 
this reduced blood brain barrier permeability (Yanagisawa et al., 2014). This highlights 
the importance of getting the correct balance between the number of fluorine atoms and 
hydrophilicity of a probe for animal studies. This needs consideration when synthesising 
probes for future experiments. 
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Given that there is ample evidence to suggest that PD is a multisystem disorder with both 
central and peripheral alpha-synuclein deposition, (Beach et al., 2010) and there is 
temporal progression of  Lewy body deposition  with disease progression (Braak et al., 
2002), future studies should focus on developing 19F probes which not only label 
dopaminergic neurons but also alpha-synuclein deposits. Such tools may be useful in 
monitoring disease progression and in evaluating effects of treatments which target alpha 
synuclein deposition. Feasibility of imaging alpha-synuclein deposits in PD using 
radionuclide ligands has been assessed before. For example Bagchi et al (2013) 
synthesised a radiolabelled alpha-synuclein fibril ligand (SIL23) and demonstrated that 
the compound could bind to alpha-synuclein fibrils in a PD mouse model and also in post-
mortem human PD brains, but not in controls (Bagchi et al., 2013). The ligand binding 
sites also correlated with the amount of alpha synuclein (Bagchi et al., 2013). This 
approach in imaging PD pathology, may also be useful in early disease when current 
clinical diagnostic criteria have low sensitivity in differentiating PD from its atypical 
forms (Bagchi et al., 2013). Ideally, ligands should have a higher selectivity for insoluble 
alpha-synuclein fibrils which are characteristically found in synucelopathies than tau and 
amyloid β42 which are seen in other atypical parkinsonian syndromes (Bagchi et al., 
2013). At present no studies have assessed the utility of 19F probes in imaging alpha-
synuclein, therefore further work in this area is warranted.
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CHAPTER 8: SUMMARY OF FINDINGS AND FUTURE DIRECTIONS 
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Hospitalisation in PD 
This project provided further confirmation of high rates of hospitalisation in both early 
and advanced PD. Disease related complications contributed to a large proportion of non-
elective admissions.  
A systematic review of literature was performed in order to identify models of care which 
can be adopted in PD to reduce unplanned hospital admissions. Results of the review 
highlighted a significant gap in literature for effective interventions. A number of 
inferences were drawn from the results of available retrospective studies. These suggested 
that frequent specialist consultations which allow earlier detection and treatment of 
complications, as well timely alteration of medication for controlling PD symptoms may 
reduce hospital admissions. Although, this aids in identifying individuals who are at risk 
for hospitalisation, this intervention may not be applicable in countries where individuals 
pay for their health insurance. Furthermore, cost effectiveness of this intervention needs 
to be evaluated. Jarman et al (2002) showed that involvement of PD nurses in the 
management of PD patients in a community setting was cost neutral (Jarman et al., 2002).. 
In the UK, PD nurses already provide care in both the community and secondary care 
settings, but their effectiveness on reducing PD hospitalisation has not been 
systematically assessed. PD nurse specialists run community based clinics and also offer 
domiciliary/nursing visits for those with limited mobility. Availability and provision of 
these services vary across the country, therefore the resultant effect on PD hospitalisation, 
if any, may not be apparent. The majority of the non-elective PD admissions in this study 
were for infections, falls and fractures and other non-motor symptoms which cannot be 
easily prevented. Considering these complexities in PD management, assessing the role 
of PD nurses only, in reducing hospitalisation is unlikely to produce significant results. 
A multifaceted approach may be more appropriate, where the community PD nurse plays 
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a central role in identifying those at high risk of admission in the community and then 
referring to other teams for management in the community. For example physiotherapy  
for falls management, early referral to the primary care physicians for treatment of urinary 
tract infections, involving speech and language therapist for those with dysphagia and at 
risk of aspiration, or other PD specialists for management of other motor or non-motor 
symptoms. For PD patients who are discharged from hospital, early community review 
or home visits can potentially reduce re-admission rates. Future RCTs should therefore 
consider cluster randomisation, where PD patients within the catchment area of a number 
of hospitals, are assigned to the active arm, where there is access to frequent nurse led 
community clinics, domiciliary/nursing home visits, early reviews post discharge from 
hospital, and referral to the multidisciplinary team. The number of hospital admissions 
and accident and emergency visits in these clusters is then compared with the control 
group which continues with the current practice. Disadvantages of such a randomised trial 
is the difficulty in designing the study and blinding participants.  
Effect of telemedicine on reducing PD hospital admissions has not been evaluated before. 
A recent US study demonstrated the feasibility of teleconsultations in patients with 
PD.(Beck et al., 2017) The study also showed similar quality of life measures in patients 
who had teleconsultations compared to those who had standard hospital outpatient 
reviews. (Beck et al., 2017) Considering the lower costs associated with teleconsultations, 
(Beck et al., 2017)  and that previous retrospective studies have shown a trend towards 
reduced hospital admissions with frequent specialist consultations,(Willis et al., 2012, 
Ney et al., 2013) future studies should consider assessing the effect of frequent remote 
consultations on PD hospitalisation. 
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Patient and carer targeted educational programmes coupled with frequent specialist 
consultation were shown to be effective in other chronic conditions, (Gibson et al., 2002) 
and therefore should also be examined in individuals with PD. 
Evaluation of the effect of dopaminergic medication on various aspects of hospitalisation 
was performed and showed no difference in hospital admission rates or length of stay 
among patients treated with different medications in both early and advanced disease. The 
prospective and randomised nature of the data used in the analyses allowed for definitive 
conclusions to be drawn from the results. Although these treatments are efficacious, they 
do not address the non-motor aspects of the disease, and have no effect on other disease 
complications such as infections, low mineral bone density, and fractures. Future 
interventions should involve preventive strategies for disease related complications. Since 
fracture prevention measures have been shown to reduce hospitalisation in other patients 
groups, examining the effect of bisphosphonates on hospital admissions rates for fractures 
in PD patients may be warranted. Considering the complexity of managing PD, it is likely 
that a preventive approach which addresses motor and non-motor complications in early 
disease, and community-based management of palliative aspects of the condition in end-
stage disease may be effective in reducing hospitalisation. 
The third aspect of hospitalisation assessed in the project was the accuracy of recording 
PD diagnosis when patients are discharged from hospital. Significant data recording 
errors where identified, which may have a negative impact on healthcare planning 
decisions and potentially leads to under-resourcing of PD services. In addition to this, 
hospitals may not be reimbursed correctly for the services they provide. Other chronic 
conditions are also likely to be under-reported during hospital admissions, where the 
disease may not be the primary reason for hospitalisation. Recommendations to improve 
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coding errors may include training coders, use of electronic records, and outpatients 
clinical coding of these conditions by senior clinicians. This also requires further 
prospective evaluation. 
In terms of improving inpatient care, medication errors in PD can be reduced by involving 
PD experts during hospital admissions (Hou et al., 2012).  The National Service 
Framework for long-term conditions quality requirements highlight the need for meeting 
patient’s specific needs during hospitalisation and importance of assessment by teams 
with the appropriate expertise in with chronic neurological illnesses (Department of 
Health Long-term Conditions NSF Team, 2005). In addition, emphasis is placed on the 
importance of adherence to PD medication regimes and assisting patients who self-
medicate in order to prevent symptom worsening and development of other complications 
(Department of Health Long-term Conditions NSF Team, 2005). As discussed above, 
current inpatient PD management falls short of these quality of care standards. 
Involvement of PD specialists during hospital admission is likely to improve the quality 
of care of patients as suggested by a previous study (Cheng et al., 2007). In the post-
operative period, early consultation by a neurologist was shown to shorten hospital stay 
and was also shown to improve UPDRS scores (Mehta et al., 2008). Other authors have 
recommended computerised alert systems which trigger early referral to a PD nurse 
specialist when a PD patient is admitted (Derry et al., 2010). Training nurses and doctors 
on management of PD and incorporating important aspects of PD management into 
hospital guidelines may be beneficial (Magdalinou et al., 2007, Chou et al., 2011). For 
example, providing information on alternative formulation of PD drugs, contraindicated 
drugs and potential complications of medication errors. The UK NICE guidelines 
recommend that PD patients should be allowed to take their own medication, (NICE 
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guidelines [CG35], 2006) which may also improve adherence to medication doses and 
timing. Evaluating effects of these measures on inpatient outcome may be informative. 
MRI tool for imaging in Parkinson disease 
Preliminary experiments in the development of an MRI sensitive probe for use in PD 
were conducted. Results of these experiments provide a basis for future work. The 
lanthanide compounds examined so far showed minimal and non-specific cellular 
accumulation in PC12 cells.  The current study also demonstrated poor lanthanide 
fluorescence signal and lack of consistency in lanthanide cellular uptake between the 
experiments. In addition results of a previous pilot study could not be replicated. These 
findings suggests that performing further studies using lanthanide compounds and similar 
screening methods may be futile.  
Several issues which arose during the course of this study should be addressed before 
conducting further studies. Firstly, fluorescence microscopy may not be sensitive in 
detecting minimal cellular uptake.  Other highly sensitive assay methods such as ICP-
MS, which can measure small amounts of metals at single cell level, (Zheng et al., 2015) 
should also be considered in future cellular uptake experiments. Secondly, if lanthanide 
compounds are to be considered for future work, complexes with greater luminescence 
should be developed.  Since the structure of a molecule determines its function and 
influences the selectivity of the compound for a receptor, (Deschamps, 2005) rational 
drug design should be used in developing complexes which are DAT specific. Methods 
such as X-ray crystallography can provide complete and accurate information on 
molecular structure (Deschamps, 2005) and should be considered in designing future 
lanthanide complexes. This may increase specificity of future lanthanide probes for DAT. 
Another limitation of using fluorescence microscopy was the long duration of 
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experiments, which caused difficulties in controlling for variables such as temperature, 
and cell viability, which can interfere with cellular uptake. This method is therefore not 
ideal for rapid screening of compounds. Automated methods which allow rapid screening 
of several compounds under a controlled environment such as FLIPR tetra should be 
considered. Collaboration with other groups working on similar projects will allow 
sharing of ideas and expertise which can provide different approaches of tackling some 
the problems faced in the current study and thus improve the quality of future work.  
This project also investigated DAT function in a human dopaminergic cell line 
(LUHMES cells). Uniform and avid NTUA cellular uptake was observed across all 
experiments. The observed GBR and desipramine sensitive NTUA uptake in the cell 
neurite extensions implies that a higher DAT expression in the neurites extensions of 
these cells. This is consistent with previous work which demonstrated higher DAT 
expression in dopaminergic neuron terminals in the striatum when compared to the 
substantia nigra (Hoffman et al., 1998).  
NTUA uptake in the cell bodies of differentiated LUHMES cells could not be suppressed 
by DAT/NET/SERT blockers. It is feasible that the avid NTUA accumulation may have 
been as a result of a high intracellular VMAT vesicle density, on which the monoamine 
transporter blockers had no influence. The lack of NTUA uptake inhibition by the 
monoamine blockers, may also be to do with the high NTUA concentration (1:10) used 
in this study. Further work using lower NTUA concentration (1:100) should be conducted 
to verify DAT function in these cells. This will also provide further evidence for utility 
of this cell line in screening future DAT probes. It is important to note that the initial 
validation studies for NTUA used cell lines transfected with human DAT and at even 
higher NTUA concentration (1:1),(Jorgensen et al., 2008) , suggesting different saturation 
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kinetics between the cell lines. It is also plausible that NTUA uptake by the LUHMES 
cells was via other amino acid transporters which could not be suppressed by the blockers 
used in the study. Further characterisation of other transporters present on LUHMES is 
required, in order to determine if NTUA is an appropriate control for future experiments.  
Another goal of this project was to assess the feasibility of using a 19F MRI probe for 
labelling dopaminergic neurons in PD. Although experiments performed so far showed 
no detectable 19F NMR signal when cellular uptake of 19F fluoro DL-DOPA and 2, 3, 5, 
6-tetrafluorotyrosine was assessed, a 19F signal at mM concentration was detected. The 
lack of detectable signal in the cellular uptake experiments suggests that the 19F 
concentration was low. Probes which can accumulate in cells in sufficient amounts to 
allow detection by NMR spectroscopy should be developed. Synthesising tri- or tetra-
fluorinated-DOPA may resolve this problem. If successful, the compounds should be 
tested in cells before proceeding to tests in animals. No definitive conclusions can be 
drawn regarding the usefulness of these compounds from the few experiments performed.   
Alternatively 19F probes which target other aspects of the disease pathology, for example 
alpha-synuclein deposition, should be developed. Such probes may be valuable as 
diagnostic biomarkers. Additionally, since Lewy body pathology spreads with disease 
progression, (Braak et al., 2002) alpha-synuclein probes may also have utility in 
monitoring disease progression. Ongoing animal studies have shown promising results 
from using immunotherapy against alpha-synuclein, (Lee and Lee, 2016) so 19F alpha-
synuclein probes may be a useful biomarker in examining the effects of such therapies in 
future clinical trials. Feasibility of using 19F MRI probes in proteinopathies has already 
been demonstrated in animal models of Alzheimer’s disease which is encouraging 
(Tooyama et al., 2016). Collaborative work and knowledge gained from these studies 
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could provide insights into how similar 19F alpha-synuclein probes for imaging in PD can 
be developed. Evidence for alpha-synuclein imaging in PD using radionuclide probes is 
also emerging. For example, a recent study funded by the Michael J fox Foundation 
identified a panel of compounds, some of which showed specificity for Lewy body 
pathology when tested in human tissue sections (Neal et al., 2013).This is a significant 
step forward and lessons learnt in the development of these compounds can also be used 
in designing 19F probes. 
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